Welcome to the American Diabetes Association’s hybrid 84th Scientific Sessions in sunny Orlando.

As the world’s largest meeting on diabetes, the Scientific Sessions is both a leading educational gathering and a unique opportunity to network with colleagues from over 115 countries. We couldn’t be more excited to reconnect and accelerate progress towards preventing and curing diabetes and improving the lives of all people affected by diabetes.

This guide includes maps and the day-at-a-glance schedule. For full program details, use the online planner/mobile app. The 84th Scientific Sessions app is compatible with iOS and Android devices.

Table of Contents

02  Maps
10  Day at a Glance
10  Friday, June 21
14  Saturday, June 22
22  Sunday, June 23
30  Monday, June 24
36  Notes
### DAY-AT-A-GLANCE SCHEDULE

**American Diabetes Association® 84th Scientific Sessions**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.-</td>
<td>Welcome to the 84th ADA Scientific Sessions —Keynote Address by Robert</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>M. Califf, MD and Panel Discussion</td>
</tr>
<tr>
<td></td>
<td>(<em>Includes Livestream</em>)</td>
</tr>
<tr>
<td></td>
<td>West Hall B3-6 (General Session)</td>
</tr>
<tr>
<td>11:30 a.m.-</td>
<td><strong>PATHWAY SYMPOSIUM</strong></td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td><em>Pathway to Stop Diabetes</em> (<em>Includes Livestream</em>)  <em>/</em></td>
</tr>
<tr>
<td>12:45 p.m.-</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
</tr>
<tr>
<td>1:45 p.m.</td>
<td><em>AC-OR06-1</em> Metabolic Pathways to Protection—Innovative Approaches in</td>
</tr>
<tr>
<td></td>
<td>Diabetes—Induced Kidney Disease</td>
</tr>
<tr>
<td></td>
<td>Room: W308</td>
</tr>
<tr>
<td>12:45 p.m.-</td>
<td><em>BM-OR06-1</em> Tools for Health Care Professionals That Assist in</td>
</tr>
<tr>
<td>1:45 p.m.</td>
<td>Personalizing Care</td>
</tr>
<tr>
<td></td>
<td>Room: W319</td>
</tr>
<tr>
<td>12:45 p.m.-</td>
<td><em>AC-OR06-1</em> Back to the Basics (Sciences) of Exercise and Diabetes</td>
</tr>
<tr>
<td>1:45 p.m.</td>
<td>Room: W304 E-H</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><em>BM-OR05-1</em> Exploring the Impact of Food/Food Additives on</td>
</tr>
<tr>
<td></td>
<td>Insulin Sensitivity and Postprandial Glucose (With ADA Presidents’</td>
</tr>
<tr>
<td></td>
<td>Select Abstract Presentation)</td>
</tr>
<tr>
<td></td>
<td><em>INCLUDES LIVESTREAM</em></td>
</tr>
<tr>
<td></td>
<td>Room: W335</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><em>BM-OR06-1</em> Tools for Health Care Professionals That Assist in</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>Personalizing Care</td>
</tr>
<tr>
<td></td>
<td>Room: W319</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><em>BM-OR06-1</em> Back to the Basics (Sciences) of Exercise and Diabetes</td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td>Room: W304 E-H</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><strong>ASK THE EXPERT</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><em>CT-AE14-1</em> How Will Artificial Intelligence Change Diabetes Clinical</td>
</tr>
<tr>
<td></td>
<td>Practice? (<em>Includes Livestream</em>)</td>
</tr>
<tr>
<td></td>
<td>Room: W320 (Chapin Theater)</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><strong>DEBATE</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><em>EC-OR03-1</em> Race and Ethnicity-Based Cut Points in Diabetes Screening</td>
</tr>
<tr>
<td></td>
<td>and Diagnosis—Benefit or Harm for Reducing Disparities? (*Includes</td>
</tr>
<tr>
<td></td>
<td>Livestream*)</td>
</tr>
<tr>
<td></td>
<td>Room: W320 (Chapin Theater)</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><em>CT-OR05-1</em> Secreted Factors and Insulin Action</td>
</tr>
<tr>
<td></td>
<td>Room: W304 A-D</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><em>IB-OR05-1</em> New Technology—The Inpatient Setting (<em>INCLUDES LIVESTREAM</em>)</td>
</tr>
<tr>
<td></td>
<td>Room: W314</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><em>IB-DB01-1</em> Setting the Record Straight—Does SARS-CoV-2 Cause Type 1</td>
</tr>
<tr>
<td></td>
<td>Diabetes? (<em>INCLUDES LIVESTREAM</em>)</td>
</tr>
<tr>
<td></td>
<td>Room: W155 (Valencia Ballroom)</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><em>IB-OR05-1</em> New Frontier in Immunometabolism</td>
</tr>
<tr>
<td></td>
<td>Room: W308</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><em>IB-OR06-1</em> Emerging New Players in Metabolic Regulation</td>
</tr>
<tr>
<td></td>
<td>Room: W314</td>
</tr>
<tr>
<td>2:00 p.m.-</td>
<td><strong>ORAL PRESENTATIONS</strong></td>
</tr>
<tr>
<td>3:30 p.m.</td>
<td><em>IB-OR06-1</em> Emerging New Players in Metabolic Regulation</td>
</tr>
<tr>
<td></td>
<td>Room: W314</td>
</tr>
</tbody>
</table>

**Registration Hours:** 8:00 a.m.-6:30 p.m.  
**Shop ADA Hours:** 9:00 a.m.-6:30 p.m.  
**Exhibit Hall Hours:** 6:30 p.m.-8:30 p.m.
FRIDAY, JUNE 21, 2024    DAY-AT-A-GLANCE SCHEDULE

American Diabetes Association® 84th Scientific Sessions

Registration Hours: 8:00 a.m.-6:30 p.m.
Shop ADA Hours: 9:00 a.m.-6:30 p.m.
Exhibit Hall Hours: 8:30 p.m.-10:00 p.m.
Poster Hall Hours: 8:30 p.m.-10:00 p.m.

American Diabetes Association Networking Reception    Exhibit Hall (West A1-A3)

Shop ADA Hours:

9:00 a.m.-6:30 p.m.

Exhibit Hall (West A1-A3)

Poster Hall Hours:

8:30 p.m.-10:00 p.m.

American Diabetes Association Networking Reception    Exhibit Hall (West A1-A3)
### Acute and Chronic Complications

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.–</td>
<td>SYMPOSIUM AC-SY10-1.5 SELECT Trial—New Looks at Glycemia, Inflammation, and Heart Failure (INCLUDES LIVESTREAM)</td>
<td>W415B (Valencia Ballroom)</td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td>SYMPOSIUM AC-SY11-1.5 Navigating the Spatial Landscape—Omics in Diabetic Kidney Disease</td>
<td>W208</td>
</tr>
<tr>
<td>9:15 a.m.</td>
<td>SYMPOSIUM BM-SY11-1.5 ADA Education Recognition Program (ERP)—Diversifying Diabetes Self-Management Education and Support (DSMES) Delivery Models</td>
<td>W304 A-G</td>
</tr>
</tbody>
</table>

### Behavioral Medicine, Clinical Nutrition, Education, and Exercise

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.–</td>
<td>SYMPOSIUM BM-SY13-1.5 Type 2 Diabetes and Exercise—Where Do We Stand?</td>
<td>W314</td>
</tr>
<tr>
<td>8:15 a.m.</td>
<td>SYMPOSIUM BM-SY14-1.5 NIDDK Early Career Investigator Symposium—Leveraging Social Support to Improve Diabetes Self-Management and Health Outcomes—Innovative Methods and Interventions</td>
<td>W311</td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td>SYMPOSIUM BM-SY15-1.5 ADA Education Recognition Program (ERP)—Diversifying Diabetes Self-Management Education and Support (DSMES) Delivery Models</td>
<td>W304 A-G</td>
</tr>
</tbody>
</table>

### Clinical Diabetes/Therapeutics

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.–</td>
<td>PANEL CT-PN06-1.5 Newly-Diagnosed Type 2 Diabetes—What Should Be the Focus of Management in 2024? (INCLUDES LIVESTREAM)</td>
<td>W307</td>
</tr>
<tr>
<td>8:20 a.m.</td>
<td>PANEL CT-PN16-1.5 The Role of the Interdisciplinary Team in Technology Onboarding in Primary Care</td>
<td>W415C (Valencia Ballroom)</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>SYMPOSIUM CT-SY23-1.5 Navigating the Early Phases of Pediatric Type 1 Diabetes</td>
<td>W310</td>
</tr>
</tbody>
</table>

### Epidemiology/Genetics

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.–</td>
<td>PANEL EG-PN05-1.5 Diabetes Genome-Wide Association Study—Why Keep Going?</td>
<td>W307</td>
</tr>
<tr>
<td>8:20 a.m.</td>
<td>SYMPOSIUM CT-SY27-1.5 ADA Diabetes Care Symposium—The Final Frontier—Implementing the Learning from Implementation Science</td>
<td>W300</td>
</tr>
<tr>
<td>8:30 a.m.</td>
<td>SYMPOSIUM CT-SY48-1.5 The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Multiple Daily Insulin Injections in Adults with Type 1 Diabetes—Results of the INHALE-3 Randomized Trial (INCLUDES LIVESTREAM)</td>
<td>W320 (Chapin Theater)</td>
</tr>
</tbody>
</table>

### Professional Development

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m.–</td>
<td>SYMPOSIUM CT-SY55-1.5 ADA Chief Executive Officer Remarks; President, Health Care &amp; Education Address; and Outstanding Educator in Diabetes Award Lecture (INCLUDES LIVESTREAM)</td>
<td>West Hall B3-4 (General Session)</td>
</tr>
<tr>
<td>9:45 a.m.–</td>
<td>ADA Chief Executive Officer Remarks; President, Health Care &amp; Education Address; and Outstanding Educator in Diabetes Award Lecture (INCLUDES LIVESTREAM)</td>
<td>West Hall B3-4 (General Session)</td>
</tr>
</tbody>
</table>
### Acute and Chronic Complications

#### Behavioral Medicine, Clinical Nutrition, Education, and Exercise

<table>
<thead>
<tr>
<th>Time</th>
<th>Professional Interest Group</th>
<th>Room</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m.– 12:30 p.m.</td>
<td>PROFESSIONAL INTEREST GROUP AC-IG02-1</td>
<td>W206</td>
<td>Discussion on Foot Care—Lower Extremity Complications</td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP BM-IG02-1</td>
<td>W206</td>
<td>Discussion on Exercise Physiology—Syncing Up on Universal Antibody Screening</td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP BM-IG02-1</td>
<td>W206</td>
<td>Discussion on Nutritional Sciences and Metabolism—The Science of Ultra-Processed Foods and Impacts on Metabolic Diseases</td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP BM-IG02-1</td>
<td>W206</td>
<td>Discussion on Women’s Interprofessional Network of the ADA (WIN ADA)—How to Say “No” So You Can Say “Yes”—Optimizing Time Management</td>
</tr>
</tbody>
</table>

### Clinical Diabetes/Therapeutics/Genetics

<table>
<thead>
<tr>
<th>Time</th>
<th>Professional Interest Group</th>
<th>Room</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m.– 12:30 p.m.</td>
<td>PROFESSIONAL INTEREST GROUP CT-IG02-1</td>
<td>W207</td>
<td>Discussion on Diabetes in Youth—Perspectives on Universal Antibody Screening</td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP CT-IG02-1</td>
<td>W207</td>
<td>Discussion on Pregnancy and Reproductive Health—Should Continuous Glucose Monitoring Be Used in Pregnancy Complicated by Gestational Diabetes?</td>
</tr>
</tbody>
</table>

### Epidemiology/Genetics

<table>
<thead>
<tr>
<th>Time</th>
<th>Professional Interest Group</th>
<th>Room</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 a.m.– 12:30 p.m.</td>
<td>EPOSTER THEATER ePoster02 (*)</td>
<td>W206</td>
<td>Diabetes and CVD—Heartbreak in Motion</td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP IB-IG01-1</td>
<td>W311</td>
<td>Discussion on Islet Biology, Development, and Function—Right on Target—Strategies to Selectively Regenerate and Protect Beta Cells</td>
</tr>
</tbody>
</table>

### General Poster Session—Poster Hall (West Hall A4-B2, Second Level)

- **Session Break** (Take this opportunity to visit the Exhibit and Poster Halls)

<table>
<thead>
<tr>
<th>Time</th>
<th>Professional Development</th>
<th>Room</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 p.m.– 1:30 p.m.</td>
<td>PROFESSIONAL DEVELOPMENT PD-01-1</td>
<td>W307</td>
<td>Creating Talks That Are Talked About—How to Bring Memorability to Your Presentation(s) INCLUDES LIVESTREAM</td>
</tr>
<tr>
<td>Time</td>
<td>Acute and Chronic Complications</td>
<td>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</td>
<td>Clinical Diabetes/Therapeutics</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>1:30 p.m.-3:00 p.m.</td>
<td><strong>ORAL PRESENTATIONS</strong> AC-OR02-1.5 Cell and Molecular Approaches to Diabetes-Related Foot Complications</td>
<td><strong>ORAL PRESENTATIONS</strong> BM-OR01-1.5 Social Drivers of Health and Advance towards Social Justice</td>
<td><strong>DEBATE</strong> CT-DE01-1.5 Innovation or Access in Diabetes Technology—What Should Be Our Global Priority?</td>
</tr>
<tr>
<td></td>
<td><strong>EPOSTER THEATER</strong> ePoster05</td>
<td><strong>EPOSTER THEATER</strong> ePoster09</td>
<td><strong>EPOSTER THEATER</strong> ePoster06</td>
</tr>
<tr>
<td></td>
<td>(*) From Macrovascular to Microvascular</td>
<td>(*) From Macrovascular to Microvascular</td>
<td>(*) From Macrovascular to Microvascular</td>
</tr>
<tr>
<td></td>
<td>Room: Exhibit Hall (West A1-A3) aPoster Theater B</td>
<td>Room: Exhibit Hall (West A1-A3) aPoster Theater B</td>
<td>Room: Exhibit Hall (West A1-A3) aPoster Theater B</td>
</tr>
</tbody>
</table>

(*) Continuing Education Credit is Not Awarded for this Session.
## Day-at-a-Glance Schedule

**American Diabetes Association® 84th Scientific Sessions**

**Saturay, June 22, 2024**

### 3:15 p.m.–4:15 p.m.

**Panel**
- AC-PN03-1: From the Cutting Room Floor—Semi-live Surgery for Healing Diabetic Foot Ulcers for the Referring Practitioner
  - Room: W206

**Symposium**
- BM-SY06-1: Optimizing Outcomes of GLP-1+/GIP Receptor Agonists—How to Help Patients Succeed
  - Room: W315

**Symposium**
- BM-SY18-1: International Consensus Statement and Movement to End Diabetes Stigma
  - Room: W201

**Symposium**
- AC-SY02-1: Diabetic Retinopathy Care and Screening—Is Artificial Intelligence Changing the Future?
  - Room: W206

**Symposium**
- AC-SY14-1: The Many Faces of Kidney Disease in Diabetes—Not All Are Diabetic Nephropathy
  - Room: W207

**Symposium**
- AC-SY16-1: Updates in Autonomic Neuropathy
  - Room: W208

**Symposium**
- BM-SY06-1.5: The Evolution of Diabetes Behavioral Care
  - Room: W209

**Symposium**
- BM-SY18-1.5: Hyperglycemic Crises in Diabetes
  - Room: W310

### 4:30 p.m.–6:00 p.m.

**Symposium**
- BM-SY01-1: The Evolution of Diabetes Behavioral Care
  - Room: W307

**Symposium**
- CT-ME40-1.5: Innovation Challenge
  - Room: West Hall B3-4 (General Session)

**Symposium**
- CT-SY09-1.5: Diabetes and the Lung—Cause and Consequence
  - Room: W310

**Symposium**
- CT-SY29-1.5: Heterogeneity of Diabetes—Pathophysiology to Global Considerations
  - Room: W310 (Draper Theatre)

**Panel**
- AC-PN08-1: Beyond Statins—Treating and Evaluating Residual Atherosclerotic Cardiovascular Disease Risk
  - Room: W207

**Symposium**
- CT-PN11-1: GLP-1 +/- GIP Receptor Agonists in the Perioperative Setting—To Stop or Not to Stop?
  - Room: W415C (Valencia Ballroom)

**Symposium**
- CT-PN19-1: Health Care Policy and Diabetes—How to Improve Population Health from Multiple Perspectives
  - Room: W320 (Chapin Theater)

**Symposium**
- CT-SY34-1: Hyperglycemic Crises in Diabetes
  - Room: W314

**Symposium**
- IA-DB01-1: Boosting Energy Expenditure in Obesity—Debating the Potential of Thermogenic Adipose Tissue and Skeletal Muscle Bioenergetics as Antiobesity Targets in Humans
  - Room: W304 A-D

**Symposium**
- IP-SY06-1: Intermittent Fasting in Various Forms of Diabetes Care
  - Room: W414

**Symposium**
- IP-OR08-1: Towards Targeted Weight-Loss Therapy—New Considerations for GLP-1RA or Surgery
  - Room: W304 A-D

**Symposium**
- IP-SY13-1: How I Feel Matters, Too—The Psychosocial Aspects of Automated Insulin Delivery
  - Room: W415A (Valencia Ballroom)

**Symposium**
- IP-SY34-1: Hyperglycemic Crises in Diabetes
  - Room: W314

**Symposium**
- CT-PN11-1: GLP-1 +/- GIP Receptor Agonists in the Perioperative Setting—To Stop or Not to Stop?
  - Room: W415C (Valencia Ballroom)

**Symposium**
- CT-PN19-1: Health Care Policy and Diabetes—How to Improve Population Health from Multiple Perspectives
  - Room: W320 (Chapin Theater)

**Symposium**
- CT-SY34-1: Hyperglycemic Crises in Diabetes
  - Room: W314

**Symposium**
- IA-DB01-1: Boosting Energy Expenditure in Obesity—Debating the Potential of Thermogenic Adipose Tissue and Skeletal Muscle Bioenergetics as Antiobesity Targets in Humans
  - Room: W304 A-D

**Symposium**
- IP-SY06-1: Intermittent Fasting in Various Forms of Diabetes Care
  - Room: W414

**Symposium**
- IP-OR08-1: Towards Targeted Weight-Loss Therapy—New Considerations for GLP-1RA or Surgery
  - Room: W304 A-D

**Symposium**
- IP-SY13-1: How I Feel Matters, Too—The Psychosocial Aspects of Automated Insulin Delivery
  - Room: W415A (Valencia Ballroom)
<table>
<thead>
<tr>
<th>8:00 a.m.—9:30 a.m.</th>
<th>Acute and Chronic Complications</th>
<th>Behavioral Medicine, Clinical Nutrition, Education, and Exercise</th>
<th>Clinical Diabetes/Therapeutics</th>
<th>Epidemiology/Genetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>PANEL</td>
<td>Ac-PN10-1.5</td>
<td>A Multidisciplinary Approach—Challenging Cases from the Cardiometabolic Clinic (INCLUDES LIVESTREAM)</td>
<td>Room: W207</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>AC-SY13-1.5</td>
<td>The Changing Climate of Diabetic Kidney Disease—Environmental Triggers and Vulnerabilities</td>
<td>Room: W206</td>
<td></td>
</tr>
<tr>
<td>PANEL</td>
<td>BM-SY10-1.5</td>
<td>Loneliness Is a Real Heartbreaker (INCLUDES LIVESTREAM)</td>
<td>Room: W114</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>CT-PN10-1.5</td>
<td>Noninsulin Treatment for Type 1 Diabetes</td>
<td>Room: W311</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>CT-PN10-1.5</td>
<td>Metformin Reexamined—Pleiotropic Effects in Mother and Offspring in Humans and Animal Models</td>
<td>Room: W107</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>CT-PN10-1.5</td>
<td>Joint ADA/ISPAD Symposium—Pediatric Diabetes Insights and Innovations</td>
<td>Room: W105 (Valencia Ballroom)</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>CT-PN10-1.5</td>
<td>The State of Health Equity and Disability—Supporting Diabetes Technology Usage in People Who Are Deaf/Hard of Hearing or Blind/Low Vision</td>
<td>Room: W316</td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>CT-PN10-1.5</td>
<td>Diabetes and Organ Transplantation—Pathophysiology, Inpatient and Outpatient Management</td>
<td>Room: W206</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9:45 a.m.—11:15 a.m.</th>
<th>President, Medicine &amp; Science Address and National Scientific &amp; Health Care Achievement Awards Presentation</th>
<th>West Hall B3-4 (General Session)</th>
<th>Immunology/Beta-Cell Replacement</th>
<th>Insulin Action/Molecular Metabolism</th>
<th>Obesity/Integrated Physiology</th>
<th>Inlet Biology/Insulin Secretion</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYMPOSIUM</td>
<td>CT-SY21-1.5</td>
<td>Translating Type 1 Diabetes Risk Alleles to Therapy</td>
<td>Room: W304 A-D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>CT-SY21-1.5</td>
<td>Metabolite Transport and Molecular Metabolism</td>
<td>Room: W304 E-H</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>CT-SY21-1.5</td>
<td>ADA Diabetes Journal Symposium—It Is All in Your Head—Central Nervous System Control of Systemic Metabolism</td>
<td>Room: W306</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td>CT-SY21-1.5</td>
<td>Severe GLP-1RA Side Effects in Obesity Treatment—Fact or Fiction? (INCLUDES LIVESTREAM)</td>
<td>Room: W305 (Valencia Ballroom)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Room Details</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 a.m.–</td>
<td>PROFESSIONAL INTEREST GROUP AC-IG01-1 Discussion on Diabetes and Cardiovascular Disease—Obesity</td>
<td>W206</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 p.m.</td>
<td>and Diabetes—Innovative Research to Inform Clinical Practice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP AC-IG03-1 Discussion on Eye Health—Novel Diabetes Therapies in</td>
<td>W207</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetic Retinopathy—A Basic Science and Preclinical Perspective</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP BM-IG01-1 Discussion on Behavioral Medicine and Psychology—Including</td>
<td>W208</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>the Excluded in Behavioral Diabetes Research</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP BM-IG03-1 Discussion on Diabetes Self-Management Education and Support</td>
<td>W208</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>——Change the Way We Talk about DSMES!</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP CT-IG02-1 Discussion on Diabetes in Primary Care—Tackling Diabetes</td>
<td>W304 A-D</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>in Primary Care—Training and Workforce Development</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PROFESSIONAL INTEREST GROUP CT-IG06-1 Discussion on Clinical Centers and Programs—Challenges</td>
<td>W304 E-H</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>in Management of Diabetes in Older Adults and in Primary Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>WORKSHOP</td>
<td>W307</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CT-WS37-1 Improving Care for Deaf People with Diabetes Who Use ASL Interpreters—A Hands-On</td>
<td>W311</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Workshop</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EPOSTER THEATER ePoster07 (*) Improving Efficacy and Safety of Incretin-Based Therapies</td>
<td>Exhibit Hall (West A1-A3) ePoster Theater A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 p.m.–</td>
<td>General Poster Session—Poster Hall (West Hall A4-B2, Second Level)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Session Break (Take this opportunity to visit the Exhibit and Poster Halls)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EPOSTER THEATER ePoster10 (*) New Progress in Clinical Screening and Interventions for ASCVD</td>
<td>Exhibit Hall (West A1-A3) ePoster Theater B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Risk Mitigation in Metabolic Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EPOSTER THEATER ePoster19 (*) Exploring Eating Behaviors and Weight Loss in Youth and Adults with</td>
<td>Exhibit Hall (West A1-A3) ePoster Theater A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Type 1 and Type 2 Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 p.m.–</td>
<td>General Poster Session—Poster Hall (West Hall A4-B2, Second Level)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 p.m.</td>
<td>Session Break (Take this opportunity to visit the Exhibit and Poster Halls)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(*) Continuing Education Credit is Not Awarded for this Session.
### Acute and Chronic Complications

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 p.m.—3:00 p.m.</td>
<td>ORAL PRESENTATIONS AC-OR03-1: Continuous Glucose Monitoring—Can It Reduce Hypoglycemia Burden? Room: W307</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS AC-OR02-1: Emerging Small Molecule Biomarkers of ASCVD Risk in Metabolic Disease Room: W208</td>
</tr>
<tr>
<td></td>
<td>DEBATE BM-OR01-1: The Role of Artificial Intelligence in Transforming Nutrition and Diabetes Care—Ready for Prime Time or Not Quite? Room: W301</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS BM-OR02-1: Multifaceted Insights into Behavioral and Psychosocial Care for Youth and Families Room: W314</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS CT-OR03-1: Novel Approaches to Treatment and Characterization of Diabetes in Pregnancy (With Norbert Freinkel Award Lecture) (With ADA Presidents’ Select Abstract Presentation) INCLUDES LIVESTREAM Room: W410D (Valencia Ballroom)</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS CT-OR04-1: Weighing Opportunities of Incretin-Based Therapy in Obesity (With ADA Presidents’ Select Abstract Presentation) Room: W410C (Valencia Ballroom)</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS CT-OR01-1.5: New Technology—AID Focus Room: W315</td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-OR02-1: Global Burden of Cardiovascular Disease in People with Diabetes INCLUDES LIVESTREAM Room: W310 (Draper Theater)</td>
</tr>
<tr>
<td></td>
<td>EPOSTER THEATER ORAL PRESENTATIONS (*) Type 2 Diabetes—Prevention, Treatment, and Technology Room: Exhibit Hall (West A1-A3) ePoster Theater A</td>
</tr>
<tr>
<td>2:15 p.m.—4:15 p.m.</td>
<td>ORAL PRESENTATIONS AC-OR01-1: Lower Extremity Complications with Systemic Effects Room: W306</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS AC-OR02-1: Physiologic Responses to Hypoglycemia—New Insights Room: W307</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS AC-OR03-1: Diabetic Kidney Disease INCLUDES LIVESTREAM Room: W308</td>
</tr>
<tr>
<td></td>
<td>PANEL BM-OR01-1: Educating Clinicians in the Latest Inpatient Management Strategies from Both Sides of the Pond Room: W311</td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM BM-OR02-1: The Future of Diabetes Nutrition Interventions—Innovation in Practice INCLUDES LIVESTREAM Room: W410B (Valencia Ballroom)</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS CT-OR02-1: Clinical Contributions in Type 1 Diabetes and Exercise Room: W314</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS CT-OR03-1: New Insights and Treatments in Management of Youth with Type 1 Diabetes Mellitus Room: W315</td>
</tr>
<tr>
<td></td>
<td>3/25PM-4:00PM ES-KW-1: Kelly West Award for Outstanding Achievement in Epidemiology Lecture INCLUDES LIVESTREAM Room: W320 (Chapin Theater)</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS IBC-OR01-1: Preclinical/Clinical Efforts for Beta-Cell Replacement Therapy Room: W324 A-D</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS IBC-OR02-1: Novel Pathways in Metabolic Regulation Room: W334 A-I</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS IBC-OR03-1: Risk Factors Reimagined—Beyond Obesity in Metabolic Risk Room: W338</td>
</tr>
<tr>
<td></td>
<td>ORAL PRESENTATIONS IBC-OR04-1: Endgame—Oral Abstracts on Beta-Cell Apoptosis (With ADA Presidents’ Select Abstract Presentation) INCLUDES LIVESTREAM Room: W414</td>
</tr>
</tbody>
</table>

(*) Continuing Education Credit Is Not Awarded for this Session.
<table>
<thead>
<tr>
<th>Time</th>
<th>Panel/Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:30 p.m.–6:00 p.m.</td>
<td><strong>Acute and Chronic Complications</strong> - Diabetic Foot Disparities—Treatment With and Without a Multidisciplinary Team&lt;br&gt;Room: W206</td>
</tr>
</tbody>
</table>
Acute and Chronic Complications
Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Clinical Diabetes/Therapeutics
Epidemiology/Genetics

8:00 a.m.–9:30 a.m.
SYMPOSIUM
AC-SY15-1.5
A Means to an Endpoint—Establishing Meaningful Outcomes in Clinical Neuropathy Trials
Room: W206

SYMPOSIUM
BM-SY08-1.5
Innovative Programs That Take on the Challenge of Hard-to-Reach Populations
(INCLUDES LIVESTREAM)
Room: W415B (Valencia Ballroom)

ORAL PRESENTATIONS
CT-0457-1.5
New Technology—Omics to Understand Genome-Wide Association Study—What’s the Mechanism?
Room: W334

SYMPOSIUM
CT-0457-1.5
Myth Busters on “Category X” Drugs in Pregnancy—Evidence for Stopping Commonly Used Medications during Pregnancy, Preconception, and Lactation
(INCLUDES LIVESTREAM)
Room: W414

SYMPOSIUM
CT-0457-1.5
Cost and Quality—Improving Diabetes Care and the Cost of Ongoing Inequalities
Room: W331

SYMPOSIUM
CT-0457-1.5
Towards Innovative and Equitable Care in Youths-Onset Type 2 Diabetes
Room: W335

SYMPOSIUM
CT-0457-1.5
ADA Symposium—Major Advances and Discoveries in Diabetes—The Year in Review
Room: W415C (Valencia Ballroom)

SYMPOSIUM
CT-0457-1.5
Consensus Monitoring Guidance in Early-Stage Type 1 Diabetes
(INCLUDES LIVESTREAM)
Room: W320 (Chapin Theater)

9:45 a.m.–11:15 a.m.
Outstanding Scientific Achievement Award Lecture and Banting Medal for Scientific Achievement Award Lecture
(includes livestream)
West Hall B3-4 (General Session)

11:30 a.m.–12:30 p.m.
EPOSTER THEATER
ePoster13
(*) Tailoring Diabetes Self-Management Education to Improve Success
Room: Exhibit Hall (West A1-A3) ePoster Theater A

PROFESSIONAL INTEREST GROUP
CT-0210-1.5
Discussion on Diabetes Technology—Enhancing Clinic Efficiency through the Integration of Diabetes Technologies
Room: W334 A-D

PROFESSIONAL INTEREST GROUP
CT-0210-1.5
Discussion on Health Care Delivery and Quality Improvement
Room: W304 E-H

PROFESSIONAL INTEREST GROUP
EG-0210-1.5
Discussion on Public Health and Epidemiology—Kids Are Not Little Adults—Challenges and Opportunities in the Use of Pharmacotherapy for Youth With and at Risk for Type 2 Diabetes
Room: W207

PROFESSIONAL DEVELOPMENT
PD-03-1
Negotiations
(INCLUDES LIVESTREAM)
Room: W307

MONDAY, JUNE 24, 2024
DAY-AT-A-GLANCE SCHEDULE
American Diabetes Association® 84th Scientific Sessions

Registration Hours: 7:30 a.m.–3:30 p.m.
Shop ADA Hours: 7:30 a.m.–4:30 p.m.
Exhibit Hall Hours: 10:00 a.m.–2:00 p.m.
Poster Hall Hours: 7:30 a.m.–2:00 p.m.

(*) Continuing Education Credit is Not Awarded for this Session.
### General Poster Session—Poster Hall (West Hall A4-B2, Second Level)
**Session Break** (Take this opportunity to visit the Exhibit and Poster Halls)

#### 12:30 p.m.–1:30 p.m.

**General Poster Session**—Poster Hall (West Hall A4-B2, Second Level)

<table>
<thead>
<tr>
<th>Title</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPOSTER THEATER ePoster15 (*) Creative Strategies for Care Improvement</td>
<td>West Hall A4-B2</td>
</tr>
<tr>
<td>SYMPOSIUM AC-SY09-1.5 Demystifying Impaired Awareness of Hypoglycemia—Diagnosis, Experience, and Treatment in the Real World</td>
<td>W207</td>
</tr>
<tr>
<td>SYMPOSIUM BI-SY08-1.5 How Diabetes Technology Is Changing Diabetes Care in the Real World</td>
<td>W311</td>
</tr>
<tr>
<td>SYMPOSIUM BM-SY07-1.5 Impact of Precision Medicine on Diabetes</td>
<td>W316</td>
</tr>
<tr>
<td>SYMPOSIUM CT-SY07-1.5 Just Do It—Incorporating What We Know into What We Do</td>
<td>W315</td>
</tr>
<tr>
<td>SYMPOSIUM CT-SY06-1.5 ADA Diabetes Care/Diabetes/Diabetologia Symposium—The Heterogeneity of Type 1 Diabetes Treatment</td>
<td>W304 A-D</td>
</tr>
<tr>
<td>SYMPOSIUM CT-SY05-1.5 Lancet Journal Symposium—Time for a Paradigm Shift? Should We Treat Early Gestational Diabetes Mellitus?</td>
<td>W304 E-H</td>
</tr>
<tr>
<td>SYMPOSIUM CT-SY04-1.5 The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist—Once-Weekly Semaglutide and the FLOW Trial Results</td>
<td>W410 (Valencia Ballroom)</td>
</tr>
</tbody>
</table>

### General Poster Session—Poster Hall (West Hall A4-B2, Second Level)
**Session Break** (Take this opportunity to visit the Exhibit and Poster Halls)

#### 1:30 p.m.–3:00 p.m.

**SYMPOSIUM BM-SY17-1.5 Nutrition and Diabetes Self-Management Education and Support (DSMES)**
Room: W415 (Valencia Ballroom)

**SYMPOSIUM BM-SY16-1.5 Just Do It—Incorporating What We Know into What We Do**
Room: W315

**SYMPOSIUM BM-SY15-1.5 ADA Diabetes Care/Diabetes/Diabetologia Symposium—The Heterogeneity of Type 1 Diabetes—Pathogenesis, Treatment, and Prevention (INCLUDES LIVESTREAM)**
Room: W304 A-D

**SYMPOSIUM CT-SY05-1.5 Impact of Precision Medicine on Diabetes**
Room: W316

**SYMPOSIUM CT-SY04-1.5 The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist—Once-Weekly Semaglutide and the FLOW Trial Results (INCLUDES LIVESTREAM)**
Room: W410 (Valencia Ballroom)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15 p.m.–4:15 p.m.</td>
<td>SYMPOSIUM AC-SY11-1 Cardiovascular Disease Risk Prediction in Obesity and Type 2 Diabetes—Emerging Tools for the Clinician</td>
<td>Room: W206</td>
</tr>
<tr>
<td></td>
<td>ASK THE EXPERT BM-AE04-1 The Highs and Lows of Cannabis Use in Diabetes—Behavioral and Psychosocial Considerations</td>
<td>Room: W314</td>
</tr>
<tr>
<td></td>
<td>PANEL BM-NE02-1 Are We Close to Closing the Loop? Automated Insulin Delivery during Exercise</td>
<td>Room: W501 (Valencia Ballroom)</td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-SY15-1 Improving Culture of Quality in Pediatric Centers—Lessons from the Type 1 Diabetes Exchange Quality Improvement Collaborative</td>
<td>Room: W35</td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-SY16-1 Results from a Randomized Trial of Intensive Glucose Management Using Continuous Glucose Monitoring (CGM) Versus Usual Care in Hospitalized Adults with Type 2 Diabetes—The TIGHT Study (INCLUDES LIVESTREAM)</td>
<td>Room: W310 (Chapin Theater)</td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-SY17-1 Use of SGLT2i in Youth with Type 1 Diabetes—Results from ATTEMPT (The Adolescent Type 1 Diabetes Treatment with SGL2i for hyperglycEMia &amp; hyperPerfusion Trial) (INCLUDES LIVESTREAM)</td>
<td>Room: W14</td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM CT-SY18-1 Prevalence of Hypercortisolism in Difficult-to-control Type 2 Diabetes</td>
<td>Room: W158 (Valencia Ballroom)</td>
</tr>
<tr>
<td></td>
<td>DEBATE CT-DB04-1 Early Abnormal Glucose Metabolism in Pregnancy—To Treat or Not to Treat</td>
<td>Room: W311</td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM EG-SY16-1 Diabetes Genetic Convergence—Shared Networks of Rare and Common Variants</td>
<td>Room: W207</td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM EG-SY17-1 Do Immune or Beta Cells Drive Transition from Stage 1 to Stage 3 Type 1 Diabetes?</td>
<td>Room: W304 A-D</td>
</tr>
<tr>
<td></td>
<td>SYMPOSIUM IBC-SY08-1 The Future of Diabetes Care as Cell Replacement or Regeneration Therapies (INCLUDES LIVESTREAM)</td>
<td>Room: W307</td>
</tr>
<tr>
<td></td>
<td>PANEL IP-PN01-1 Leptin, 30 Years Later</td>
<td>Room: W304 E-H</td>
</tr>
<tr>
<td></td>
<td>PANEL IP-PN09-1 Ripple Effects after the Advent of Highly Effective Antiobesity Pharmacotherapy—Pharmacoequity in the United States</td>
<td>Room: W308</td>
</tr>
</tbody>
</table>

**Day at a Glance**

- **Registration Hours:** 7:30 a.m.-3:30 p.m.
- **Shop ADA Hours:** 7:30 a.m.-4:30 p.m.
- **Exhibit Hall Hours:** 10:00 a.m.-2:00 p.m.
- **Poster Hall Hours:** 3:30 a.m.-2:00 p.m.
Program information is subject to change at any time. For full program details, please use the online planner/mobile app.

The mission of the American Diabetes Association is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

© 2024 American Diabetes Association.
84th SCIENTIFIC SESSIONS PROGRAM

FRIDAY, JUNE 21, 2024

Scientific Sessions
10:30 a.m.-11:30 a.m.

Special Lectures and Addresses
Session Number: WP-01-1
Welcome to the 84th ADA Scientific Sessions—Keynote Address by Robert M. Califf, MD and Panel Discussion (Includes Livestream)
Room: West Hall B3-4 (General Session)
Chair: Robert A. Gabbay, MD, PhD
10:30 a.m.-10:35 a.m. Welcome to the 84th ADA Scientific Sessions!
Charles Henderson
10:35 a.m.-10:40 a.m. Introduction
Mandeep Bajaj, MBBS
10:40 a.m.-11:10 a.m. Keynote Address—The Dissociation between Technology Advances and Health Outcomes for Diabetes in the US—What Should We Do Differently?
Robert M. Califf, MD
11:10 a.m.-11:15 a.m. Introduction of Panel
Robert A. Gabbay, MD, PhD
11:10 a.m.-11:30 a.m. Panel Discussion
Alice Y.Y. Cheng, MD, FRCPC
Robert M. Califf, MD
Christopher S. Holliday, PhD, MPH, MA, FACHE
Griffin Rodgers, MD, MACP

Pathway Symposium
Session Number: PTH-01-1
"Pathway to Stop Diabetes" (Includes Livestream)
Room: West Hall B3-4 (General Session)
Chair: Robert A. Gabbay, MD, PhD
11:40 a.m.-11:48 a.m. Introduction
Robert A. Gabbay, MD, PhD
11:48 a.m.-11:56 a.m. Is There Such a Thing as Good Fat?
Paul Cohen, MD, PhD
11:56 a.m.-12:02 p.m. Decoding the Puzzle—Unveiling Type 2 Diabetes Genetics via Multi-Omic Insights
Debora Sobreira, PhD
12:02 p.m.-12:11 p.m. Early Encounters—Diabetes Exposure Before Birth Shapes Brain Pathways and Metabolic Risk
Kathleen A. Page, MD
12:11 p.m.-12:15 p.m. Closing Remarks
Marlon Pragnell, PhD
12:45 p.m.-1:45 p.m.

Debate
Theme Area: Epidemiology/Genetics
Session Number: EG-DB01-1
Race and Ethnicity-Based Cut Points in Diabetes Screening and Diagnosis—Benefit or Harm for Reducing Disparities? (Includes Livestream)
Room: W320 (Chapin Theater)
Chair: Alan Kinlaw, PhD
12:45 p.m.-1:00 p.m. Using Race and Ethnicity-Based Cut Points Has the Potential to REDUCE Health Disparities in the Diagnosis of Diabetes
Quyen Ngo-Metzger, MD, MPH
1:00 p.m.-1:15 p.m. Using Race and Ethnicity-Based Cut Points Has the Potential to INCREASE Health Disparities in the Diagnosis of Diabetes
Jessica Cerdeña, MD, PhD
1:15 p.m.-1:25 p.m. Rebuttal
Quyen Ngo-Metzger, MD, MPH
1:25 p.m.-1:35 p.m. Rebuttal
Jessica Cerdeña, MD, PhD
1:35 p.m.-1:45 p.m. Question and Discussion Period

Debate
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-DB01-1
Setting the Record Straight—Does SARS-CoV-2 Cause Type 1 Diabetes? (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Mark A. Atkinson, PhD
12:45 p.m.-1:00 p.m. SARS-CoV-2 Infests Human Beta Cells and Compromises Beta-Cell Function
Peter K. Jackson, PhD
1:00 p.m.-1:15 p.m. Infection Does Not Equal Causation—Unraveling the Complicated Relationship Between SARS-CoV-2 and Diabetes
Carmella Evans-Molina, MD, PhD
1:15 p.m.-1:20 p.m. Rebuttal
Peter K. Jackson, PhD
1:20 p.m.-1:25 p.m. Rebuttal
Carmella Evans-Molina, MD, PhD
1:25 p.m.-1:45 p.m. Question and Discussion Period
12:45 p.m.-1:45 p.m.  
(continued)

Oral Presentations  
Theme Area: Acute and Chronic Complications  
Session Number: AC-OR06-1  
Multiorgan Cross Talk in Lipid Metabolism  
Room: W206  
Chair: Rebecca Haeusler, PhD

12:45 p.m.-1:00 p.m.  
1-OR  The Improvement Effects of Glucokinase Loss-of-Function Mutation on Lipid Metabolism  
Presenting Author: Ziyan Xie, PhD

2-OR  WITHDRAWN

1:00 p.m.-1:15 p.m.  
3-OR  Lipoprotein(a) Levels and Epicardial Adipose Tissue in Diabetes—Unraveling Novel Connections  
Presenting Author: Emmanuel Cosson, Professor

1:15 p.m.-1:30 p.m.  
4-OR  Fat Contents in Pancreatic Body and Liver Are Synergistic Risk Factors for Impaired Glucose Regulation in PCOS  
Presenting Author: Tao Tao, Doctorate
12:45 p.m.-1:45 p.m.  
(continued)

**Oral Presentations**

*Theme Area: Acute and Chronic Complications*

**Session Number: AC-OR11-1**

**Metabolic Pathways to Protection—Innovative Approaches in Diabetes-Induced Kidney Disease**

Room: W207  
Chair: Kalie L. Tommerdahl, MD

12:45 p.m.-1:00 p.m.

**5-OR**  
Renal Hypermetabolism in Youth-Onset Type 2 Diabetes (T2D)—A C-11 Acetate PET Scan Analysis  
Presenting Author: Melissa Leroux, BS

1:00 p.m.-1:15 p.m.

**6-OR**  
Renal Cell Type—Associated Therapeutic Effects of Semaglutide in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease  
Presenting Author: Michael Christensen, PhD

1:15 p.m.-1:30 p.m.

**7-OR**  
Causal Associations between Glyoxalase 1 Expression and Kidney Disease in Type 1 Diabetes  
Presenting Author: Krishna Adeshara, PhD

1:30 p.m.-1:45 p.m.

**8-OR**  
Longitudinal Patterns of Heterogeneity in Metabolic Decompensation among Diabetes Prevention Program Outcomes Study (DPPOS) Participants over 20 Years  
Presenting Author: Emily Kobayashi, BS
12:45 p.m.-1:45 p.m.  
(continued)

Oral Presentations

Theme Area: Acute and Chronic Complications
Session Number: AC-OR13-1

Innovative Approaches in Diagnosing and Managing Diabetic Neuropathy (With ADA Presidents' Select Abstract Presentation) *(Includes Livestream)*

Room: W307

Chair: Kara R. Mizokami-Stout, MD

12:45 p.m.-1:00 p.m.

9-OR  ADA Presidents' Select Abstract: Targeting Inflammation with Salsalate in Type 1 Diabetes Neuropathy (TINSAL–T1DN Trial)

Presenting Author: Lynn Ang, MD

1:00 p.m.-1:15 p.m.

10-OR  Diffusion Tensor Imaging and T2 Mapping of the Tibial Nerve Can Detect Nerve Damage in Type 2 Diabetes

Presenting Author: Hyeong-Kyu Park, MD

1:15 p.m.-1:30 p.m.

11-OR  Combined DPNCheck and SUdoscan as a Screening Tool for DPN—The Sheffield Prospective Study

Presenting Author: Mohummad Shaan Goonoo, MBBS, MRCPE

12-OR  WITHDRAWN
12:45 p.m.-1:45 p.m.
(continued)

**Oral Presentations**  
*Theme Area: Acute and Chronic Complications*

**Session Number: AC-OR15-1**

**Innovations in Diabetic Eye Care—Advancements, Therapeutic Strategies, and Disease Associations**

*Room: W208*

**Chair: Renu A. Kowluru, MS, PhD**

---

12:45 p.m.-1:00 p.m.

13-OR  
**Relationship between Visit-to-Visit Variability of HbA1c and Development/Progression of Diabetic Retinopathy**

Presenting Author: Masahiro Yuki, MD

---

1:00 p.m.-1:15 p.m.

14-OR  
**Autonomous Artificial Intelligence Diabetic Eye Exams Mitigates Disparities in Screening Completion for Youth**

Presenting Author: T.Y. Alvin Liu, MD

---

1:15 p.m.-1:30 p.m.

15-OR  
**Diabetic Retinopathy (DR) Is Associated with Markers of Alzheimer's Disease (AD) in Type 1 Diabetes (T1D)**

Presenting Author: Meghan E. Pauley, DO

---

1:30 p.m.-1:45 p.m.

16-OR  
**Preadministration of SGLT2 Inhibitor Reduces Frequency of Anti-VEGF Agent Administration in Patients with Mild Diabetic Macular Edema—A Multicenter Randomized Controlled Open-Label Trial**

Presenting Author: Ryoichi Ishibashi, MD, PhD
FRIDAY, JUNE 21, 2024

12:45 p.m.-1:45 p.m.
(continued)

Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR04-1
Exploring the Impact of Food/Food Additives on Insulin Sensitivity and Postprandial Glucose
(With ADA Presidents' Select Abstract Presentation)
Room: W315
Chair: Lorena Drago, MS, RDN, CDN, CDCES

12:45 p.m.-1:00 p.m.
17-OR ADA Presidents' Select Abstract: Oral Bisphenol A Administration Decreased Peripheral Insulin Sensitivity in Healthy Adults
Presenting Author: Todd Hagobian, PhD

1:00 p.m.-1:15 p.m.
18-OR The Effect of a Dietary Intervention on Insulin Sensitivity in Type 1 Diabetes and the Role of Dietary Advanced Glycation End-Products—A 12-Week Randomized Clinical Trial
Presenting Author: Hana Kahleova, MD, PhD, MBA

1:15 p.m.-1:30 p.m.
19-OR Sucralose Consumption Decreases Insulin Sensitivity and Modifies the Gut Microbiota in Healthy Individuals
Presenting Author: Alonso Romo-Romo, PhD

1:30 p.m.-1:45 p.m.
20-OR Digital Twin (DT) Technology in Type 2 Diabetes Remission and Glycemic Improvement—Eighteen Months Results from a Randomized Controlled Trial
Presenting Author: Paramesh Shamanna, MD
12:45 p.m.-1:45 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Session Number: BM-OR06-1**  
**Tools for Health Care Professionals That Assist in Personalizing Care**  
Room: W314  
Chair: Curtis L. Triplett, PharmD, CDCES

12:45 p.m.-1:00 p.m.

21-OR **Use of Electronic Best Practice Advisories (BPA) to Increase Referral to Diabetes Self-Management Education and Support (DSMES) Services**  
Presenting Author: Laura A. Young, MD, PhD

1:00 p.m.-1:15 p.m.

22-OR **Burden of Diabetes Survey—Perspectives from People Living with Diabetes in the United States**  
Presenting Author: Kirsten Yehl, MS, MLIS

1:15 p.m.-1:30 p.m.

23-OR **Streamlining Diabetes Device Integration into the Electronic Health Record**  
Presenting Author: Roma Gianchandani, MD

1:30 p.m.-1:45 p.m.

24-OR **Inaccurate and Unaware—Perceived and Objective Diabetes Knowledge among Adults with Type 2 Diabetes**  
Presenting Author: Colter K. Clayton, BS
12:45 p.m.-1:45 p.m.  
(continued)

Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR08-1
Back to the Basics (Sciences) of Exercise and Diabetes
Room: W304 E-H
Chair: John R. Ussher, PhD

12:45 p.m.-1:00 p.m.
25-OR Two Weeks of Exercise Alters Neuronal Extracellular Vesicle Insulin Signaling in Adults with Prediabetes
Presenting Author: Steven K. Malin, PhD

1:00 p.m.-1:15 p.m.
26-OR METTL3 Is Essential for Exercise-Induced Cardiac Benefits in Diabetic Cardiomyopathy
Presenting Author: Jiayi Kang, BS

1:15 p.m.-1:30 p.m.
27-OR Effect of Acute Exercise and Exercise Training on the Ability of Insulin to Clear Branched-Chain Amino Acids from Plasma in Obesity and Type 2 Diabetes
Presenting Author: Pauline M. Møller, MS

1:30 p.m.-1:45 p.m.
28-OR Posttranslational Modifications in Skeletal Muscle Direct Divergent Metabolic Responses to Different Exercise Training Modes
Presenting Author: Mark W. Pataky, PhD
12:45 p.m.-1:45 p.m.  
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics  
Session Number: CT-OR03-1  
Practicable Methods to Improve Metabolic Parameters  
Room: W311  
Chair: Michael J. Haller, MD

12:45 p.m.-1:00 p.m.  
29-OR Analysis of Fib-4 Index Changes in Adults with Type 2 Diabetes in an Effective Comprehensive Diabetes Care Program  
Presenting Author: Rubén Silva-Tinoco, MD

1:00 p.m.-1:15 p.m.  
30-OR Diabetes Rescue, Engagement, and Management (D-REM)—Results of a Pragmatic Clinical Trial of a Community Paramedicine Program to Improve Diabetes Care  
Presenting Author: Rozalina G. McCoy, MD, MS

1:15 p.m.-1:30 p.m.  
31-OR ROCKET Type 1 Diabetes—Launching Diabetes Self-Management Habits in Youth with New-Onset Type 1 Diabetes  
Presenting Author: Guido Alarcon, MD

1:30 p.m.-1:45 p.m.  
32-OR First Impact on A1C of Medically Underserved Patients with Type 2 Diabetes Using a Hybrid Chronic Care Model  
Presenting Author: Joyce Y. Lee, PharmD, APh, FCCP, BCPS, BCACP, CDCES
12:45 p.m.-1:45 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR11-1
Diabetes Potpourri
Room: W415C (Valencia Ballroom)
Chair: Tamara Spaic, MD

12:45 p.m.-1:00 p.m.
33-OR  The Risk of Heart Failure Hospitalization after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk
Presenting Author: Helen Tesfaye, PharmD, MSc

1:00 p.m.-1:15 p.m.
34-OR  The Effect of Combined Activin A and Myostatin Blockade on Body Composition—A Phase 1 Trial
Presenting Author: Dinko Gonzalez Trotter, PhD

1:15 p.m.-1:30 p.m.
35-OR  Lantidra, First FDA Approved Cellular Therapy to Treat Type 1 Diabetes
Presenting Author: Yi Li, PhD

1:30 p.m.-1:45 p.m.
36-OR  Modulation of Cardiorenal Benefits for GLP-1RAs Treatment by GLP1R Genetic Variants
Presenting Author: Qiaochu Xue, PhD, MPH
12:45 p.m.-1:45 p.m.  
(continued)

**Oral Presentations**

*Theme Area: Clinical Diabetes/Therapeutics*

**Session Number: CT-OR16-1**

**New Technology—The Inpatient Setting (Includes Livestream)**

Room: W414  
Chair: Jayachidambaram Ambalavanan, MD

12:45 p.m.-1:00 p.m.

**37-OR**  
**Effectiveness of Continuous Glucose Monitoring on Short-Term In-Hospital Mortality among Frail Critically Ill Patients with COVID-19—An Exploratory, Prospective, Randomized, Open-Label, Parallel, Single-Center, Randomized Clinical Trial**  
Presenting Author: Yun Shen, Doctor

1:00 p.m.-1:15 p.m.

**38-OR**  
**Implementation of an EHR-Integrated Hospital-Wide CGM Protocol for Insulin Dosing**  
Presenting Author: Susan M. Seav, MD

1:15 p.m.-1:30 p.m.

**39-OR**  
**Real-Time Continuous Glucose Monitoring—Guided Glucose Management in Hospitalized Patients with Diabetes Receiving Short-Term Continuous Subcutaneous Insulin Infusion—A Randomized Clinical Trial**  
Presenting Author: Yaxin Wang, MD

1:30 p.m.-1:45 p.m.

**40-OR**  
**The Association of Continuous Glucose Monitoring Metrics with Hospital Related Clinical Outcomes**  
Presenting Author: Kristen L. Flint, MD
12:45 p.m.-1:45 p.m.  
(continued)

Oral Presentations  
Theme Area: Insulin Action/Molecular Metabolism  
Session Number: IA-OR05-1  
Secreted Factors and Insulin Action  
Room: W304 A-D  
Chair: Katrin Svensson, PhD

12:45 p.m.-1:00 p.m.  
41-OR Insulin Regulates Exosomal MicroRNA Secretion from Adipocytes Completing a Novel Feedback Loop  
Presenting Author: Marsel Lino, PhD

1:00 p.m.-1:15 p.m.  
42-OR A Small Intestinal Bile Acid Modulates the Gut Microbiome to Improve Glucose Regulation following Bariatric Surgery  
Presenting Author: Yingjia Chen, PhD

1:15 p.m.-1:30 p.m.  
43-OR Endothelial Cell Regeneration by Secretome Secreted from P53-Silenced Bone Marrow-Derived BMSCs  
Presenting Author: Seshagiri Rao Nandula, PhD

1:30 p.m.-1:45 p.m.  
44-OR Cell Intrinsic Alterations in miRNA Expression and Secretion in Muscle in Type 2 Diabetes  
Presenting Author: Allah Nawaz, PhD
**FRIDAY, JUNE 21, 2024**

12:45 p.m.-1:45 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Obesity/Integrated Physiology*  
*Session Number: IP-OR06-1*  
**New Frontier in Immunometabolism**  
Room: W308  
Chair: Pingwen Xu, PhD

45-OR **WITHDRAWN**

12:45 p.m.-1:00 p.m.

46-OR **Palmitic Acid Coordinates Impaired Adipose Tissue ICOS-high Treg Immunosuppression and Systemic Metabolic Disturbance during Obesity**  
Presenting Author: Weitong Su, Bachelor’s Degree

1:00 p.m.-1:15 p.m.

47-OR **OPA1 Reprogrammes Macrophage Metabolism to Enforce Tolerance of Inflammation in Obesity**  
Presenting Author: Daixi Wang, PhD

1:15 p.m.-1:30 p.m.

48-OR **Novel Lipidated Interleukin-22 Reduces Body Weight and Improves Glucose Homeostasis in Mice**  
Presenting Author: Martijn van de Bunt, MD, DPhil
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.

**Ask the Expert**
*Theme Area: Clinical Diabetes/Terapeutics*
*Session Number: CT-AE14-1.5*

**How Will Artificial Intelligence Change Diabetes Clinical Practice?** *(Includes Livestream)*
Room: W320 (Chapin Theater)
Chair: Edward C. Chao, DO

- 2:00 p.m.-2:20 p.m. *Artificial Intelligence in Health Care and the Future of Diabetes Data Science*
  Boris Kovatchev, PhD

- 2:20 p.m.-2:40 p.m. *Artificial Intelligence and the Future of Diabetes Devices*
  Peter G. Jacobs, PhD

- 2:40 p.m.-3:00 p.m. *Artificial Intelligence and the Future of the Multidisciplinary Team*
  Mudassir M. Rashid, PhD

- 3:00 p.m.-3:30 p.m. *Question and Discussion Period*
2:00 p.m.-3:30 p.m.
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR10-1.5
Emerging Molecular Mechanisms of ASCVD Progression in Cardiometabolic Disease (With Edwin Bierman Award Lecture) *(Includes Livestream)*
Room: W307
Chair: Helmy Siragy, MD

2:00 p.m.-2:30 p.m.
**Edwin Bierman Award Lecture**

*Diabetes and Cardiovascular Disease—The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications*
Darren K. McGuire, MD, MHSc, FAHA, FACC, FESC

2:30 p.m.-2:45 p.m.
**49-OR**
GPSM1 Regulates Atherosclerosis Progression by Controlling Macrophage Chemotaxis through PKA/KLF4/PMP22-MAPK Pathway
Presenting Author: Yuemei Zhang, PhD

2:45 p.m.-3:00 p.m.
**50-OR**
Metabolic Dysfunction Attenuates D-dopachrome Tautomerase (DDT) Expression in the Heart—A Key Mechanism Exacerbates Myocardial Post-ischemic Injury
Presenting Author: Lisha Li, MSc, MD

3:00 p.m.-3:15 p.m.
**51-OR**
Vascular Sorbs2 Deficiency Is an Independent Risk of Vascular Complications in Diabetes
Presenting Author: Tong Lu, MD, PhD
2:00 p.m.-3:30 p.m. (continued)

**Oral Presentations**

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

**Session Number: BM-OR03-1.5**

**Exploring Dimensions of Diversity in Diabetes Distress (With Richard R. Rubin Award Lecture)**

(Includes Livestream)

Room: W415B (Valencia Ballroom)

Chair: Elizabeth A. Beverly, PhD

2:00 p.m.-2:30 p.m.

**Richard R. Rubin Award Lecture**

*Richard R. Rubin Award Lecture—Life Lessons and Diabetes Research*

Paula M. Trief, PhD

2:30 p.m.-2:45 p.m.

**52-OR**  Emotional Distress and Insulin Initiation in the GRADE Trial

Presenting Author: Caroline A. Presley, MD, MPH

2:45 p.m.-3:00 p.m.

**53-OR**  Individual Sources of Diabetes Distress—A Precision Mental Health Approach Combining Ecological Momentary Assessment and Continuous Glucose Monitoring

Presenting Author: Dominic Ehrmann, PhD

3:00 p.m.-3:15 p.m.

**54-OR**  Feasibility of a Multidisciplinary Pilot Intervention for Parent/Caregiver Diabetes Distress

Presenting Author: Einas Alkhatib, MD

3:15 p.m.-3:30 p.m.

**55-OR**  Diabetes Distress among Persons Living with Latent Autoimmune Diabetes of Adults in the Canadian Cohort BETTER—A Cross-Sectional Study

Presenting Author: Maya Nehme, BSc
2:00 p.m.-3:30 p.m. (continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR01-1.5
Screening for and Delaying Vascular Complications
Room: W315
Chair: Mohammed K. Ali, MD, MSc, MBA

2:00 p.m.-2:15 p.m.
56-OR Impact of Delays in Statin Therapy Due to Statin Nonacceptance on Cardiovascular Outcomes in Patients with Diabetes
Presenting Author: Alexander Turchin, MD, MS

2:15 p.m.-2:30 p.m.
57-OR Enhancing Diabetic Eye Disease Detection through Autonomous Artificial Intelligence Implementation in a Federally Qualified Health Center
Presenting Author: Milibeth Castro, MPH

2:30 p.m.-2:45 p.m.
58-OR Screening for Diabetic Retinopathy Increases by 32% with Education and Intervention Program in Primary Care
Presenting Author: Lesley Simon, BA

2:45 p.m.-3:00 p.m.
59-OR Improving Diabetic Kidney Disease Screening in a Veterans Affairs Primary Care Clinic
Presenting Author: Kristina P. Frangella, PharmD, BCPS, CDE, BCACP

3:00 p.m.-3:15 p.m.
60-OR Implementing a Machine-Learning Model to Predict Risk of Chronic Kidney Disease (CKD) Progression
Presenting Author: Thomas Ferguson, MSc

3:15 p.m.-3:30 p.m.
61-OR Effectiveness of Telemedicine plus Conventional Care vs. Conventional Care Alone in Reducing Complications of Diabetes—A Pilot Study
Presenting Author: Jothydev Kesavadev, MD, FRCP, FACP, FACE
2:00 p.m.-3:30 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-OR04-1.5*

**Novel Insights from CGM Use during Pregnancy**  
*Room: W208*  
*Chair: Amy M. Valent, DO, MCR*

2:00 p.m.-2:15 p.m.  
**62-OR**  
Continuous Glucose Monitoring in Pregnancies with Type 1 Diabetes—A Retrospective Study  
Presenting Author: Stephanie A. Fisher, MD, MPH

2:15 p.m.-2:30 p.m.  
**63-OR**  
Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes  
Presenting Author: Zoey Li, MS

2:30 p.m.-2:45 p.m.  
**64-OR**  
Continuous Glucose Monitoring among Pregnant Individuals with Glucose Intolerance  
Presenting Author: Rachel D. Gordon, MD

2:45 p.m.-3:00 p.m.  
**65-OR**  
Continuous Glucose Monitoring Metrics and Suboptimal Pregnancy Outcomes in Women with Gestational Diabetes—Secondary Analysis of the DiGest Trial  
Presenting Author: Claire L. Meek, MB, ChB, MRCP, FRCPath, PhD

3:00 p.m.-3:15 p.m.  
**66-OR**  
Using Continuous Glucose Monitoring to Identify Neonatal Hypoglycemia following Gestational Diabetes—The DiGest Newborn Study  
Presenting Author: Danielle Jones, BSc, MSc

3:15 p.m.-3:30 p.m.  
**67-OR**  
Postprandial Glycemic Patterns throughout Uncomplicated Pregnancies  
Presenting Author: Anders L. Carlson, MD
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR07-1.5
New Approaches to Prevent or Reverse Diabetes
Room: W415C (Valencia Ballroom)
Chair: Catherine Kim, MD, MPH

2:00 p.m.-2:15 p.m.
68-OR Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention
Presenting Author: Maria J. Redondo, MD, PhD, MPH

2:15 p.m.-2:30 p.m.
69-OR Preclinical Studies Indicate That Inspanin Is a New Class of Antidiabetes Agent
Presenting Author: Nikhil Dhurandhar, PhD

2:30 p.m.-2:45 p.m.
70-OR PROTECT Per-Protocol Analysis—Preserving β-Cell Function in Children and Adolescents with Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)
Presenting Author: Kevan C. Herold, MD

2:45 p.m.-3:00 p.m.
71-OR Rates of Remission and Metabolic Responses in Data-Driven High-Risk Prediabetes Clusters
Presenting Author: Sarah Katzenstein, MD

3:00 p.m.-3:15 p.m.
72-OR Mechanisms of Prediabetes Remission in People with Weight Gain after Lifestyle Intervention
Presenting Author: Arvid Sandforth, MD

3:15 p.m.-3:30 p.m.
73-OR The Plant-Based Substance Totum-63 (T63) Reduces Fasting Plasma Glucose and HbA1c in People with Prediabetes or Type 2 Diabetes (T2D)—A 24-Week Multicenter Randomized Controlled Trial (REVERSE-IT)
Presenting Author: Andre Marette, PhD
2:00 p.m. - 3:30 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-OR13-1.5*

**New Technology—What’s New? (With ADA Presidents’ Select Abstract Presentation)**  
*Room: W311*  
*Chair: Chlodys Johnstone, PA-C*

2:00 p.m. - 2:15 p.m.

**74-OR**  
ADA Presidents’ Select Abstract: CGM Metrics from Five Studies Identify Participants at High Risk of Imminent Type 1 Diabetes (T1D) Development  
*Presenting Author: Peter Calhoun, PhD*

2:15 p.m. - 2:30 p.m.

**75-OR**  
In-Silico Replay of Insulin Degludec and Liraglutide Clinical Trial Data in Subjects with Type 2 Diabetes  
*Presenting Author: Mohammadreza Ganjirjenaki, Bachelor’s Degree*

2:30 p.m. - 2:45 p.m.

**76-OR**  
Diabetes Technology and Waste—A Real-World Study in a Specialized Practice in Germany  
*Presenting Author: Lutz Heinemann, PhD*

2:45 p.m. - 3:00 p.m.

**77-OR**  
Time in Range Is Associated with Glucagon/C-Peptide Index Ratio in Type 2 Diabetes Patients  
*Presenting Author: Miki Kamigishi, MD*

3:00 p.m. - 3:15 p.m.

**78-OR**  
Breath Acetone Correlates with Capillary Beta Hydroxybutyrate in Type 1 Diabetes  
*Presenting Author: Kai Jones, MD*

3:15 p.m. - 3:30 p.m.

**79-OR**  
A Novel Decision Support System for Automated Adaptations of Insulin Injections in Type 1 Diabetes—A Randomized Controlled Trial  
*Presenting Author: Alessandra Kobayati, BSc, PhD Candidate*
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Epidemiology/Genetics*  
*Session Number: EG-OR01-1.5*

**Diabetes and the Liver—A Canary in the Coal Mine**  
Room: W207  
Chair: Justin Echouffo Tcheugui, MD, PhD

2:00 p.m.-2:15 p.m.  
80-OR  UNABLE TO ATTEND

2:15 p.m.-2:30 p.m.  
81-OR  Comparison of Screening Pathways of Advanced Fibrosis Due to MASLD in Diabetology  
Presenting Author: Cyrielle Caussy, MD, PhD

2:30 p.m.-2:45 p.m.  
82-OR  Association of Diabetic Complications and Various Comorbidities with Major Adverse Cardiovascular Events in Type 2 Diabetes and Their Development over Time—A Danish Registry-Based Case-Control Study  
Presenting Author: Nicklas H. Rasmussen, MD, PhD

2:45 p.m.-3:00 p.m.  
83-OR  Metabolic Dysfunction—Associated Steatotic Liver Disease and Nonalcoholic Fatty Liver Disease Have Similar Clinical Profiles and Mortality  
Presenting Author: Zobair Younossi, MD, MPH

3:00 p.m.-3:15 p.m.  
84-OR  Performance of FIB-4 Score in Predicting Mortality among Patients with Nonalcoholic  
Presenting Author: Zobair Younossi, MD, MPH

3:15 p.m.-3:30 p.m.  
85-OR  The Impact of Type 2 Diabetes (T2D) on the Outcomes of Liver Transplantation in the United States from 2007–2022  
Presenting Author: Zobair Younossi, MD, MPH
Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-OR01-1.5
Adipocyte Differentiation and Function
Room: W308
Chair: Phillip J. White, PhD

86-OR  WITHDRAWN

2:00 p.m.-2:15 p.m.
87-OR  A PKA to mTORC1 Signaling Axis Controls Metabolic Homeostasis via Phosphorylation of Raptor
Presenting Author: Fubiao Shi, PhD

2:15 p.m.-2:30 p.m.
88-OR  Glucose Regulation of Adipose Tissue Browning by CBP/p300 and HDAC3 Mediated Reversible Acetylation of CREBZF
Presenting Author: Yu Li, PhD

2:30 p.m.-2:45 p.m.
89-OR  UNABLE TO ATTEND

2:45 p.m.-3:00 p.m.
90-OR  Neddylation Targets Cullin 3 to Regulate Adipocyte Differentiation
Presenting Author: Hongyi Zhou, PhD

3:00 p.m.-3:15 p.m.
91-OR  Selenite-Induced Glutathione Peroxidase 3 In the Control of Insulin Receptor Expression in Adipocytes
Presenting Author: Robert Hauffe, PhD
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.  
(continued)

**Oral Presentations**  
*Theme Area: Immunology/Beta-Cell Replacement*  
*Session Number: IBC-OR01-1.5*

**Immune Features of Immune Therapy and Evolution—Fickle or Fixed?**  
Room: W304 A-D  
Chair: Cate Speake, PhD

2:00 p.m.-2:15 p.m.  
92-OR **Defining Type 1 Diabetes Endotypes**  
Presenting Author: Amina Bedrat, PhD

2:15 p.m.-2:30 p.m.  
93-OR **Clonal Expansion of Islet Reactive CD4 T-Cells with Early Disease Progression in Type 1 Diabetes**  
Presenting Author: Karen Cerosaletti, PhD

2:30 p.m.-2:45 p.m.  
94-OR **Pathogenic Action of GAD65 Autoantibodies on Islet Function in Type 1 Diabetes**  
Presenting Author: Ian Sweet, PhD

2:45 p.m.-3:00 p.m.  
95-OR **Diurnal Variation of Islet Autoantibodies in Established Type 1 Diabetes**  
Presenting Author: Linda A. DiMeglio, MPH, MD

3:00 p.m.-3:15 p.m.  
96-OR **Pancreatic Adverse Events and Mortality in Patients with Immune Checkpoint Inhibitor–Associated Diabetes Mellitus—A 10-Year Follow-up Study**  
Presenting Author: Shafaq Raza Rizvi, MBBS

3:15 p.m.-3:30 p.m.  
97-OR **Preclinical Characterization of MTX-101, a Novel KIRxCD8 Targeting Bispecific CD8 Treg Modulator**  
Presenting Author: Courtney Crane, PhD
2:00 p.m.-3:30 p.m.
(continued)

**Oral Presentations**

*Theme Area: Islet Biology/Insulin Secretion*

*Session Number: IB-OR01-1.5*

**Fueling the Fire—Islet Stimulus–Secretion Coupling**

Room: W206

Chair: Yumi Imai, MD

2:00 p.m.-2:15 p.m.
**98-OR**  
**β-Cell Dysfunction and Mitochondrial Loss Occur Independently of Insulitis in Type 1 Diabetes Pathogenesis**  
Presenting Author: Mollie Huber, BS

2:15 p.m.-2:30 p.m.
**99-OR**  
**SLC7A2-Dependent Arginine Transport in α-Cells Signals Arginine tone to Regulate Insulin Secretion**  
Presenting Author: Jade Stanley, BS

2:30 p.m.-2:45 p.m.
**100-OR**  
**Investigating the Mechanisms of Cross Talk between Endocrine Beta Cells and Pericytes in Pancreatic Islets**  
Presenting Author: Luciana Mateus Goncalves, PhD

2:45 p.m.-3:00 p.m.
**101-OR**  
**Revelations in Regulation—Sodium/Potassium ATPase Subunit Control of Beta-Cell Cation Handling and Insulin Secretion**  
Presenting Author: Matthew Dickerson, PhD

3:00 p.m.-3:15 p.m.
**102-OR**  
**A Novel Strategy for Detecting In Vivo Functional β-Cells Using Positron Emission Tomography (PET) Imaging**  
Presenting Author: Junfeng Li, PhD

3:15 p.m.-3:30 p.m.
**103-OR**  
**Signaling Mechanisms Underlying Islet Compensation in a Novel Mouse Model of β-Cell Replication Deficiency**  
Presenting Author: Hannah R. Foster, PhD
FRIDAY, JUNE 21, 2024

2:00 p.m.-3:30 p.m.
(continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR01-1.5
Actions of Incretins in the Brain and Beyond (Includes Livestream)
Room: W414
Chair: Daisy Duan, MD

2:00 p.m.-2:15 p.m.
104-OR State-Dependent Activity in Hindbrain Glucagon-Like Peptide 1-Producing Neurons Regulates Consummatory and Valence Behavior through Functionally Interconnected Hypothalamic and Limbic Circuits
Presenting Author: James A. Hardaway, PhD

2:15 p.m.-2:30 p.m.
105-OR Single-Cell Multiomic Analysis of the Effect of GIP and GIP-1 Mono- and Multi-agonism on the Hypothalamus and Hindbrain
Presenting Author: Robert M. Gutgesell, HBSc, MSc

2:30 p.m.-2:45 p.m.
106-OR Semaglutide Reduces Tumor Burden in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH with Advanced Fibrosis and HCC
Presenting Author: Henrik H. Hanse, PhD

2:45 p.m.-3:00 p.m.
107-OR Brain GLP-1R Is Likely Required for Peripheral Liraglutide Treatment on Stimulating Hepatic FGF21
Presenting Author: Jia Nuo Feng, BS (Hons)

3:00 p.m.-3:15 p.m.
108-OR Insulin Resistance Is Associated with Alterations in the Dynamics of Incretin Secretion
Presenting Author: Gianfranco Di Giuseppe, MD

3:15 p.m.-3:30 p.m.
109-OR GIP Acutely Blunts Insulin- and GLP-1-Induced Muscle Microvascular Perfusion
Presenting Author: Jia Liu, PhD
2:00 p.m.-3:30 p.m. (continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR05-1.5
Emerging New Players in Metabolic Regulation
Room: W314
Chair: Meilian Liu, PhD

2:00 p.m.-2:15 p.m.
110-OR  Paternal Metabolism Modulates the Metabolome of Offspring during the Early Embryonic Period
Presenting Author: Rafael Ferraz-Bannitz, PhD

2:15 p.m.-2:30 p.m.
111-OR  Vascular Endothelium-Specific ROCK2 Deficiency Inhibits the Progression of Obesity via Adipocyte Browning
Presenting Author: Shinji Ohashi, MD

2:30 p.m.-2:45 p.m.
112-OR  A Novel Function of Endothelial Insulin-Like Growth Factor 1 Receptor—Regulation of Gastrointestinal Microbiota as a Defensive Mechanism against Obesity-Induced Metabolic Dysfunction
Presenting Author: Natalie J. Haywood, PhD

2:45 p.m.-3:00 p.m.
113-OR  Lipocalin-2, a Mitokine That Mediates White-to-Brown Fat Cross Talk
Presenting Author: Fenfen Wang, PhD

3:00 p.m.-3:15 p.m.
114-OR  Proteome-Wide Analysis of USP2 Substrates Revealed Its Role in Thermogenesis via Stabilization of EBF2
Presenting Author: Yuejie Xu, Doctor

3:15 p.m.-3:30 p.m.
115-OR  Adipose m6A Reader YTHDF2 Regulates White Adipose Tissue Growth and Metabolism
Presenting Author: Ruoyu Zhou, MD
3:45 p.m.-5:15 p.m.

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY01-1.5
Systemic Medications for Diabetic Retinopathy—Protective and Risk Factors
Room: W208
Chair: Thomas W. Gardner, MD, MS
3:45 p.m.-3:55 p.m. Introduction
3:55 p.m.-4:15 p.m. The Effect of Fenofibrate on Progression of Diabetic Retinopathy—Results from the LENS Trial
David Preiss, MBChB, MRCP, FRCP, PhD
4:15 p.m.-4:30 p.m. Role of Systemic Pharmacotherapy in the Prevention and Management of Diabetic Macular Edema
Andrew J. Barkmeier, MD
4:30 p.m.-4:45 p.m. The FAME 1 Eye Trial
Alicia Jenkins, MBBS, MD, FRACP, FRCP
4:45 p.m.-5:00 p.m. GLP-1 Receptor Agonist and Diabetic Retinopathy Worsening
Satish K. Garg, MD
5:00 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY07-1.5
Sex and Gender Dimorphism in Cardiovascular Disease Risk in Diabetes
Room: W308
Chair: Wendy L. Bennett, MD, MPH
3:45 p.m.-4:05 p.m. Sex and Gender-Specific Cardiovascular Disease Risk Factors
Wendy L. Bennett, MD, MPH
4:05 p.m.-4:25 p.m. Is High-Density Lipoprotein a Risk Factor for Men?
Ernst J. Schaefer, MD
4:25 p.m.-4:45 p.m. Impact of Biological and Chromosomal Sex on Postprandial Lipid Metabolism
Karen Reue, PhD
4:45 p.m.-5:05 p.m. Sex Differences in Lipoprotein Metabolism
John M. Stafford, MD, PhD
5:05 p.m.-5:15 p.m. Question and Discussion Period
FRIDAY, JUNE 21, 2024

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY17-1.5
Joint Diabetes Care/Centers for Disease Control and Prevention Symposium—Pressure Points and Future Directions in the Prevention of Acute and Chronic Diabetes-Related Complications (Includes Livestream)
Room: W307
Co-Chairs: Christopher S. Holliday, PhD, MPH, MA, FACHE and Steven E. Kahn, MB, ChB
3:45 p.m.-4:05 p.m. Trends and Inequalities in Diabetes-Related Complications among U.S. Adults with Diabetes, 2000–2020
Ryan Saelee, MPH, PhD
4:05 p.m.-4:25 p.m. Ameliorating Care Fragmentation to Prevent Diabetes-Related Microvascular Complications
Francisco J. Pasquel, MD, MPH
4:25 p.m.-4:45 p.m. Advancing Cardiometabolic Health and Reducing Cardiovascular Risk in Diabetes through Academic–Community–Government–Industry Partnerships
Joshua J. Joseph, MD, MPH, FAHA
4:45 p.m.-4:55 p.m. Discussant
Shivani A. Patel, PhD
4:55 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY05-1.5
Consensus or Controversy? Hot Topics in Nutrition 2024
Room: W314
Chair: Holly J. Willis, PhD, RDN, CDCES
3:45 p.m.-4:05 p.m. The WHO Said WHAT? Use of Nonnutritive Sweeteners for Weight Management, Prediabetes, and Diabetes
Katherine Appleton, PhD, RNutr
4:05 p.m.-4:25 p.m. Does the Gut Rule? Influence of the Microbiome on Diabetes and Obesity
Abby Johnson, PhD, RD
4:25 p.m.-4:45 p.m. Counting Calories or Counting the Hours—Time-Restricted Eating
Krista Varaday, PhD
4:45 p.m.-5:05 p.m. Protein Quantity, Quality, and Timing for Weight Management and Glycemia
Alpana Shukla, MD
5:05 p.m.-5:15 p.m. Question and Discussion Period
3:45 p.m.-5:15 p.m.
(continued)

Case Studies

Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-CS12-1.5
New Tools, Old Approaches—Rethinking Glucose Monitoring in Real-Life Settings
Room: W311
Chair: Natalie J. Bellini, DNP, FNP-BC, BC-ADM
3:45 p.m.-4:05 p.m. The Time Was Yesterday—Continuous Glucose Monitoring (CGM) in the Inpatient Setting
Eileen R. Faulds, PhD, RN, FNP-BC, CDCES
4:05 p.m.-4:25 p.m. Classroom or Clinic? Continuous Glucose Monitoring (CGM) in the School Setting
Christine March, MD, MS
4:25 p.m.-4:45 p.m. Let Campers (and Counselors) Sleep! Remote Glucose Monitoring at Camp
Jamie R. Wood, MD
4:45 p.m.-5:05 p.m. Continuous Glucose Monitoring (CGM) in Long-Term Care Facilities
Medha Munshi, MD
5:05 p.m.-5:15 p.m. Question and Discussion Period

Symposium

Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY08-1.5
Important Safety Information—Off-Target Effects of New Therapies for Diabetes (Includes Livestream)
Room: W414
Chair: John B. Buse, MD, PhD
3:45 p.m.-4:05 p.m. GLP-1 Receptor Agonists
Tina Vilsbøll, MD, DMSc
4:05 p.m.-4:25 p.m. SGLT2 Inhibitors
Ronald M. Goldenberg, MD, FRCPC, FACE
4:25 p.m.-4:45 p.m. New Insulin Formulations
Anne L. Peters, MD
4:45 p.m.-5:05 p.m. Fixed-Ratio Insulin Combinations
Liana K. Billings, MD, MMSc
5:05 p.m.-5:15 p.m. Question and Discussion Period
FRIDAY, JUNE 21, 2024

3:45 p.m.-5:15 p.m.
(continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY33-1.5
Standards of Care 2024 Updates and Cost of Diabetes in United States
Room: W315
Chair: Nuha El Sayed, MD, MMSc
3:45 p.m.-4:30 p.m. Team-Based Care
   Nuha El Sayed, MD, MMSc
   Jason L. Gaglia, MD, MMSc
   Grazia Aleppo, MD, FACE, FACP
   Dennis Bruemmer, MD, PhD
   Ildiko Lingvay, MD, MPH, MSCS
   Nicola Napoli, MD, PhD
4:30 p.m.-4:45 p.m. Economic Costs of Diabetes in the United States
   Nuha El Sayed, MD, MMSc
   Raveendhara Bannuru, MD, PhD, FAGE
4:45 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY49-1.5
SURMOUNT-OSA Trial Results and Potential Role of Tirzepatide in Treating Obesity-Related Obstructive Sleep Apnea (Includes Livestream)
Room: W320 (Chapin Theater)
Co-Chairs: Ania M. Jastreboff, MD, PhD and Atul Malhotra, MD
3:45 p.m.-4:00 p.m. Cardiometabolic Consequences of OSA—Towards Personalized Treatment
   Esra Tasali, MD
4:00 p.m.-4:15 p.m. Current Therapeutic Landscape for Treating Sleep Apnea and Potential Role of Incretins
   Vaishnavi Kundel, MD, MS
4:15 p.m.-4:25 p.m. Tirzepatide and SURMOUNT-OSA—Rationale, Hypotheses, and Study Design
   Richard J. Schwab, MD
4:25 p.m.-4:45 p.m. SURMOUNT-OSA—Efficacy and Safety
   Atul Malhotra, MD
4:45 p.m.-4:55 p.m. Putting SURMOUNT-OSA Results in Context, and Implications Regarding Treatment of Patients with Obesity-Related OSA
   Louis J. Aronne, MD, FACP, DABOM
4:55 p.m.-5:15 p.m. Question and Discussion Period
Symposium
Theme Area: Epidemiology/Genetics
Session Number: EG-SY02-1.5
United States Veterans and Diabetes—Not Gone and Not Forgotten
Room: W207
Chair: Dina H. Griauzde, MD, MSc
3:45 p.m.-4:05 p.m. Diabetes and Complications in Veterans
   Elizabeth M. Litkowski, PhD
4:05 p.m.-4:25 p.m. Mental Health and Diabetes in Veterans
   Naomi Kane, PhD
4:25 p.m.-4:45 p.m. Million Veterans Program
   Themistocles (Tim) Assimes, MD, PhD
4:45 p.m.-5:05 p.m. Telehealth Interventions to Improve Outcomes in Veterans with Diabetes
   Matthew J. Crowley, MD, MHS
5:05 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-SY05-1.5
Joint ADA/IPITA Symposium—Clinical Beta-Cell Replacement Therapy Today (Includes Livestream)
Room: W415B (Valencia Ballroom)
Co-Chairs: Michael R. Rickels, MD, MS and Melena Bellin, MD
3:45 p.m.-4:05 p.m. Evaluation of the Patient with Diabetes for Beta-Cell Replacement
   Anna Lam, MD, MSc
4:05 p.m.-4:25 p.m. The Psychological Impact of Islet or Pancreas Transplantation
   Jane Speight, MSc, PhD, CPsychol, FBPsS
4:25 p.m.-4:45 p.m. Monitoring and Treatment of Recipients for Rejection or Type 1 Diabetes Recurrence
   Michiel Nijhoff, MD, MSc
4:45 p.m.-5:05 p.m. Update on Clinical Trials Using Stem-Cell Replacement
   Piotr Witkowski, MD, PhD
5:05 p.m.-5:15 p.m. Question and Discussion Period
FRIDAY, JUNE 21, 2024

3:45 p.m.-5:15 p.m.
(continued)

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-SY03-1.5
The Second Act—Redefining the Signaling Mediators of Glucose Uptake in Muscle
Room: W304 A-D
Chair: Paul M. Titchenell, PhD
3:45 p.m.-4:05 p.m. Control of Glucose Transport by Novel Insulin-Signaling Pathways
   Lykke Sylow, PhD
4:05 p.m.-4:25 p.m. Control of Muscle Glucose Metabolism by the Adipokine Isthmin-1
   Katrin Svensson, PhD
4:25 p.m.-4:45 p.m. Linking Mitochondrial Energetics to Insulin Sensitivity and Glucose Metabolism
   P. Darrell Neufer, PhD
4:45 p.m.-5:05 p.m. Regulation of GLUT4 by TUG Proteins
   Jonathan Bogan, MD
5:05 p.m.-5:15 p.m. Question and Discussion Period

Symposium
Theme Area: Obesity/Integrated Physiology
Session Number: IP-SY07-1.5
CNS Effects of GLP-1RA—Beyond Diabetes and Obesity
Room: W304 E-H
Chair: Janice J. Hwang, MD
3:45 p.m.-4:15 p.m. GLP-1RA in Alcohol Use Disorder
   Lorenzo Leggio, MD, PhD
4:15 p.m.-4:45 p.m. GLP-1RA and Thirst
   Derek Daniels, PhD
4:45 p.m.-5:15 p.m. GLP-1 Actions on Neurodegeneration and Neuroinflammation
   Nigel H. Greig, PhD

Symposium
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-SY02-1.5
Taking a Closer Look—Subcellular Approaches to Islet Biology
Room: W206
Chair: Rafael Arrojo e Drigo, PhD
3:45 p.m.-4:15 p.m. Contributions of the Microtubule Cytoskeleton to Beta-Cell Biology
   Irina Kaverina, PhD
4:15 p.m.-4:45 p.m. Cilia, Microvilli, and Membrane Localized Glycolysis in The Beta Cell
   Matthew J. Merrins, PhD
4:45 p.m.-5:15 p.m. Metabolic Control of Beta-Cell Secretory Capacity
   Samuel B. Stephens, PhD
Beyond Glucose and Weight Reduction—Additional Effects of Incretin-Based Therapies
Room: W415C (Valencia Ballroom)
Chair: Michael A. Nauck, MD

3:45 p.m.-4:00 p.m.
116-OR GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice
Presenting Author: Rajamannar Thennati, PhD

4:00 p.m.-4:15 p.m.
117-OR Effects of Triple-Hormone Receptor Agonist Retatrutide on Lipid Profiling in Participants with Obesity
Presenting Author: Valentina Pirro, PhD

4:15 p.m.-4:30 p.m.
118-OR The Apelin Receptor Agonist Azelaprag Increases Weight Loss in Diet-Induced Obese Mice on Incretin Agonists and Restores Body Composition and Muscle Function to That of Lean Controls
Presenting Author: Paul Rubin, MD

4:30 p.m.-4:45 p.m.
119-OR Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Ultra-Long-Acting GLP-1 Receptor Agonist (ZT002) in Healthy Subjects
Presenting Author: Yuanyuan Zhang, PhD

4:45 p.m.-5:00 p.m.
120-OR Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT-2
Presenting Author: Naveed Sattar, MD, PhD

5:00 p.m.-5:15 p.m.
121-OR Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study
Presenting Author: Rajamannar Thennati, PhD
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m.

**Debate**
*Theme Area: Acute and Chronic Complications*
Session Number: AC-DB05-1
**Sulfonylureas in Type 2 Diabetes Management—Should They Stay or Should They Go? (Includes Livestream)**
Room: W307
Chair: Rozalina G. McCoy, MD, MS

5:30 p.m.-5:45 p.m. *Sulfonylureas Remain Useful Agents in the Management of Type 2 Diabetes*
Elbert S. Huang, MD, MPH, FACP

5:45 p.m.-6:00 p.m. *We Need to Stop Using Sulfonylureas for the Treatment of Type 2 Diabetes*
Deborah J. Wexler, MD, MSc

6:00 p.m.-6:05 p.m. *Rebuttal*
Elbert S. Huang, MD, MPH, FACP

6:05 p.m.-6:10 p.m. *Rebuttal*
Deborah J. Wexler, MD, MSc

6:10 p.m.-6:30 p.m. *Question and Discussion Period*

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
Session Number: CT-SY35-1
**Liver Health in Diabetes (Includes Livestream)**
Room: W320 (Chapin Theater)
Co-Chairs: Mandeep Bajaj, MD and Kenneth Cusi, MD

5:30 p.m.-5:40 p.m. *Introduction, New Nomenclature and Team-Based Care*
Mandeep Bajaj, MD
Kenneth Cusi, MD

5:40 p.m.-5:50 p.m. *Epidemiology/Hepatology*
Zobair Younossi, MD, MPH

5:50 p.m.-6:00 p.m. *Primary Care*
Caroline R. Richardson, MD

6:00 p.m.-6:05 p.m. *Nutrition*
Karen Corbin, PhD, RD

6:05 p.m.-6:10 p.m. *Physical Activity and Exercise*
Elizabeth J. Pekas, PhD

6:10 p.m.-6:20 p.m. *Endocrinology and Obesity*
Michael Roden, MD

6:20 p.m.-6:30 p.m. *Question and Discussion Period*
FRIDAY, JUNE 21, 2024

5:30 p.m.–6:30 p.m.
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR07-1

New Biomarkers to Inform Lipid Therapies in Diabetes (With ADA Presidents' Select Abstract Presentation)
Room: W206
Chair: Laura den Hartigh, PhD

5:30 p.m.–5:45 p.m.
122-OR ADA Presidents' Select Abstract: Lower Plasma Levels of Truncated Apolipoprotein C-I Are Associated with Increased Risk of Diabetes Multiethnic Study of Atherosclerosis
Presenting Author: Juraj Koska, MD, PhD

5:45 p.m.–6:00 p.m.
123-OR MiR103 as a Potential Inhibitor for Dyslipidemia through Modulation of ANGPTL8 Level
Presenting Author: Jehad Abubaker, PhD

6:00 p.m.–6:15 p.m.
124-OR Intervention of Select Lipid Signaling Reduces Type 1 Diabetes Incidence
Presenting Author: Sasanka Ramanadham, PhD

6:15 p.m.–6:30 p.m.
125-OR New Lipid Biomarkers for Worsening Glucose Tolerance in Nondiabetic Relatives of People with Type 2 Diabetes
Presenting Author: Ismail Syed, MS, PhD
5:30 p.m.-6:30 p.m.
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR14-1
Unraveling Molecular Signatures, Biomarkers, and Methods for Neuropathy, Cognitive Decline, and Foot Ulcers
Room: W208
Chair: Rayaz A. Malik, MD, PhD

5:30 p.m.-5:45 p.m.
126-OR Differences of Three-Dimensional Pathology of Dorsal Root Ganglia in Neuropathy of Type 1 and Type 2 Diabetes Mellitus
Presenting Author: Hiroki Mizukami, MD, PhD

5:45 p.m.-6:00 p.m.
127-OR Identification of Exosomal miRNA as a Novel Causal Biomarker for Cognitive Impairment in Type 2 Diabetes Mellitus—Triangulating Evidence from Mendelian Randomization Analyses and Multicenter Cohort
Presenting Author: Sijue Yang, PhD Candidate

6:00 p.m.-6:15 p.m.
128-OR Investigating C-Fiber Activity Using Depolarizing Stimuli Provides Insight into the Natural Course of Diabetic Polyneuropathy
Presenting Author: Zoltan Kender, MD, PhD

6:15 p.m.-6:30 p.m.
129-OR Increased Triglyceride Levels Are Associated with a Distinct Lipid-Associated Protein Biomarker Profile of Diabetic Foot Ulcers
Presenting Author: Marija Petkovic, PhD
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m.
(continued)

Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR05-1
Medical Nutrition Therapy—Moving Beyond Traditional Outcome Measures
Room: W314
Chair: Gretchen Benson, RDN, CDCES

5:30 p.m.-5:45 p.m.
130-OR Mediterranean Diet and Gestational Diabetes—What Is the Role of Exposure to Persistent Organic Pollutants
Presenting Author: Guoqi Yu, PhD

5:45 p.m.-6:00 p.m.
131-OR A Multiomics Study of Individual Responses to Long-Term Mediterranean Diet Interventions in the DIRECT-PLUS Trial
Presenting Author: Danyue Dong, PhD

6:00 p.m.-6:15 p.m.
132-OR Structured Medical Nutrition Therapy Improves Glycemia, Reduces Percentage Body Fat while Maintaining Fat-Free Mass in Individuals with Overweight/Obesity and Type 2 Diabetes
Presenting Author: Adham Mottalib, MD

6:15 p.m.-6:30 p.m.
133-OR Efficacy of a Culturally Tailored Mediterranean-Like Diet Intervention on Cardiometabolic Risk Factors
Presenting Author: Josiener Mattei, PhD, MPH
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m.  
(continued)

Oral Presentations  
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
Session Number: BM-OR07-1  
Innovative Diabetes Self-Management Education across Diverse Populations  
Room: W308  
Chair: Rebecca Longo, MSN, ACNP-BC, CDCES  

5:30 p.m.-5:45 p.m.  
134-OR  
The Safety and Efficacy of Virtual Insulin Pump Initiation in Children and Adolescents with Type 1 Diabetes in the United States  
Presenting Author: Margaret Pellizzari, MBA, MS, RN, CDCES, CPT, FADCES

5:45 p.m.-6:00 p.m.  
135-OR  
UNABLE TO ATTEND

6:00 p.m.-6:15 p.m.  
136-OR  
Examining New-Onset Type 1 Diabetes Educational Practices among Centers in the T1D Exchange Quality Improvement Collaborative (T1DX-QI)  
Presenting Author: Ryan McDonough, DO

6:15 p.m.-6:30 p.m.  
137-OR  
Outcomes of Real-World Deployment of the Dulce Digital Texting Education Platform for Low-Income Diverse Populations with Diabetes  
Presenting Author: Monica Ruiz, MA
5:30 p.m.-6:30 p.m.  
(continued)

Oral Presentations  
Theme Area: Clinical Diabetes/Therapeutics  
Session Number: CT-OR12-1  
SGLT2 Inhibition Impact on Human Physiology  
Room: W415C (Valencia Ballroom)  
Chair: Hiddo L. Heerspink, PhD

5:30 p.m.-5:45 p.m.  
138-OR Pioglitazone Amplifies the Decrease in HbA1c and Prevents the Increase in Plasma Ketone Caused by Dapagliflozin in Type 1 Diabetes Mellitus Patients  
Presenting Author: Gozde Baskoy, MD

5:45 p.m.-6:00 p.m.  
139-OR Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate—A Randomized Trial  
Presenting Author: Siham Abdelgani, MD

6:00 p.m.-6:15 p.m.  
140-OR The Coronary Flow Reserve Increase after Dapagliflozin Treatment in Patients with Type 2 Diabetes Is Maintained after Four Years—A Four-Year DAPAHEART Follow-up Study  
Presenting Author: Cassandra Morciano, MD

6:15 p.m.-6:30 p.m.  
141-OR Cardioprotective Effect of Empagliflozin and Modification of Sirtuins and Their Noncoding RNAs Regulators in Patients with Myocardial Infarction  
Presenting Author: Anna Nowak, MD
5:30 p.m.-6:30 p.m.  
(continued)

**Oral Presentations**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-OR17-1*

**New Technology—Equity and Access**
Room: W315  
Chair: Priya Prahalad, MD, PhD

5:30 p.m.-5:45 p.m.

**142-OR**  
A1C and Average Glucose Discordance—Personalized A1C Improves the Discrepancy, Particularly in Black Individuals  
Presenting Author: Ramzi Ajjan, MD, PhD, FRCP, MMedSci

5:45 p.m.-6:00 p.m.

**143-OR**  
A1C Change after Initiating Continuous Glucose Monitoring (CGM) for People with Diabetes in a Large U.S. Managed Health Care Plan  
Presenting Author: Gregory J. Norman, PhD

6:00 p.m.-6:15 p.m.

**144-OR**  
A Randomized Clinical Trial of Automated Insulin Delivery in Elderly with Type 1 Diabetes  
Presenting Author: Yogish C. Kudva, MD

6:15 p.m.-6:30 p.m.

**145-OR**  
Assessing the Current State of Diabetes Care in Long-Term Facilities Using Continuous Glucose Monitoring  
Presenting Author: Medha Munshi, MD
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m. (continued)

Oral Presentations

Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR18-1
Pediatric Obesity and Type 2 Diabetes
Room: W311
Chair: Fida Bacha, MD, FAAP

5:30 p.m.-5:45 p.m.

146-OR Clustering Pediatric Type 2 Diabetes Patients Exposes Differential Responses to Therapeutic Interventions
Presenting Author: Raymond J. Kreienkamp, MD, PhD

5:45 p.m.-6:00 p.m.

147-OR Obesity Is Associated with Increased Clearance and Reduced Drug Exposure to Metformin in Youth with Type 2 Diabetes
Presenting Author: Shylaja Srinivasan, MD, MAS

6:00 p.m.-6:15 p.m.

148-OR Increased Insulin Secretion and Decreased Insulin Sensitivity in South Asian Youth without Diabetes
Presenting Author: Sheela N. Magge, MD, MSCE

6:15 p.m.-6:30 p.m.

149-OR Liver Health in Adolescents with Youth-Onset Type 2 Diabetes
Presenting Author: Amy S. Shah, MD, MS
5:30 p.m.-6:30 p.m. 
(continued)

Oral Presentations
Theme Area: Epidemiology/Genetics
Session Number: EG-OR03-1
The New Frontier in Risk Profiling for Diabetes—Blood, Guts, and Glory
Room: W207
Chair: Sagar B. Dugani, MD, PhD, MPH

5:30 p.m.-5:45 p.m.
150-OR Gut Microbial Metabolism of Bile Acids, Mediterranean Diet and Cardiometabolic Risk in the DIRECT-PLUS Trial
Presenting Author: Peipei Gao, MSc

5:45 p.m.-6:00 p.m.
151-OR Metabolomics Profiles Underlying Development of Microvascular Complications in the Diabetes Prevention Project Outcome Study (DPPOS)
Presenting Author: Wei Perng, PhD, MPH

6:00 p.m.-6:15 p.m.
152-OR Sex Differences in Metabolomics and Risk of Coronary Heart Disease in Type 2 Diabetes
Presenting Author: Yilin Yoshida, PhD, MPH

6:15 p.m.-6:30 p.m.
153-OR Gut Microbiota, Blood Metabolome, and Incident Type 2 Diabetes in U.S. Hispanics
Presenting Author: Kai Luo, PhD
FRIDAY, JUNE 21, 2024

5:30 p.m.-6:30 p.m.
(continued)

Oral Presentations
Theme Area: Epidemiology/Genetics
Session Number: EG-OR06-1
Type 1 Diabetes Genome, Epigenome, and CRISPR Screens (Includes Livestream)
Room: W414
Chair: Catherine C. Robertson, PhD

5:30 p.m.-5:45 p.m.
154-OR Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention
Presenting Author: Lu You, PhD

5:45 p.m.-6:00 p.m.
155-OR Genetic Variation and Time to Progression in TN10 (Teplizumab)
Presenting Author: Dominika A. Michalek, BS, MS

6:00 p.m.-6:15 p.m.
156-OR Genome-Wide CRISPR Screen Identified That Alternative Splicing Regulates in Insulin Secretion
Presenting Author: Siying Wei, PhD

6:15 p.m.-6:30 p.m.
157-OR Epigenome-Wide Discovery of the Maternal Effect in Type 1 Diabetes Risk
Presenting Author: Randi K. Johnson, MPH, PhD
Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-OR06-1
Clinical Efforts to Study the Pathogenesis of Insulin Resistance
Room: W304 E-H
Chair: Daniel F. Vatner, MD, PhD

5:30 p.m.-5:45 p.m.  
158-OR  Relationship between Obesity, Sarcopenia, and Insulin Resistance in Older Adults  
Presenting Author: Ali A. Rizvi, MD

5:45 p.m.-6:00 p.m.  
159-OR  Sequential Measurements of Insulin Resistance in the Assessment of Individuals Participating in Diabetes Prevention Programs  
Presenting Author: Michael J. McPhaul, MD

6:00 p.m.-6:15 p.m.  
160-OR  PI3K Inhibition with Single-Dose Alpelisib as a Model of Insulin Resistance in Healthy Adults  
Presenting Author: Joshua R. Cook, MD, PhD

6:15 p.m.-6:30 p.m.  
161-OR  Type A Insulin Resistance Can Be Misdiagnosed as Type 1 or Type 2 Diabetes—A Cautionary Tale  
Presenting Author: Kaci Wirthwein, BA
5:30 p.m.-6:30 p.m.  
(continued)

Oral Presentations  
Theme Area: Immunology/Beta-Cell Replacement  
Session Number: IBC-OR03-1  
Immune and Adipose Tissue Intersection  
Room: W304 A-D  
Chair: Clive Wasserfall, MS, PhD

5:30 p.m.-5:45 p.m.  
162-OR  Sustained TNF-a Transcription Triggered in Obesity through H3K9/K18 Acetylation Is Associated with Metabolic Impairments  
Presenting Author: Rasheed Ahmad, PhD

5:45 p.m.-6:00 p.m.  
163-OR  RNAseq Analysis Reveals Temporal Dynamics of Colonic Immune Response to High-Fat Diet in Mice  
Presenting Author: Lena Keller, MS, PhD Student

6:00 p.m.-6:15 p.m.  
164-OR  Macrophage Ucp1 Deficiency Inhibits Cold Exposure–Induced Insulin Sensitivity in High-Fat Diet Mice  
Presenting Author: Liming Sun, Doctor Degree

6:15 p.m.-6:30 p.m.  
165-OR  Lipid Signaling in Macrophages Contributes to Inflammatory Transcriptome in Immune Cells  
Presenting Author: Abdulaziz Almutairi, MS
5:30 p.m.-6:30 p.m.  
(continued)

**Oral Presentations**  
Theme Area: Islet Biology/Insulin Secretion  
Session Number: IB-OR05-1  
Islet Potpourri Oral Abstracts *(Includes Livestream)*  
Room: W415B (Valencia Ballroom)  
Chair: Barak Blum, PhD

5:30 p.m.-5:45 p.m.
166-OR  The Alpha–Catenin–Cholesterol Biosynthesis Axis Regulates Tight Junction Formation in Pancreatic Islets  
Presenting Author: Wilma Tixi, PhD

5:45 p.m.-6:00 p.m.
167-OR  Targeting Alpha Cells to Treat Hypoglycemia in Type 1 Diabetes  
Presenting Author: Julia Panzer, PhD

6:00 p.m.-6:15 p.m.
168-OR  Perilipin 2 Regulates Fatty Acid Trafficking to Mitochondria through Microlipophagy in Beta Cells  
Presenting Author: Siming Liu, MD, PhD

6:15 p.m.-6:30 p.m.
169-OR  LC3+ Extracellular Vesicles (EVs) Are Associated with Altered β-Cell Autophagy, Islet Inflammation, and Diabetes  
Presenting Author: Jerry Xu, PhD
6:30 p.m.-8:30 p.m.

American Diabetes Association Networking Reception

Exhibit Hall (West A1-A3)
Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY09-1.5
SELECT Trial—New Looks at Glycemia, Inflammation, and Heart Failure (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Darren K. McGuire, MD, MHSc, FAHA, FACC, FESC
8:00 a.m.-8:20 a.m. SELECT—An Overview of the Study and the Weight Outcomes
Donna H. Ryan, MD
8:20 p.m.-8:40 p.m. Semaglutide and Prediabetes Progression/Regression in People with Vascular Disease—What Have We Learned from SELECT?
Steven E. Kahn, MB, ChB
8:40 a.m.-9:00 a.m. Role of Glycemia on Cardiovascular Outcomes—New Data from SELECT
Ildiko Lingvay, MD, MPH, MSCS
9:00 a.m.-9:20 a.m. Heart Failure and Inflammation Outcomes in SELECT
Jorge Plutzky, MD
9:20 a.m.-9:30 a.m. Discussant
Shivani Misra, MD, PhD

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY12-1.5
Navigating the Spatial Landscape—Omics in Diabetic Kidney Disease
Room: W208
Chair: Jennifer A. Schaub, MD
8:00 a.m.-8:30 a.m. Mapping the Transcriptomic Universe—Spatial Transcriptomics in Deciphering Diabetic Nephropathy
Parker C. Wilson, MD, PhD
8:30 a.m.-9:00 a.m. Metabolites in 3D—How Spatial Metabolomics Revolutionizes Our Understanding of Diabetic Kidney Disease
Kumar Sharma, MD
9:00 a.m.-9:30 a.m. A Deeper Look at Proteins—Spatial Proteomics in Diabetic Kidney Pathogenesis
Victor Puelles, MD, PhD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY13-1.5
Type 2 Diabetes and Exercise—Where Do We Stand?
Room: W314
Chair: Judith G. Regensteiner, PhD
8:00 a.m.-8:30 a.m. Incretin-Based Pharmacotherapy, (Osteo)sarcopenia, and Exercise
Samuel Klein, MD
8:30 a.m.-9:00 a.m. It’s About Time—The Interaction of Exercise and Meal Timing
Melissa Erickson, PhD
9:00 a.m.-9:30 a.m. Maintaining Muscle Mass and Metabolic Health—Resistance Exercise in Type 2 Diabetes
Ronald J. Sigal, MD, MPH, FRCPC
8:00 a.m.-9:30 a.m. (continued)

Session Type: Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY14-1.5
NIDDK Early Career Investigator Symposium—Leveraging Social Support to Improve Diabetes Self-Management and Health Outcomes—Innovative Methods and Interventions
Room: W311
Co-Chairs: Maureen Monaghan Center, PhD and Miranda Broadney, MD, MPH
8:00 a.m.-8:05 a.m. Welcome Remarks from the NIDDK Director
   Griffin Rodgers, MD, MACP
8:05 a.m.-8:20 a.m. You’re Not the Boss of Me!—Innovative Methods and Analyses to Assess the Impact of Caregivers on Diabetes Management and Psychosocial Outcomes of Adolescents with Diabetes
   Daniel R. Tilden, MD, MPH
8:20 a.m.-8:35 a.m. Innovative Methods and Analyses to Assess the Impact of Supportive Others on Diabetes Self-Management and Outcomes—Evaluation of Social Support and Social Networks in Rural-Dwelling Older Adults with Type 2 Diabetes
   Brittany L. Smalls, PhD, MHSA, MSHPsych
8:35 a.m.-8:50 a.m. Interventions Leveraging Social Support to Improve Diabetes Self-Management and Outcomes—Adaptation and Tailoring of a Type 1 Diabetes Education and Support (T1DES) Intervention to Improve Diabetes Distress among Black Young Adults
   Teaneise L. Davis, PhD
8:50 a.m.-9:05 a.m. Leveraging Social Support to Improve Diabetes Self-Management and Outcomes—Mobile Health Interventions for Adults with Type 2 Diabetes and Support Persons
   Lindsay S. Mayberry, PhD
9:05 a.m.-9:30 a.m. Panel—Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY15-1.5
ADA Education Recognition Program (ERP)—Diversifying Diabetes Self-Management Education and Support (DSMES) Delivery Models
Room: W304 A-D
Chair: Gene Arnold, MS, RD, LD, CDE
8:00 a.m.-8:15 a.m. Aligning Therapeutic Education with DSMES
   Zoltan Pataky, MD
8:15 a.m.-8:30 a.m. Improving Diabetes Management in the Elderly—DSMES in Home Health
   Kyle Lavergne, DNP
8:30 a.m.-8:45 a.m. Operationalizing Delivery of DSMES in Home Health
   Rena’ Thompson, RN, WTA, CDCES
8:45 a.m.-9:00 a.m. Providing DSMES within Blue Cross and Blue Shield
   Linda Roberto, RN
9:00 a.m.-9:15 a.m. Innovative Approaches to State-Funded Delivery of DSMES at Scale
   Gene Arnold, MS, RD, LD, CDCES
9:15 a.m.-9:30 a.m. Question and Discussion Period
8:00 a.m.-9:30 a.m.  
(continued)

Panel  
**Theme Area: Clinical Diabetes/Therapeutics**  
Session Number: CT-PN06-1.5  
**Newly-Diagnosed Type 2 Diabetes—What Should Be the Focus of Management in 2024? (Includes Livestream)**  
Room: W307  
Chair: Ravi Retnakaran, MD, FRCPC

8:00 a.m.-8:15 a.m.  **Treat Obesity First!**  
Ania M. Jastreboff, MD, PhD

8:15 a.m.-8:30 a.m.  **Prevent Future Complications!**  
Roopa Mehta, MD, PhD

8:30 a.m.-8:45 a.m.  **Achieve Remission!**  
Roy Taylor, MD

8:45 a.m.-9:00 a.m.  **It’s Still about Glucose, Until Proven Otherwise**  
David M. Nathan, MD

9:00 a.m.-9:30 a.m.  **Panel Discussion**

Panel  
**Theme Area: Clinical Diabetes/Therapeutics**  
Session Number: CT-PN16-1.5  
**The Role of the Interdisciplinary Team in Technology Onboarding in Primary Care**  
Room: W415C (Valencia Ballroom)  
Chair: Richard M. Bergenstal, MD

8:00 a.m.-8:20 a.m.  **Is Primary Care the Best Place for Continuous Glucose Monitoring (CGM) Initiation?**  
Eden Miller, DO

8:20 a.m.-8:40 a.m.  **What Is the Role of Primary Care Practices in Automated Insulin Delivery?**  
Sean Oser, MD, MPH

8:40 a.m.-9:00 a.m.  **Diabetes Care and Education Specialists as Technology Champions**  
Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM

9:00 a.m.-9:20 a.m.  **Patient Perspective**  
Zachary Jones

9:20 a.m.-9:30 a.m.  **Question and Discussion Period**
8:00 a.m.-9:30 a.m. (continued)

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY23-1.5*

**Navigating the Early Phases of Pediatric Type 1 Diabetes**
Room: W315
Chair: Stephen E. Gitelman, MD

- **8:00 a.m.-8:20 a.m.** Patient Perspective
  Amanda Twigg, MD
- **8:20 a.m.-8:40 a.m.** Pediatric Type 1 Diabetes Screening Programs
  Anette-Gabriele Ziegler, MD
- **8:40 a.m.-9:00 a.m.** Continuous Glucose Monitoring (CGM) and Early Stage Type 1 Diabetes
  Andrea Steck, MD
- **9:00 a.m.-9:20 a.m.** The Economics of Early-Stage Type 1 Diabetes Detection and Treatment
  R. Brett McQueen, PhD
- **9:20 a.m.-9:30 a.m.** Question and Discussion Period

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY27-1.5*

**ADA Diabetes Care Symposium—The Final Frontier—Implementing the Learning from Implementation Science**
Room: W308
Chair: John B. Buse, MD, PhD

- **8:00 a.m.-8:20 a.m.** Diabetes Prevention—What Do We Know Now That We Didn't Know 20 Years Ago?
  Brian Oldenburg, MPsychol, PhD
- **8:20 a.m.-8:40 a.m.** Using Telehealth to Improve Diabetes Control in Real-World Practice
  Matthew J. Crowley, MD, MHS
- **8:40 a.m.-9:00 a.m.** Multifactorial Cardiovascular Risk Reduction—The COORDINATE-Diabetes Implementation Example
  Jennifer B. Green, MD
- **9:00 a.m.-9:20 a.m.** Commentary and Future Direction
  Nisa M. Maruthur, MD, MHS
- **9:20 a.m.-9:30 a.m.** Question and Discussion Period
8:00 a.m.-9:30 a.m. (continued)

Panel
Theme Area: Epidemiology/Genetics
Session Number: EG-PN05-1.5
Diabetes Genome-Wide Association Study—Why Keep Going?
Room: W207
Chair: Cassandra N. Spracklen, PhD
8:00 a.m.-8:20 a.m. Type 1 Diabetes Multiancestry Genome-Wide Association Study
Stephen S. Rich, PhD, FAHA
8:20 a.m.-8:40 a.m. Type 2 Diabetes Global Genetics Initiative
Eleftheria Zeggini, PhD
8:40 a.m.-9:00 a.m. Type 2 Diabetes Genome-Wide Association Study Cluster Partitioning
Miriam Udler, MD, PhD
9:00 a.m.-9:20 a.m. Type 2 Diabetes Genome-Wide Association Studies in Underrepresented Populations
Adebowale A. Adeyemo, MD
9:20 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-SY06-1.5
Clinical Beta-Cell Replacement Therapy in the Near Future (Includes Livestream)
Room: W414
Chair: Melena Bellin, MD
8:00 a.m.-8:20 a.m. How to Design the Optimal Beta-Cell Surrogate
Cristina Nostro, PhD
8:20 a.m.-8:40 a.m. Materials to Prevent Immune Rejection
Alice A. Tomei, PhD
8:40 a.m.-9:00 a.m. Islet Vascularization
Appakalai N. Balamurugan, PhD
9:00 a.m.-9:20 a.m. Integration of Tools for Monitoring Therapeutic Success
Katy Digovich
9:20 a.m.-9:30 a.m. Question and Discussion Period
SATURDAY, JUNE 22, 2024

8:00 a.m.-9:30 a.m.
(continued)

**Symposium**
*Theme Area: Obesity/Integrated Physiology*
*Session Number: IP-SY08-1.5*

**Obesity in United States Hispanic/Latino Populations—Challenges and Strategies**
Room: W304 E-H
Chair: Rodolfo J. Galindo, MD

- 8:00 a.m.-8:20 a.m. *Obesity Inequity among Hispanic/Latino Adults and Children in the United States—Drivers and Implications*
  Erica G. Soltero, PhD
- 8:20 a.m.-8:40 a.m. *Metabolic-Dysfunction—Associated Steatotic Liver Disease among Hispanic/Latino Children and Adults*
  Jeffrey Schwimmer, MD
- 8:40 a.m.-9:00 a.m. *Tailoring Obesity Treatments to the United States Hispanic/Latino Population—Success and Challenges*
  Jaime P. Almandoz, MD, MBA, FTOS

9:00 a.m.-9:20 a.m. *Neighborhood Determinants of Health and Policy Changes—Lessons Outside the United States*
  Carolina Perez-Ferrer, PhD

9:20 a.m.-9:30 a.m. *Question and Discussion Period*

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY45-1.5*

**The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Multiple Daily Insulin Injections in Adults with Type 1 Diabetes—Results of the INHALE-3 Randomized Trial (Includes Livestream)**
Room: W320 (Chapin Theater)
Chair: Roy W. Beck, MD, PhD

- 8:00 a.m.-8:10 a.m. *Inhaled Insulin’s History and Study Rationale*
  Halis K. Akturk, MD
- 8:10 a.m.-8:20 a.m. *Study Methods and Participant Baseline Characteristics*
  Yogish C. Kudva, MD
- 8:20 a.m.-8:30 a.m. *Study Results I—Comparison of Inhaled Insulin vs. Rapid-Acting Analogue Insulin in Users of Automated Insulin Delivery or Multiple Daily Insulin Injections during Standardized In-Clinic Meal Challenges*
  Ruth S. Weinstock, MD, PhD
- 8:30 a.m.-8:40 a.m. *Study Results II—Primary Efficacy, Safety, and Quality of Life Outcomes*
  Carol J. Levy, MD, CDCES
- 8:40 a.m.-8:50 a.m. *Study Results III—Effect of Inhaled Insulin-Degludec Compared with Automated Insulin Delivery and in Subgroups According to Participant Characteristics*
  Grazia Aleppo, MD, FACE, FACP
- 8:50 a.m.-9:00 a.m. *Critique of Study Design and Results*
  Irl B. Hirsch, MD
- 9:00 a.m.-9:10 a.m. **Use of Inhaled Insulin in Clinical Practice**
  Thomas Blevins, MD
- 9:10 a.m.-9:30 a.m. *Question and Discussion Period*
**Symposium**
*Theme Area: Islet Biology/Insulin Secretion*
*Session Number: IB-SY05-1.5*

**The Good, The Bad, and The Ugly of Lipids in the Beta-Cell Microenvironment**
*Room: W206*
*Chair: Marc Prentki, PhD*

8:00 a.m.-8:30 a.m. *Lipoproteins-Induced Beta-Cell Impairment and Impact on the Action of Beta-Cell—Derived Exosomes*
Victor García-González, PhD

8:30 a.m.-9:00 a.m. *Glucose Metabolism Primers Lipogenesis in the β-cell Through Epigenomic Signaling*
Matthew Worthman, PhD

9:00 a.m.-9:30 a.m. *Cholesterol Redistribution in Pancreatic Beta-Cells—A Flexible Path to Regulate Insulin Secretion*
Carla Perego, PhD
SATURDAY, JUNE 22, 2024

9:45 a.m.-11:15 a.m.

Special Lectures and Addresses
Session Number: HCE-01
ADA Chief Executive Officer and Chairman of the Board Fireside Chat; President, Health Care & Education Address; and Outstanding Educator in Diabetes Award Lecture *(Includes Livestream)*
Room: West Hall B3-4 (General Session)
9:45 a.m.-10:10 a.m. **ADA Chief Executive Officer and Chairman of the Board Fireside Chat**
Charles Henderson
Rhodes Ritenour, JD
10:10 a.m.-10:13 a.m. **Introduction of President, Health Care & Education Address**
Robert A. Gabbay, MD, PhD
10:13 a.m.-10:43 a.m. **Lessons Learned—Diabetes Education for One and All**
Patti Urbanski, MEd, RD, LD, CDCES, FADCES
10:43 a.m.-10:45 a.m. **Introduction of Outstanding Educator Award**
Patti Urbanski, MEd, RD, LD, CDCES, FADCES
10:45 a.m.-11:15 a.m. **Meeting People Where They Are—Improving Diabetes Care and Outcomes through Education and Collaboration**
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

11:30 a.m.-12:30 p.m.

Professional Interest Group
**Theme Area: Acute and Chronic Complications**
Session Number: AC-IG02-1
Discussion on Foot Care—Lower Extremity Complications
Room: W206
Chair: Laura Shin, DPM, PhD
11:30 a.m.-11:35 a.m. **Introduction**
11:35 a.m.-12:20 p.m. **Current Surgical Techniques in Diabetic Foot/Ankle Reconstruction**
Patrick R. Burns, DPM
12:20 p.m.-12:30 p.m. **Question and Discussion Period**
Professional Interest Group
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-IG02-1
Discussion on Exercise Physiology—Syncing Up—Exploring the Interplay of Circadian Rhythms and Exercise
Room: W304 A-D
Chair: Melissa Erickson, PhD
11:30 a.m.-11:36 a.m. Introduction
11:36 a.m.-11:54 a.m. Exercise Timing and Metabolic Rhythmicity in Type 2 Diabetes
Juleen R. Zierath, PhD
11:54 a.m.-12:12 p.m. Interaction of Circadian System and Physical Activity on Cardiovascular Health
Jingyi Qian, PhD
12:12 p.m.-12:30 p.m. Does Timing of Exercise Matter? Time of Day Effects of Physical Activity on Glycemic Outcomes
Roeland J.W. Middelbeek, MD, MSc

Professional Interest Group
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-IG04-1
Discussion on Nutritional Sciences and Metabolism—The Science of Ultraprocessed Foods and Impacts on Metabolic Diseases
Room: W304 E-H
Chair: Ranee Chatterjee Montgomery, MD, MPH
11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-11:55 a.m. Challenges and Opportunities of Ultraprocessed Food Research
Lauren E. O’Connor, PhD
11:55 a.m.-12:15 p.m. Ultraprocessed Foods and Chronic Disease Across the Lifespan
William Heerman, MD, MPH
12:15 p.m.-12:30 p.m. Question and Discussion Period

Professional Interest Group
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-IG05-1
Discussion on Women’s Interprofessional Network of the ADA (WIN ADA)—How to Say “No” So You Can Say “Yes”—Optimizing Time Management
Room: W308
Chair: Rebecca L. Scalzo, PhD
11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-11:55 a.m. How to Say “No” So You Can Say “Yes”—Optimizing Time Management
Linda M. DiMeglio, MD, MPH
11:55 a.m.-12:15 p.m. Panel Discussion
Jane E. B. Reusch, MD
Darleen A. Sandoval, PhD
12:15 p.m.-12:30 p.m. Question and Discussion Period
11:30 a.m.-12:30 p.m.  
(continued)

Professional Interest Group  
Theme Area: Clinical Diabetes/Therapeutics  
Session Number: CT-IG03-1  
Discussion on Diabetes in Youth—Perspectives on Universal Antibody Screening  
Room: W207  
Co-Chairs: Stuart A. Weinzimer, MD and Persis V. Commissariat, PhD, CDCES  
11:30 a.m.-11:35 a.m.  Introduction  
11:35 a.m.-11:55 a.m.  Universal Antibody Screening—Pediatric Perspective  
Desmond Schatz, MD  
11:55 a.m.-12:15 p.m.  Universal Antibody Screening—Behavioral Medicine Perspective  
Suzanne B. Johnson, PhD  
12:15 p.m.-12:30 p.m.  Question and Discussion Period

Professional Interest Group  
Theme Area: Clinical Diabetes/Therapeutics  
Session Number: CT-IG05-1  
Discussion on Pregnancy and Reproductive Health—Should Continuous Glucose Monitoring Be Used in Pregnancy Complicated by Gestational Diabetes?  
Room: W208  
Co-Chairs: Camille E. Powe, MD and Greyne O'Malley, MD  
11:30 a.m.-11:35 a.m.  Introduction  
11:35 a.m.-11:50 a.m.  Continuous Glucose Monitoring Should Be Used Now in Pregnancy Complicated by Gestational Diabetes  
Eleanor M. Scott, BM, BS, MD, FRCP  
11:50 a.m.-12:05 p.m.  Continuous Glucose Monitoring Should Not Yet Be Used in Pregnancy Complicated by Gestational Diabetes  
Christina M. Scifres, MD  
12:05 p.m.-12:10 p.m.  Rebuttal  
Eleanor M. Scott, BM, BS, MD, FRCP  
12:10 p.m.-12:15 p.m.  Rebuttal  
Christina M. Scifres, MD  
12:15 p.m.-12:30 p.m.  Question and Discussion Period
11:30 a.m.-12:30 p.m.  
(continued)

**Professional Interest Group**  
*Theme Area: Islet Biology/Insulin Secretion*  
*Session Number: IB-IG01-1*

**Discussion on Islet Biology, Development, and Function—Right on Target—Strategies to Selectively Regenerate and Protect Beta Cells**  
*Room: W311*  
*Chair: Jeffrey S. Tessem, PhD*

- **11:30 a.m.-11:35 a.m.** Introduction
- **11:35 a.m.-11:50 a.m.** *Islet Cell Targeting Using a ZnT8 Ab for Beta-Cell Mass Imaging and Regeneration*  
  Dax Fu, PhD
- **11:50 a.m.-12:05 p.m.** *Nanoparticle Targeting of the Beta Cell*  
  Nikki L. Farnsworth, PhD
- **12:05 p.m.-12:20 p.m.** *Zinc Targeting of the Beta Cell*  
  Wen-Hong Li, PhD
- **12:20 p.m.-12:30 p.m.** Question and Discussion Period

**Professional Development**  
*Theme Area: Professional Development*  
*Session Number: PD-01-1*

**Creating Talks That Are Talked About—How to Bring Memorability to Your Presentation(s)**  
*(Includes Livestream)*  
*Room: W307*  
*Chair: Barbara Eichorst, MS, RD, CDCES*

- **11:30 a.m.-12:30 p.m.** *Creating Talks That Are Talked About—How to Bring Memorability To Your Presentation(s)*  
  Kari Goetz, BFA, MA
11:30 a.m.-12:30 p.m.
(continued)

**ePoster Theater**
*Theme Area: Acute and Chronic Complications*
*Session Number: ePoster01*
(*) **Diabetic Kidney Disease—From Genetic Pathways to Social Determinants**
*Room: Exhibit Hall (West A1-A3) ePoster Theater A*
*Moderator: Laura Pyle, PhD*

(*) *Continuing Education Credit Is Not Awarded for this Session.*

11:30 a.m.-11:40 a.m.
396-P  Consequences of Knockout of the Histone Demethylase KDM6B from Myeloid Cells Are Context Dependent in Diabetic Kidney Disease
*Presenting Author: Lisa Y. Q. Hong, BSc*

11:40 a.m.-11:50 a.m.
397-P  The C/EBPβ-XOR Axis and Genetic Risk for Diabetic Kidney Disease
*Presenting Author: Ilse S. Daehn, PhD*

11:50 a.m.-12:00 p.m.
398-P  Dissecting Adiponectin Receptor Expression in Renal Vasculature and Its Correlation with Insulin Sensitivity in Type 1 Diabetes
*Presenting Author: Kalie L. Tommerdahl, MD*

12:00 p.m.-12:10 p.m.
399-P  Association of Social Determinants of Health with Initiation of Novel Glucose-Lowering Drugs in Patients with Diabetes—A Post Hoc Analysis of the Kidney-CHAMP Trial
*Presenting Author: Linda-Marie U. Lavenburg, DO, MS*

12:10 p.m.-12:20 p.m.
400-P  KidneyIntelX Impact on ADA DKD Prevention Model Metrics
*Presenting Author: Steven Coca, DO, MS*
SATURDAY, JUNE 22, 2024

11:30 a.m.-12:30 p.m. (continued)

ePoster Theater
Theme Area: Epidemiology/Genetics
Session Number: ePoster02
(*) Diabetes and CVD—Heartbreak in Motion
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Janet K. Snell-Bergeon, PhD, MPH

(*) Continuing Education Credit Is Not Awarded for this Session.

11:30 a.m.-11:40 a.m.
1266-P The Risk of Major CV Events after Initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in Patients with Type 2 Diabetes and Low-to-Moderate CV Risk
Presenting Author: Elisabetta Patorno, MD, DrPH

11:40 a.m.-11:50 a.m.
1366-P Cardiovascular Complications (Myocardial Infarction, Stroke, and End-Stage Renal Disease) and Mortality in Youth-Onset Type 1 and Type 2 Diabetes Based on National Health Insurance Service (NHIS) Data
Presenting Author: Sungeun Kim, Doctor

11:50 a.m.-12:00 p.m.
1376-P Association of Lung Function and Glycemic Control with All-Cause and Cardiovascular Mortality in Persons with Type 2 Diabetes
Presenting Author: Chia-Ing Li, PhD

1377-P WITHDRAWN

12:10 p.m.-12:20 p.m.
1437-P Blood Pressure (BP) Trajectories and 32-Year Cardiovascular Disease (CVD) Incidence in Women and Men with Type 1 Diabetes (T1D)
Presenting Author: Rachel G. Miller, PhD
12:30 p.m.-1:30 p.m.

**ePoster Theater**  
*Theme Area: Clinical Diabetes/Therapeutics*  
Session Number: ePoster03  
(*Insights into the Treatment, Mechanistic Underpinnings, and Determinants of Outcomes in Pregancies Complicated by Diabetes*  
Room: Exhibit Hall (West A1-A3) ePoster Theater A  
Moderator: Samantha F. Ehrlich, PhD, MPH

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.  
1213-P  
The Effect of Bile Acid–RNA Methylation on Intergenerational Inheritance of Diabetes Mellitus by Microbiota Vertical Transmission  
Presenting Author: Qinyuan Xie, PhD

12:40 p.m.-12:50 p.m.  
1214-P  
Prepregnancy Use of Glucagon–Like Peptide 1 Receptor Agonists and Gestational Weight Gain in Type 2 Diabetes  
Presenting Author: Jacqueline Maya, MD

12:50 p.m.-1:00 p.m.  
1215-P  
Maternal Glycemia Associations with Cord Blood DNA Methylation in the Hyperglycemia and Adverse Pregnancy Outcome Study  
Presenting Author: Monica E. Bianco, MD

1:00 p.m.-1:10 p.m.  
1216-P  
Maternal Obesity and Human Milk Metabolomics—Unraveling the Link to Infant Obesity Risk  
Presenting Author: Lewis DeCicco, BS

1:10 p.m.-1:20 p.m.  
1217-P  
Insulin Sensitivity and Insulin Secretion Differentially Affect Birthweight and Postpartum Glucose  
Presenting Author: Emily A. Rosenberg, MD
SATURDAY, JUNE 22, 2024

12:30 p.m.-1:30 p.m. (continued)

ePoster Theater
Theme Area: Clinical Diabetes/Therapeutics
Session Number: ePoster04
(*) Pediatric Research Update—Type 1 Diabetes, Type 2 Diabetes, Obesity
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Sarah A. MacLeish, DO

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.
1161-P Are There Sex Differences in Response to Metabolic/Bariatric Surgery among Adolescents with Severe Obesity?
Presenting Author: Subin Jang, MPH

12:40 p.m.-12:50 p.m.
1162-P Global Burden Attributable to High Body Mass Index in Young Adults from 1990 to 2019, with Projections to 2050
Presenting Author: Jingxuan Wang, BS

12:50 p.m.-1:00 p.m.
1163-P Type 2 Diabetes Remission Persists Ten Years after Adolescent Metabolic and Bariatric Surgery
Presenting Author: Justin R. Ryder, PhD

1:00 p.m.-1:10 p.m.
1164-P Effect of Metformin on Gut Microbial Metabolites in Overweight and Obese Youth with Type 1 Diabetes (T1D)
Presenting Author: Elizabeth R. Flammer, MS

1:10 p.m.-1:20 p.m.
1165-P Untangling the Interactions of Glycemic Control and Obesity on Hypothalamic Gliosis in Youth with Type 1 Diabetes
Presenting Author: Alyssa Huang, MD
12:30 p.m.-1:30 p.m.

Session Break
(Take this opportunity to visit the Exhibit and Poster Halls)

1:30 p.m.-3:00 p.m.

Debate
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-DB15-1.5
Innovation or Access in Diabetes Technology—What Should Be Our Global Priority?
Room: W415C (Valencia Ballroom)
Chair: David M. Maahs, MD, PhD
1:30 p.m.-1:50 p.m.  Access Should Be Our Top Priority!
Apoorva Gomber, MBBS, MD, MPH
1:50 p.m.-2:10 p.m.  Innovation Should Be Our Top Priority!
Rayhan Lal, MD
2:10 p.m.-2:25 p.m.  Rebuttal
Apoorva Gomber, MBBS, MD, MPH
2:25 p.m.-2:40 p.m.  Rebuttal
Rayhan Lal, MD
2:40 p.m.-3:00 p.m.  Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY30-1.5
ADA Primary Care Council—What Does a Person with Diabetes Need from Their Primary Care Team? (Includes Livestream)
Room: W320 (Chapin Theater)
Chair: Kevin A. Peterson, MD, MPH
1:30 p.m.-3:00 p.m.  Team-Based Care
Benjamin M. Bluml, RPh
Sarah Candler, MD, MPH, FACP
Andrea Haynes, MD
Cara Orr, MS, MMS, PA-C
Kimberly D. Broughton-Miller, DNP, APRN, FNP-C, ENP-C, FAANP
Pamela Stamm, PharmD, BCPS, BCACP, CDCES, FASHP, FACCIP
Greg Cohen, DO, FACOFP
Symposium
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-SY03-1.5
Channeling Mechanisms Underlying Islet Function and Dysfunction *(Includes Livestream)*
Room: W415B (Valencia Ballroom)
Chair: Show-Ling Shyng, PhD

1:30 p.m.-2:00 p.m.  *Impact of Intracellular Calcium Flux on Beta-Cell Insulin Secretion*
Marjan Slak Rupnik, PhD

2:00 p.m.-2:30 p.m.  *Channeling Euglycemia—TALK-1 Channel Modulation of Islet Hormone Secretion and Glucose Homeostasis*
David Jacobson, PhD

2:30 p.m.-3:00 p.m.  *Impacts of Swell Channels on Insulin Secretion*
Rajan Sah, MD, PhD
SATURDAY, JUNE 22, 2024

1:30 p.m.–3:00 p.m.  
(continued)

Oral Presentations

Theme Area: Acute and Chronic Complications
Session Number: AC-OR02-1.5
Cell and Molecular Approaches to Diabetes-Related Foot Complications (With Roger Pecoraro Award Lecture) *(Includes Livestream)*
Room: W307
Chair: Tyler Lawrence Coye, DPM

1:30 p.m.–2:00 p.m.
Roger Pecoraro Award Lecture

*Roger Pecoraro Award Lecture 2024*
Frances L. Game, BSc, MBBCh (Hons), MRCP(UK), MRCPath, FRCP

2:00 p.m.–2:15 p.m.
170-OR  Case-Control Study on Whole-Methylome Analysis of Monocytes in Acute Diabetic Charcot Foot—Identifying Differentially Methylated Genes
Presenting Author: Naween Kumar, MD

2:15 p.m.–2:30 p.m.
171-OR  Tissue Nanotransfection–Based Endothelial-Targeted Epigenetic Gene Editing In Vivo to Rescue Diabetic Ischemic Wounds
Presenting Author: Kanhaiya Singh, PhD

2:30 p.m.–2:45 p.m.
172-OR  Lineage Tracing of Vasculogenic Fibroblasts In Vivo and Their Significance in the Rescue of Diabetic Ischemic Tissue
Presenting Author: Kanhaiya Singh, PhD

2:45 p.m.–3:00 p.m.
173-OR  A Clinical Study of Novel Antimicrobial Peptide PL-5 Topical Spray for Mild to Moderate Infectious Wounds of Diabetic Foot
Presenting Author: Li Qian, MD, PhD
**Oral Presentations**

**Theme Area: Acute and Chronic Complications**

**Session Number: AC-OR03-1.5**

**Hypoglycemia in the Real World—Who’s Really at Risk?**

Room: W208

Chair: Michael Bancks, PhD, MPH

1:30 p.m.-1:45 p.m.

**174-OR** Genetic Variation in GLP-1R Modify the Risk of Hypoglycemia in Response to Intensive Glycemic Control in Adults with Type 2 Diabetes

Presenting Author: Qiaochu Xue, PhD, MPH

1:45 p.m.-2:00 p.m.

**175-OR** Level 3 Hypoglycemia in Diabetes—An Age-Old but Not (Just) Old-Age Problem (INPHORM, USA)

Presenting Author: Alexandria Ratzi-Leewing, PhD

2:00 p.m.-2:15 p.m.

**176-OR** Association between Clustering of Hypoglycemic Symptoms, Psychological Traits, and Problem-Solving Abilities in Adults with Type 1 Diabetes

Presenting Author: Naoki Sakane, MD, PhD

2:15 p.m.-2:30 p.m.

**177-OR** Time Below Range (TBR) and Its Link to Impaired Awareness of Hypoglycemia (IAH) and Severe Hypoglycemia (SH)—Evidence from the Association of British Clinical Diabetologists (ABCD) Study

Presenting Author: Harshal Deshmukh, MB, MPH, MRCP, PhD, CCT

2:30 p.m.-2:45 p.m.

**178-OR** Assessing Hypoglycemia Awareness—Validating HypoA-Q within the T1D Exchange Registry

Presenting Author: Yu Kei Lin, MD

2:45 p.m.-3:00 p.m.

**179-OR** Assessing the Impact of Hypoglycemia among People with Diabetes in the U.S. and EU

Presenting Author: Alan Beltran, Bachelor’s Degree
Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR08-1.5
Clinical Biomarkers of ASCVD Risk Progression in Diabetes Mellitus and Metabolic Disease
Room: W308
Chair: Om Ganda, MD

1:30 p.m.-1:45 p.m.
180-OR Glycemic Markers Are Differentially Associated with Cardiovascular Imaging and Outcomes in Long-Duration Type 1 Diabetes
Presenting Author: Marc Gregory Yu, MD

1:45 p.m.-2:00 p.m.
181-OR Declining eGFR over Time Predicts the Risk of a Composite of Primary or Secondary Major Adverse Cardiovascular Events or Heart Failure Hospitalization, in People with Type 2 Diabetes—EXSCEL Post Hoc analysis
Presenting Author: Harald Sourij, MD

2:00 p.m.-2:15 p.m.
182-OR The Triglyceride–Glucose Index and the Presence of Coronary Artery Disease are Mutually Independent Predictors for the Development of Type 2 Diabetes Mellitus
Presenting Author: Andreas Leiherer, Doz Dr

2:15 p.m.-2:30 p.m.
183-OR Risk Factors for Combined Severe Diabetic Complications (CSDC) in Patients with Type 2 Diabetes Mellitus (T2DM)
Presenting Author: Tanaka Nanako, Bachelor’s Degree

2:30 p.m.-2:45 p.m.
184-OR Association between Composite Dietary Antioxidant Index and Stroke among U.S. Adults with Diabetes—Insights from NHANES
Presenting Author: Hongqiang Zhang, Master's Degree

2:45 p.m.-3:00 p.m.
185-OR The Role of Optical Coherent Tomography in the Estimation of Cardiovascular Risk in Asymptomatic Patients with Type 1 Diabetes
Presenting Author: Michal Dubsky, MD, PhD
Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR01-1.5
Social Drivers of Health and Advancement towards Social Justice
Room: W314
Chair: Persis V. Commissariat, PhD, CDCES

1:30 p.m.-1:45 p.m.
186-OR Longitudinal Effect of Diabetes Fatalism on Clinical Outcomes and QOL in AA with Type 2 Diabetes Mellitus
Presenting Author: Sandra C. Iregbu, PhD

1:45 p.m.-2:00 p.m.
187-OR Pathway between Race, Historic and Contemporary Measures of Structural Racism, and Prevalence of Diabetes in the U.S.
Presenting Author: Leonard E. Egede, MD, MS

2:00 p.m.-2:15 p.m.
188-OR Association of Social Determinants of Health with Efficacy of Metabolic Bariatric Surgery (MBS) vs. Medical Therapy (MT) for Type 2 Diabetes
Presenting Author: Mary-Elizabeth Patti, MD

2:15 p.m.-2:30 p.m.
189-OR Food Insecurity and Inability to Obtain Recommended Medications, Diabetes Technology, and Multidisciplinary Services in Youth and Young Adults with Diabetes
Presenting Author: Angela D. Liese, PhD, MPH, FACE, FAHA

2:30 p.m.-2:45 p.m.
190-OR Development and Validation of a Social Risk Screening Tool for Adults with Type 2 Diabetes
Presenting Author: Joni S. Williams, MD, MPH

191-OR WITHDRAWN
Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR02-1.5
Using Teams and Technology to Improve Outcomes
Room: W315
Chair: Peter Rossing, MD, DMSc

1:30 p.m.-1:45 p.m.

192-OR Effect of Video Conferences between Endocrinologists and Family Doctors on Levels of Recommended Medication among Persons with Type 2 Diabetes—Pragmatic RCT
Presenting Author: Thim Prætorius, PhD

1:45 p.m.-2:00 p.m.

193-OR Virtual Diabetes Optimization Program vs. Standard Endocrine Care for Veterans with Uncontrolled Diabetes
Presenting Author: Thomas Adel, BS

2:00 p.m.-2:15 p.m.

194-OR Improved Linkage to the Health System and Better Diabetes Control Due to Community-Based m-Health–Enabled Screening and Follow-up in India
Presenting Author: Sailesh Mohan, MD, MPH, PhD

2:15 p.m.-2:30 p.m.

195-OR Efficacy and Feasibility of a Telemedicine Program for Institutionalized Elderly People with Insulin-Treated Diabetes Using Continuous Glucose Monitoring and a Connected Insulin Pen Cap—The Trescasas Study
Presenting Author: Fernando Gomez-Peralta, PhD, MD

2:30 p.m.-2:45 p.m.

196-OR A Scalable Application of Artificial Intelligence (AI) to Transform Type 2 Diabetes Management in Clinical Practice
Presenting Author: Mark L. Warren, MD

2:45 p.m.-3:00 p.m.

197-OR Algorithmic Identification May Improve Racial and Ethnic Diversity of Clinical Study Recruitment
Presenting Author: Sara Jane Cromer, MD
Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR05-1.5

**Novel Insights into Pathophysiology, Diagnosis, and Outcomes in GDM**
Room: W311
Chair: Mary R. Loeken, PhD, MS

1:30 p.m.-1:45 p.m.

198-OR Should We Improve or Replace the Antenatal Oral Glucose Tolerance Test for Diagnosis of Gestational Diabetes?
Presenting Author: Laura C. Kusinski, PhD, BSc (Hons)

1:45 p.m.-2:00 p.m.

199-OR Beta-Cell IRS1 Deficiency Predisposes Female Mice to Developing Gestational Diabetes
Presenting Author: Taofeek Usman, PhD

2:00 p.m.-2:15 p.m.

200-OR Postpartum Islet-Cell Function in Individuals With and Without Gestational Diabetes
Presenting Author: Aoife M. Egan, MB, BCh, BAO

2:15 p.m.-2:30 p.m.

201-OR Fasting and Postprandial Triglycerides in Early Pregnancy Correlate with Mean Glucose and Time-in-Range by CGM at 28 Weeks of Gestation
Presenting Author: Linda A. Barbour, MD, MSPH, FACP

2:30 p.m.-2:45 p.m.

202-OR Prediction of Late Gestational Diabetes Mellitus in Those without Early GDM
Presenting Author: David Simmons, MA, MBBS, FRACP, FRCP, MD

2:45 p.m.-3:00 p.m.

203-OR Metabolic and Clinical Outcomes with One Abnormal Value on Carpenter Coustan Criteria
Presenting Author: Christina M. Scifres, MD
Oral Presentations
Theme Area: Epidemiology/Genetics
Session Number: EG-OR02-1.5
The Safety Net Unraveled—Social and Geographical Factors in Diabetes Disparities
Room: W206
Chair: Jessica L. Harding, PhD

1:30 p.m.-1:45 p.m.
204-OR Social Vulnerability, Rurality, and Prevalence of Obesity and Inactivity in U.S. Counties, 2004–2019
Presenting Author: Ben T. Varghese, MBBS, MSc

1:45 p.m.-2:00 p.m.
205-OR Association of Geographic Factors with Use of Metabolic Disease Specialty Care among Adults with Type 2 Diabetes and ASCVD
Presenting Author: Jessica Bauer, MD

2:00 p.m.-2:15 p.m.
206-OR Assessing Connection to Outpatient Care among Patients Screening Positive for Previously Undiagnosed Diabetes in the Emergency Department
Presenting Author: Vidhyasai Annem, BSA

2:15 p.m.-2:30 p.m.
207-OR Food Insecurity Patterns and Mental Health among Youth and Young Adults with Diabetes
Presenting Author: Ali M. Alfalki, MPH

2:30 p.m.-2:45 p.m.
208-OR Impact of Carbohydrate-Restricted Nutrition Therapy and Continuous Remote Care among People with Type 2 Diabetes in Rural vs. Urban Areas
Presenting Author: Shaminie J. Athinarayanan, PhD

2:45 p.m.-3:00 p.m.
209-OR Direct and Indirect Effects of Redlining on Diabetes Prevalence via Food Access
Presenting Author: Rebekah J. Walker, PhD
Oral Presentations
Theme Area: Epidemiology/Genetics
Session Number: EG-OR04-1.5
Type 2 Diabetes and Related Trait GWAS Variant Effects through Omics Profiles (With ADA Presidents' Select Abstract Presentation)
Room: W207
Chair: Adelaide Tovar, PhD

1:30 p.m.-1:45 p.m.
210-OR ADA Presidents' Select Abstract: Discovering Stimulatory State-Specific Type 2 Diabetes GWAS Mechanisms with Single-Cell Multiomics on iPSC-Derived Fibro-adipogenic Progenitor Cell Villages
Presenting Author: Christa Ventresca, PhD Candidate

1:45 p.m.-2:00 p.m.
211-OR Massively Parallel Characterization of Thousands of Type 2 Diabetes–Associated Variants in Multiple Cell Types Nominates Candidate Causal Regulatory Alleles and Mechanisms
Presenting Author: Madhav Kothari, MS

2:00 p.m.-2:15 p.m.
212-OR Differential Cell-Type-Specific Gene Expression and Chromatin Accessibility by Type 2 Diabetes Status and Physical Activity Levels in Human Skeletal Muscle
Presenting Author: Dan Ciotlos, Master's Degree

2:15 p.m.-2:30 p.m.
213-OR Widespread Age-Associated Changes in the Chromatin Architecture of Skeletal Muscle Cell Types
Presenting Author: Keagan G. Moo, BS

2:30 p.m.-2:45 p.m.
214-OR Human Genetic Study of Triglyceride to HDL-C Ratio Adjusted for BMI Identifies New Insulin Resistance-Associated Loci, Genes, Pathways, and Disease Subtypes
Presenting Author: Antonino Oliveri, PhD

215-OR UNABLE TO ATTEND
SATURDAY, JUNE 22, 2024

1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-OR02-1.5
Novel Regulators of Insulin Action and Insulin Sensitivity (Includes Livestream)
Room: W414
Chair: Terry Unterman, MD

1:30 p.m.-1:45 p.m.
216-OR CREG1 Promotes Insulin Receptor Recycling to Enhance Insulin Signaling in Hepatocytes
Presenting Author: Yechaan Joo, BS, MPH

1:45 p.m.-2:00 p.m.
217-OR Depalmitoylation Inhibition Improves Glucose Tolerance by Promoting Endothelial Insulin Transcytosis
Presenting Author: Wei Zhang, PhD

2:00 p.m.-2:15 p.m.
218-OR Disrupted Circadian Glucocorticoid Rhythms and High-Fat Diet Drive Obesity and Insulin Resistance through Distinct Mechanisms
Presenting Author: Mary Teruel, PhD

2:15 p.m.-2:30 p.m.
219-OR Loss of Insulin Signaling in Microglia Impairs Cellular Uptake of Ab and Neuroinflammatory Response Exacerbating Alzheimer-Like Neuropathology
Presenting Author: Wenqiang Chen, PhD

2:30 p.m.-2:45 p.m.
220-OR Reduced Apolipoprotein C-I Truncation Is Associated with Worsening of Insulin Resistance and Risk of Diabetes in Persons with Impaired Glucose Tolerance
Presenting Author: Juraj Koska, MD, PhD

2:45 p.m.-3:00 p.m.
221-OR Skeletal Muscle Insulin Resistance—The Rate-Limiting Step in Humans Is at the Level of the Vasculature
Presenting Author: Daniël van Raalte, MD, PhD
Oral Presentations
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-OR05-1.5
The “Barrier Reef”—Overcoming Hurdles to Beta-Cell Replacement Therapies
Room: W304 A-D
Chair: Clayton E. Mathews, PhD

1:30 p.m.-1:45 p.m.
222-OR Overcoming Islet Scarcity through In Vitro Differentiation of Human Pluripotent Stem Cells
Presenting Author: Jeffrey R. Millman, PhD

1:45 p.m.-2:00 p.m.
223-OR Characterization of Regenerative Adult Islet Progenitor Cells from Human Pancreatic Tissue
Presenting Author: Jayachandra Kuncha, PhD

2:00 p.m.-2:15 p.m.
224-OR Effect of PD-L1 Overexpression on Autoreactive T-Cell Responses toward Stem Cell–Derived Beta Cells
Presenting Author: Jessie Barra, PhD

2:15 p.m.-2:30 p.m.
225-OR Sequential Islet Transplants for Type 1 Diabetes Do Not Cumulatively Increase Hepatic Portal Venous Pressure
Presenting Author: Alice L. J. Carr, PhD, MSci

2:30 p.m.-2:45 p.m.
226-OR Immunoprivileged Hydrogels Recover Normoglycemia for Extended Duration in Immunocompetent Diabetic Animals
Presenting Author: Harald Stover, PhD
1:30 p.m.-3:00 p.m.  
(continued)

**ePoster Theater**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: ePoster05*  
(*) Learning Across Diabetes  
*Room: Exhibit Hall (West A1-A3) ePoster Theater A*  
*Moderator: Alanna Weisman, MD, PhD, FRCPC*

(*) Continuing Education Credit Is Not Awarded for this Session.

1:30 p.m.-1:40 p.m.  
**733-P** Efficacy and Safety of HS-20094 in Patients with Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial  
*Presenting Author: Lin Liu, PhD*

1:40 p.m.-1:50 p.m.  
**734-P** Use of GLP-1 Agonists and Perioperative Complications in Patients Undergoing Elective Surgery  
*Presenting Author: Carlos E. Mendez, MD, FACP*

1:50 p.m.-2:00 p.m.  
**735-P** Association between Glucagon-Like Peptide 1 Receptor Agonists and Risk of Depression in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study  
*Presenting Author: Ying Lu, BA*

2:00 p.m.-2:10 p.m.  
**843-P** Multinational Analysis of Factors Associated with Missed Bolus Insulin Injections Using Smart Pen Data  
*Presenting Author: Francisco Javier Ampudia Blasco, MD, PhD*

2:10 p.m.-2:20 p.m.  
**844-P** Insulin-Like Growth Factor Binding Protein 3 Levels Modulate the Glucose Lowering Effect of Intensive Lifestyle Intervention for Weight Loss in Type 2 Diabetes  
*Presenting Author: Wendy L. Bennett, MD*

2:20 p.m.-2:30 p.m.  
**845-P** The Menin Inhibitor Ziftomenib Induces Insulin Production and Improves Insulin Sensitivity in a Rat Model of Type 2 Diabetes Mellitus (T2DM)  
*Presenting Author: Asako McCloskey, PhD*

2:30 p.m.-2:40 p.m.  
**909-P** Impact of SGLT2 Inhibition on Glucosuria in HNF1A-MODY  
*Presenting Author: Henrik Maagensen, MD*
SATURDAY, JUNE 22, 2024

1:30 p.m.-3:00 p.m.  
(continued)

ePoster Theater
Theme Area: Acute and Chronic Complications  
Session Number: ePoster06  
(* ) From Macrovascular to Microvascular  
Room: Exhibit Hall (West A1-A3) ePoster Theater B  
Moderator: Carol H. Wysham, MD

(* ) Continuing Education Credit Is Not Awarded for this Session.

1:30 p.m.-1:40 p.m.
1791-LB Metabolic Syndrome (MS) as a Risk Factor for Myocardial Infarction (MI), Coronary Heart Disease (CHD), Stroke, and Peripheral Artery Disease (PAD) in 41,215 People with Type 1 Diabetes (PwT1D)  
Presenting Author: Jochen Seufert, MD, PhD, FRCPE

1:40 p.m.-1:50 p.m.
1799-LB Identification of Proteomics Signature for Vascular Complications in Type 2 Diabetes  
Presenting Author: Habib Francis, PhD

1:50 p.m.-2:00 p.m.
1795-LB Elevation of Endogenous Glucose Production in Persons with Dysglycemia and Impaired Cardiac Function upon Myocardial Infarction  
Presenting Author: Clara Möser

2:00 p.m.-2:10 p.m.
1937-LB Coordinated Approach to Improve Quality of Care and Address Disparities in Patients with Cardiometabolic Disease—Analysis from the Cardiometabolic Center Alliance Registry  
Presenting Author: Mikhail N. Kosiborod, MD

2:10 p.m.-2:20 p.m.
1958-LB Overnight Glycemia’s Relevance to Insulin Resistance (IR) in Type 1 Diabetes (T1D)  
Presenting Author: Melanie G. Cree, MD, PhD

2:20 p.m.-2:30 p.m.
1995-LB Prevalence, Risk Factors, and Clinical Characteristics of NAFLD in Individuals with Type 1 Diabetes Mellitus  
Presenting Author: Weiwei Jiang

(continued on next page)
2:30 p.m.-2:40 p.m.

1811-LB Improvement in Diabetic Retinopathy and Achieving Remission of Type 2 Diabetes Mellitus through Digital Twin Technology—A One-Year Intervention Study
Presenting Author: Shashank Joshi, MD, DM, FRCP, FACP, FACE

2:40 p.m.-2:50 p.m.

1817-LB Association between the Neutrophil Percentage-to-Albumin Ratio and Mortality in Patients with Diabetic Foot Ulcer
Presenting Author: Hong Zhu, PhD
3:15 p.m.-4:15 p.m.

Panel
Theme Area: Acute and Chronic Complications
Session Number: AC-PN03-1
From the Cutting Room Floor—Semi-live Surgery for Healing Diabetic Foot Ulcers for the Referring Practitioner
Room: W206
Chair: Ryan T. Crews, PhD, CCRP
3:15 p.m.-3:40 p.m. After the Referral—Watch How Podiatrists Surgically Treat Foot Ulcers
Haywan Chiu, DPM
3:40 p.m.-4:05 p.m. Kidney-Friendly Vascular Surgery Interventions for Diabetic Peripheral Arterial Disease
Michael Siah, MD
4:05 p.m.-4:15 p.m. Question and Discussion Period

Panel
Theme Area: Acute and Chronic Complications
Session Number: AC-PN08-1
Beyond Statins—Treating and Evaluating Residual Atherosclerotic Cardiovascular Disease Risk
Room: W207
Chair: Chiadi E. Ndumele, MD, PhD
3:15 p.m.-3:25 p.m. New Lipid-Lowering Pharmacotherapies in Diabetes
Erin Michos, MD, MHS
3:25 p.m.-3:35 p.m. Lp(a) Therapeutics—Are We There Yet?
Marlys Koschinsky, PhD
3:35 p.m.-3:45 p.m. Advanced Diagnostic Imaging—Is Your Lipid Therapy Good Enough?
Yasmin S. Hamirani, MD
3:45 p.m.-4:15 p.m. Panel Discussion

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY02-1
Diabetic Retinopathy Care and Screening—Is Artificial Intelligence Changing the Future?
Room: W208
Chair: Paolo S. Silva, MD
3:15 p.m.-3:30 p.m. Overview of DRCR Retina Network Studies and Standards of Diabetes Eye Care
Mohamed Elmasry, MD, PhD
3:30 p.m.-3:45 p.m. Emerging Treatment Strategies for Diabetic Retinopathy
Thomas W. Gardner, MD, MS
3:45 p.m.-4:00 p.m. Artificial Intelligence and Novel Retinal Imaging in Diabetic Retinopathy Screening
Aaron Y. Lee, MD, MSCI
4:00 p.m.-4:15 p.m. Leveraging Diabetic Retinopathy Screening Programs in Clinical Trials
David Preiss, MBChB, MRCP, FRCPath, PhD
Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY14-1
The Many Faces of Kidney Disease in Diabetes—Not All Are Diabetic Nephropathy (Includes Livestream)
Room: W307
Chair: Ashish Verma, MB, BS
3:15 p.m.-3:35 p.m. Acute Kidney Injury and Its Long-Term Consequences in Diabetes
Andrew Advani, BSc, MBChB(Hons), PhD, FRCP(UK), FRCP(Edin), FASN
3:35 p.m.-3:55 p.m. The Vascular Crossroads—Hypertension and Vascular Disease in Diabetic Kidney Disease Progression
Jeffrey B. Hodgin, MD, PhD
3:55 p.m.-4:15 p.m. Decoding Diabetic Kidney Disease—Molecular Subtypes and the Future of Nosology
Timothy Sutton, MD

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY16-1
Updates in Autonomic Neuropathy
Room: W308
Chair: Andrew J.M. Boulton, MD, DSc (Hon), FACP, FICP, FRCP
3:15 p.m.-3:35 p.m. Autonomic Dysfunction—Challenging Clinical Scenarios
Christian S. Hansen, MD, PhD
3:35 p.m.-3:55 p.m. Gastroparesis—Myths and Facts
Karen L. Jones, Dip App Sc (Nuclear Medicine), PhD
3:55 p.m.-4:15 p.m. Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY06-1
Optimizing Outcomes of GLP-1+/GIP Receptor Agonists—How to Help Patients Succeed
Room: W315
Chair: Ka Hei Karen Lau, MS, RDN, LDN, CDCES
3:15 p.m.-3:45 p.m. Is Weight Loss Everything? Nutrition and Lifestyle Are Missing Puzzle Pieces
Colleen Dawkins, FNP-C, RDN, CSOWM
3:45 p.m.-4:15 p.m. Protocol in Practice—Standing Orders for RD/RN Management of GLP-1/GIP Receptor Agonists
Maureen Chomko, RD, CDCES
3:15 p.m.–4:15 p.m.  
(continued)

**Debate**

*Theme Area: Clinical Diabetes/Therapeutics*

*Session Number: CT-DB18-1*

**Diabetes Prevention Program (DPP) vs. GLP-1RA—Which Tool Is Best to Battle the Obesity and Diabetes Epidemics?**

*Room: W304 E-H*

*Chair: Amisha Wallia, MD, MS*

3:15 p.m.–3:35 p.m.  *The Diabetes Prevention Program Is the Best Tool to Battle Prediabetes and Obesity (NDPP)*  
  David G. Marrero, PhD

3:35 p.m.–3:55 p.m.  *GLP-1RAs Are the Best Tools to Battle Prediabetes and Obesity*  
  Ildiko Lingvay, MD, MPH, MSCS

3:55 p.m.–4:00 p.m.  *Rebuttal*  
  David G. Marrero, PhD

4:00 p.m.–4:05 p.m.  *Rebuttal*  
  Ildiko Lingvay, MD, MPH, MSCS

4:05 p.m.–4:15 p.m.  *Question and Discussion Period*

**Panel**

*Theme Area: Clinical Diabetes/Therapeutics*

*Session Number: CT-PN11-1*

**GLP-1 +/- GIP Receptor Agonists in the Perioperative Setting—To Stop or Not to Stop?**

*Room: W415C (Valencia Ballroom)*

*Chair: Leigh Perreault, MD, FACE, FACP*

3:15 p.m.–3:30 p.m.  *Anesthesia Perspective*  
  Girish P. Joshi, MBBS, MD, FFARCSI

3:30 p.m.–3:45 p.m.  *Gastroenterology Perspective*  
  Jana G. Al Hashash, MD, MSc, FACG, AGAF

3:45 p.m.–4:00 p.m.  *Endocrinology Perspective*  
  Sue D. Pedersen, MD, FRCPC C-ENDO, DABOM

4:00 p.m.–4:15 p.m.  *Panel Discussion*

**Panel**

*Theme Area: Clinical Diabetes/Therapeutics*

*Session Number: CT-PN19-1*

**Health Care Policy and Diabetes—How to Improve Population Health from Multiple Perspectives (Includes Livestream)**

*Room: W320 (Chapin Theater)*

*Chair: Elbert S. Huang, MD, MPH, FACP*

3:15 p.m.–4:15 p.m.  *Health Care Policy and Diabetes—How to Improve Population Health from Multiple Perspectives*  
  Neda Laiterrapong, MD, MS, FACP
  Irl B. Hirsch, MD
  Mohammed K. Ali, MD, MSc, MBA
  Keri J. Whitaker, RN
  Aaron Winn, PhD
Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY13-1
How I Feel Matters, Too—The Psychosocial Aspects of Automated Insulin Delivery (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: William H. Polonsky, PhD, CDCES
3:15 p.m.-3:45 p.m.  It's Still a Lot of Work—Mitigating Diabetes Technology Burnout
Jill Weissberg-Benchell, PhD, CDCES
3:45 p.m.-4:15 p.m.  Psychosocial Considerations of Automated Insulin Delivery
Marisa E. Hilliard, PhD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY34-1
Hyperglycemic Crises in Diabetes
Room: W314
Co-Chairs: Nuha El Sayed, MD, MMSc  and Guillermo Umpierrez, MD, CDCES, MACP, FACE
3:15 p.m.-3:25 p.m.  Welcome and Introduction—Rationale and Methods
Guillermo Umpierrez, MD, CDCES, MACP, FACE
3:25 p.m.-3:35 p.m.  Epidemiology—Global Trends, Costs, Mortality
Georgia M. Davis, MD
3:35 p.m.-3:45 p.m.  Pathogenesis and Diagnostic Criteria
Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD
3:45 p.m.-3:55 p.m.  Management—Acute and Transition Protocol
Rodolfo J. Galindo, MD
3:55 p.m.-4:05 p.m.  Complications and Discharge Protocol
David C. Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE
4:05 p.m.-4:15 p.m.  Question and Discussion Period

Debate
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-DB01-1
Boosting Energy Expenditure in Obesity—Debating the Potential of Thermogenic Adipose Tissue and Skeletal Muscle Bioenergetics as Antiobesity Targets in Humans
Room: W304 A-D
Chair: Shingo Kajimura, PhD
3:15 p.m.-3:30 p.m.  Brown Fat Is a Regulator of Energy Balance in Humans
Denis Blondin, PhD
3:30 p.m.-3:45 p.m.  The Role of BAT in Obesity and Weight Loss
Kirsi M. Virtanen, MD
3:45 p.m.-3:50 p.m.  Rebuttal
Denis Blondin, PhD
3:50 p.m.-3:55 p.m.  Rebuttal
Kirsi M. Virtanen, MD
3:55 p.m.-4:15 p.m.  Question and Discussion Period
3:15 p.m.-4:15 p.m.  
(continued)

**Symposium**  
*Theme Area: Obesity/Integrated Physiology*  
*Session Number: IP-SY06-1*  
**Intermittent Fasting in Various Forms of Diabetes Care (Includes Livestream)**  
Room: W414  
Chair: Kelsey Gabel, RD, MS, PhD  
3:15 p.m.-3:35 p.m.  
*Possibilities of Fasting in Patients with Diabetes*  
Lisa S. Chow, MD, MS  
3:35 p.m.-3:55 p.m.  
*Can Time-Restricted Eating Inhibit the Progression of Prediabetes?*  
Courtney M. Peterson, PhD, MSc, MA, MS  
3:55 p.m.-4:15 p.m.  
*Can Time-Restricted Eating Treat Polycystic Ovary Syndrome?*  
Sofia Cienfuegos, PhD, MS

**Symposium**  
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*  
*Session Number: BM-SY18-1*  
**International Consensus Statement and Movement to End Diabetes Stigma**  
Room: W311  
Chair: Jane Speight, MSc, PhD, CPyschol, FBPsS  
3:15 p.m.-3:30 p.m.  
*International Consensus Statement for Ending Diabetes Stigma—Background, Methodology of the Consensus Statement, and Overview of Recommendations for Health Professional and Researchers*  
Matthew Garza, Bachelor's Degree  
3:30 p.m.-3:45 p.m.  
*Prevalence and Impact of Diabetes Stigma—Implications for Health Outcomes*  
Mary de Groot, PhD  
3:45 p.m.-4:00 p.m.  
*Research in Diabetes Stigma—What's Next?*  
Kevin Joiner, PhD, APRN, ANP-BC, CDCES  
4:00 p.m.-4:15 p.m.  
*Integration into Care Settings—Patient Perspective and Identifying Resources*  
Susan Guzman, PhD
SATURDAY, JUNE 22, 2024

4:30 p.m.-6:00 p.m.

**Symposium**
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY01-1.5
The Evolution of Diabetes Behavioral Care *(Includes Livestream)*
Room: W307
Chair: Mary de Groot, PhD
4:30 p.m.-5:00 p.m. Establishing the Evidence Base for Patient Empowerment in Behavioral Diabetes Care
   Gretchen Piatt, PhD, MPH
5:00 p.m.-5:30 p.m. Harnessing Advanced Methods and Technologies for Behavioral Diabetes Care
   Molly L. Tanenbaum, PhD
5:30 p.m.-6:00 p.m. Advancing Health Equity in Behavioral Diabetes Care
   Nadia Islam, MA, MPhil, PhD

**Main Event**
Theme Area: Main Event
Session Number: CT-ME40-1.5
(*) Innovation Challenge *(Includes Livestream)*
(*) Continuing Education Credit Is Not Awarded for this Session
Room: West Hall B3-4 (General Session)
Co-Chairs: Robert A. Gabbay, MD, PhD and Nicole Johnson, DrPH, MPH, MA
4:30 p.m.-6:00 p.m. Innovation Challenge
   Craig Cooper, MBA
   Bari Krein
   Sean Sullivan, PhD

**Symposium**
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY09-1.5
Diabetes and the Lung—Cause and Consequence *(Includes Livestream)*
Room: W414
Chair: Vanita R. Aroda, MD
4:30 p.m.-4:50 p.m. What Do We Know about Diabetes and the Lung?
   Juan C. Celedón, MD, DrPH
4:50 p.m.-5:10 p.m. Insulin Resistance as a Treatable Trait in Asthma
   Tianshi D. Wu, MD, MHS
5:10 p.m.-5:30 p.m. GLP-1 Receptor Agonists and the Respiratory Outcomes in Patients with Asthma and Chronic Obstructive Pulmonary Disease
   Dinah Foer, MD
5:30 p.m.-5:50 p.m. Immunometabolic Pathways in Lung Inflammation—Novel Therapeutic Opportunities
   M. Furkan Burak, MD
5:50 p.m.-6:00 p.m. Question and Discussion Period
4:30 p.m.-6:00 p.m.  (continued)

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY29-1.5*
**Heterogeneity of Diabetes—Pathophysiology to Global Considerations** *(Includes Livestream)*
*Room: W320 (Chapin Theater)*
*Chair: Stephen S. Rich, PhD, FAHA*

4:30 p.m.-4:45 p.m.  *Heterogeneity of Diabetes—A Global Perspective*
   Paul W. Franks, PhD

4:45 p.m.-5:05 p.m.  *Heterogeneity in Type 2 Diabetes*
   Shivani Misra, MD, PhD

5:05 p.m.-5:25 p.m.  *Heterogeneity in Treatment Strategies for Diabetes*
   Ronald C.W. Ma, MB, BChir, FRCP

5:25 p.m.-5:45 p.m.  *Heterogeneity from Social Determinants of Health*
   Tiffany L. Gary-Webb, PhD, MHS

5:45 p.m.-6:00 p.m.  Panel Discussion

**Panel**
*Theme Area: Insulin Action/Molecular Metabolism*
*Session Number: IA-PN02-1.5*
**Technical Challenges and Solutions in Metabolomics** *(Includes Livestream)*
*Room: W415B (Valencia Ballroom)*
*Chair: Caroline Chidley, PhD*

4:30 p.m.-4:50 p.m.  *Subcellular Metabolomics for Mapping Nutrient Responses*
   Sophie Trefely, PhD

4:50 p.m.-5:10 p.m.  *Nuclear Magnetic Resonance–Based Metabolism*
   Stanislaw Deja, PhD

5:10 p.m.-5:30 p.m.  *Stable Isotope Tracing In Vivo and Imaging Mass Spec*
   Tara TeSlaa, PhD

5:30 p.m.-5:50 p.m.  *New Metabolite ID in Metabolomics*
   Caroline Chidley, PhD

5:50 p.m.-6:00 p.m.  Question and Discussion Period
SATURDAY, JUNE 22, 2024

4:30 p.m.–6:00 p.m.
(continued)

**Oral Presentations**

**Theme Area: Clinical Diabetes/Therapeutics**

**Session Number: CT-OR09-1.5**

**Leveling Up Incretin-Based Therapy in Type 2 Diabetes**

Room: W415C (Valencia Ballroom)
Chair: Tina Vilsbøll, MD, DMSc

4:30 p.m.–4:45 p.m.

**227-OR** Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo Regardless of Insulin Sensitivity and Beta-Cell Function—Post Hoc Analysis from SURMOUNT-2
Presenting Author: Tim Heise, MD

4:45 p.m.–5:00 p.m.

**228-OR** Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids
Presenting Author: John J. Suschak, PhD

5:00 p.m.–5:15 p.m.

**229-OR** Orforglipron Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes
Presenting Author: Julio Rosenstock, MD

5:15 p.m.–5:30 p.m.

**230-OR** Comparative Effectiveness of Semaglutide in Type 2 Diabetes—Year 2 Results of a Randomized Pragmatic Clinical Trial
Presenting Author: John B. Buse, MD, PhD

5:30 p.m.–5:45 p.m.

**231-OR** Differences in Weight Reduction Efficacy of Tirzepatide in Adults Without vs. With Type 2 Diabetes with Overweight or Obesity in SURMOUNT 1 and 2
Presenting Author: Rodolfo J. Galindo, MD

5:45 p.m.–6:00 p.m.

**232-OR** Glucagon-Like Peptide 1 Receptor Agonists and Risk of Suicide/Self-Harm in U.S. Older Adults with Type 2 Diabetes—A Population-Based Cohort Study
Presenting Author: Huilin Tang, MSc
4:30 p.m.-6:00 p.m.  
(continued)

**Oral Presentations**

*Theme Area: Obesity/Integrated Physiology*

**Session Number: IP-OR08-1.5**

**Towards Targeted Weight-Loss Therapy—New Considerations for GLP-1RA or Surgery**

Room: W304 A-D

Chair: Daniel S. Hsia, MD

**233-OR WITHDRAWN**

4:30 p.m.-4:45 p.m.

**234-OR**  
Performance of a Machine-Learning Gene Risk Score Biomarker to Predict Weight-Loss Response to Tirzepatide and Semaglutide  
Presenting Author: Maria D. Hurtado, MD, PhD

4:45 p.m.-5:00 p.m.

**235-OR**  
Quality of Life and Health Utility 12 Years after Randomization to Bariatric Surgery vs. Medical Therapy in Patients with Type 2 Diabetes and Obesity—The ARMMS-T2D Study  
Presenting Author: Donald C. Simonson, MD, MPH, ScD

5:00 p.m.-5:15 p.m.

**236-OR**  
Short-Term Effects of Semaglutide and Tirzepatide on Body Composition in Patients with Obesity Undergoing a Low-Calorie Diet  
Presenting Author: Masamitsu Naka, Bachelor’s Degree

**237-OR WITHDRAWN**

5:15 p.m.-5:30 p.m.

**238-OR**  
Effect of Baseline Antihyperglycemic Medications on Weight Reduction with Tirzepatide—SURMOUNT-2 Subgroup Analysis  
Presenting Author: Sriram Machineni, MD
SUNDAY, JUNE 23, 2024

Scientific Sessions
8:00 a.m.--9:30 a.m.

Panel
Theme Area: Acute and Chronic Complications
Session Number: AC-PN10-1.5
A Multidisciplinary Approach—Challenging Cases from the Cardiometabolic Clinic (Includes Livestream)
Room: W307
Chair: Melissa L. Magwire, RN, MSN, CDCES
8:00 a.m.-9:00 a.m. A Multidisciplinary Approach—Challenging Cases from the Cardiometabolic Clinic
Chiadi E. Ndumele, MD, PhD
Bruce A. Perkins, MD, MPH, FRCP(C)
Goutham Rao, MD
Evan M. Sisson, PharmD, MHA, CDCES
9:00 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY13-1.5
The Changing Climate of Diabetic Kidney Disease—Environmental Triggers and Vulnerabilities
Room: W206
Chair: Meda E. Pavkov, MD, PhD
8:00 a.m.-8:30 a.m. Heat Waves and Kidneys—How Climate Change Aggravates Diabetic Nephropathy
Vivek Bhalla, MD
8:30 a.m.-9:00 a.m. Clear Waters Ahead? The Impacts of PFAS on Diabetic Kidney Health
Jesse Goodrich, PhD
9:00 a.m.-9:30 a.m. The Exposome Imperative—Unlocking the Full Spectrum of Exposure Sciences to Prevent Diabetic Kidney Disease
Ana Navas-Acien, MD, PhD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY02-1.5
Loneliness Is a Real Heartbreaker (Includes Livestream)
Room: W414
Chair: Kevin Joiner, PhD, APRN, ANP-BC, CDCES
8:00 a.m.-8:30 a.m. The Epidemic of Loneliness and Isolation
Anne Gaglioti, MD, MS, FAAFP
8:30 a.m.-9:00 a.m. The Link between Loneliness and Diabetes
Xuan Wang, PhD
9:00 a.m.-9:30 a.m. The Psychological Toll of Loneliness
Ariana Chao, PhD, MSN, BSN, RN
**Panel**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-PN10-1.5*
**Noninsulin Treatment for Type 1 Diabetes**
*Room: W311*
*Chair: Richard M. Bergenstal, MD*

8:00 a.m.-8:20 a.m. *Is There a Place for SGLT Inhibition in Type 1 Diabetes Mellitus?*
    Ele Ferrannini, MD

8:20 a.m.-8:40 a.m. *Is There a Place for GLP-1RA in Type 1 Diabetes Mellitus?*
    Michael A. Nauck, MD

8:40 a.m.-9:00 a.m. *Is There a Place for MRA in Type 1 Diabetes Mellitus?*
    Hiddo L. Heerspink, PhD

9:00 a.m.-9:20 a.m. *The Lived Experience*
    Wes Unger

9:20 a.m.-9:30 a.m. *Question and Discussion Period*

---

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY01-1.5*
**Metformin Reexamined—Pleiotropic Effects in Mother and Offspring in Humans and Animal Models**
*Room: W315*
*Chair: Linda A. Barbour, MD, MSPH, FACP*

8:00 a.m.-8:15 a.m. *First Do No Harm—Potential Fetal Programming Perils with Maternal Metformin Use in Pregnancy*
    Kjersti M. Aagaard, MD, PhD, FACOG

8:15 a.m.-8:30 a.m. *Effects and Consequences of Metformin Action in the Fetal Liver from Nonhuman Primates and Sheep*
    Stephanie R. Wesolowski, PhD

8:30 a.m.-8:45 a.m. *Effects of Metformin and Maternal Overnutrition on Fetal Pancreas and Islet Mitochondria in Nonhuman Primates*
    Maureen Gannon, PhD

8:45 a.m.-9:00 a.m. *Evidence for Long-Term Effects of In Utero Metformin Exposure—Where Do We Go from Here?*
    Susan Ozanne, PhD

9:00 a.m.-9:30 a.m. *Question and Discussion Period*
Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY24-1.5
Joint ADA/ISPAD Symposium—Pediatric Diabetes Insights and Innovations
Room: W415C (Valencia Ballroom)
Co-Chairs: Jamie R. Wood, MD and Eda Cengiz, MD, MHS
8:00 a.m.-8:20 a.m. What Is New in Treatment of Preschool Children with Type 1 Diabetes Mellitus?
   Carine de Beaufort, MD, PhD
8:20 a.m.-8:40 a.m. Inpatient Pediatric Diabetes Technology Use
   Erin C. Cobry, MD
8:40 a.m.-9:00 a.m. Innovations in Diabetes Education—App-Based Diabetes Technology Education and More...
   Brynn E. Marks, MD, MSHPEd
9:00 a.m.-9:20 a.m. Rethinking First-Line Therapy in Pediatric Type 2 Diabetes
   Shylaja Srinivasan, MD, MAS
9:20 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY36-1.5
The State of Health Equity and Disability—Supporting Diabetes Technology Usage in People Who Are Deaf/Hard of Hearing or Blind/Low Vision
Room: W314
Co-Chairs: Nancy A. Allen, PhD and Jeremy Quiroga
8:00 a.m.-8:20 a.m. Fostering Inclusivity—Advancing Diabetes Technology for Deaf and Hard of Hearing Individuals
   Michelle L. Litchman, PhD, FNP-BC
8:20 a.m.-8:40 a.m. Hacks to Address the Lack of Diabetes Technology Accessible for Deaf and Hard of Hearing People with Diabetes
   Ryan Layton
8:40 a.m.-9:00 a.m. Enhancing Diabetes Technology Accessibility for Individuals Who Are Blind or Have Low Vision
   Allyson S. Hughes, PhD
9:00 a.m.-9:20 a.m. Real-World Challenges Using Diabetes Technology as a Person with Low Vision
   Chelcie Rice
9:20 a.m.-9:30 a.m. Question and Discussion Period
SUNDAY, JUNE 23, 2024

8:00 a.m.-9:30 a.m.
(continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY44-1.5
Diabetes and Organ Transplantation—Pathophysiology, Inpatient and Outpatient Management
Room: W208
Chair: Boris Draznin, MD, PhD
8:00 a.m.-8:20 a.m. Diabetes and Organ Transplantation—An Overview
Archana R. Sadhu, MD, FACE
8:20 a.m.-8:40 a.m. Management of Diabetes following Liver Transplantation
Palak Choksi, MD
8:40 a.m.-9:00 a.m. Diabetes and Kidney Transplantation
Robert J. Rushakoff, MD
9:00 a.m.-9:30 a.m. Question and Discussion Period

Panel
Theme Area: Epidemiology/Genetics
Session Number: EG-PN04-1.5
When a Box Isn’t a Box—Research Frameworks for Understanding and Addressing Disparities in Type 2 Diabetes
Room: W207
Chair: Jacqueline A. Seiglie, MD, MSc
8:00 a.m.-8:20 a.m. Adapting the NIMHD Research Framework for Diabetes Disparities across the Lifespan
Eyitayo O. Owolabi, PhD, RN
8:20 a.m.-8:40 a.m. Applying Implementation Science Frameworks to Advance Diabetes Prevention Efforts
Lillian Madrigal, PhD, MPH
8:40 a.m.-9:00 a.m. National Policy Frameworks for Addressing Type 2 Diabetes
Puneet Kaur Chehal, MA, PhD
9:00 a.m.-9:20 a.m. A Pragmatic Action-Based Framework to Address Global Inequities in Diabetes
Ashby F. Walker, PhD
9:20 a.m.-9:30 a.m. Question and Discussion Period
Symposium
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-SY04-1.5
Translating Type 1 Diabetes Risk Alleles to Therapy
Room: W304 A-D
Chair: Suna Onengut-Gumuscu, PhD
8:00 a.m.-8:20 a.m. IL2RA Variation Shapes Type 1 Diabetes Risk
   Harikesh S. Wong, PhD, BSc
8:20 a.m.-8:40 a.m. HLA as a Target, Not a Predictor
   Aaron W. Michels, MD
8:40 a.m.-9:00 a.m. Targeting TYK2 for Treatment of Type 1 Diabetes
   Farooq Syed, PhD
9:00 a.m.-9:20 a.m. Fixing FOXP3+ Cells in Type 1 Diabetes
   Matthew E. Brown, BS
9:20 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-SY04-1.5
Metabolite Transport and Molecular Metabolism
Room: W304 E-H
Chair: Uptal Pajvani, MD, PhD
8:00 a.m.-8:20 a.m. Fumarate and Mitochondrial Energetics
   Jessica Spinelli, PhD
8:20 a.m.-8:40 a.m. Lipid Transport and Metabolism
   Judith Simcox, BA, PhD
8:40 a.m.-9:00 a.m. Insulin Signaling and Bile Acid Transport and Metabolism
   Rebecca Haeusler, PhD
9:00 a.m.-9:20 a.m. Mitochondrial Pyruvate Transport and Liver Metabolism
   Brian N. Finck, PhD
9:20 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Obesity/Integrated Physiology
Session Number: IP-SY11-1.5
Severe GLP-1RA Side Effects in Obesity Treatment—Fact or Fiction? (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Mary-Elizabeth Patti, MD
8:00 a.m.-8:20 a.m. Pancreatitis and Gall Bladder Disease
   Daniel J. Drucker, MD
8:20 a.m.-8:40 a.m. Suicide Risk
   John-Michael Gamble, PhD
8:40 a.m.-9:00 a.m. Thyroid Cancer
   Elizabeth N. Pearce, MD, MSc
9:00 a.m.-9:20 a.m. Fine-Tuning the Patient's GLP-1 Experience
   Beverly G. Tchang, MD
9:20 a.m.-9:30 a.m. Question and Discussion Period
8:00 a.m.-9:30 a.m.  
(continued)

Symposium
Theme Area: Obesity/Integrated Physiology  
Session Number: IP-SY12-1.5

ADA Diabetes Journal Symposium—It Is All in Your Head—Central Nervous System Control of Systemic Metabolism  
Room: W308  
Chair: Jennifer L. Estall, PhD

8:00 a.m.-8:20 a.m. Brain Defense of Glycemia in Health and Diabetes  
Zaman Mirzadeh, MD, PhD

8:20 a.m.-8:40 a.m. Central Nervous System Regulation of Systemic Glucose—Lessons Learned from the Adaptation to Exercise  
Kevin Williams, PhD

8:40 a.m.-9:00 a.m. What the Gut Says to the Brain About Food  
Laura Rupprecht, PhD

9:00 a.m.-9:20 a.m. Neural Signaling To and From Adipose Tissue in the Regulation of Metabolic Health  
Kristy L. Townsend, PhD

9:20 a.m.-9:30 a.m. Question and Discussion Period
SUNDAY, JUNE 23, 2024

9:45 a.m.-11:15 a.m.

Special Lectures and Addresses
Session Number: MSB-01
President, Medicine & Science Address and National Scientific & Health Care Achievement Awards Presentation *(Includes Livestream)*
Room: West Hall B3-4 (General Session)
9:45 a.m.-9:50 a.m.  Introduction of President, Medicine & Science  
Robert A. Gabbay, MD, PhD
9:50 a.m.-10:20 a.m.  Fighting Diabetes—A Journey That Began in Childhood  
Mandeep Bajaj, MBBS
10:20 a.m.-10:55 a.m.  National Scientific & Health Care Achievement Awards Presentation
10:55 a.m.-11:15 a.m.  Conclude

11:30 a.m.-12:30 p.m.

Professional Interest Group
*Theme Area: Acute and Chronic Complications*
Session Number: AC-IG01-1
Discussion on Diabetes and Cardiovascular Disease—Obesity and Diabetes—Innovative Research to Inform Clinical Practice
Room: W206
Chair: Heather Ferris, MD, PhD
11:30 a.m.-11:33 a.m.  Introduction
11:33 a.m.-11:48 a.m.  Ketone Metabolism and Cardiometabolic Disease  
Peter A. Crawford, MD, PhD
11:48 a.m.-12:03 p.m.  Dapagliflozin According to Body Mass Index  
Mikhail N. Kosiborod, MD
12:03 p.m.-12:18 p.m.  REAL HEALTH-Diabetes Trial  
Deborah J. Wexler, MD, MSc
12:18 p.m.-12:30 p.m.  Question and Discussion Period

Professional Interest Group
*Theme Area: Acute and Chronic Complications*
Session Number: AC-IG03-1
Discussion on Eye Health—Novel Diabetes Therapies in Diabetic Retinopathy—A Basic Science and Preclinical Perspective
Room: W207
Chair: Blake Cooper, MD, MPH
11:30 a.m.-11:35 a.m.  Introduction
11:35 a.m.-11:55 a.m.  Novel Therapies in Clinical Trials and Treatment Strategies for Diabetic Retinopathy  
T. Y. Alvin Liu, MD
11:55 a.m.-12:15 p.m.  Therapies in Development for Diabetic Retinopathy—A Basic Science  
Thomas W. Gardner, MD, MS
12:15 p.m.-12:30 p.m.  Question and Discussion Period
SUNDAY, JUNE 23, 2024

11:30 a.m.-12:30 p.m.
(continued)

Professional Interest Group
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-IG01-1
Discussion on Behavioral Medicine and Psychology—including the Excluded in Behavioral Diabetes Research
Room: W208
Chair: Marisa E. Hilliard, PhD

11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-11:45 a.m. Recruitment, Retention, and Engagement of Men from Minoritized Racial and Ethnic Groups in Behavioral Diabetes Research
   Jaclynn M. Hawkins, PhD, MSW
11:45 a.m.-11:55 a.m. Recruitment, Retention, and Engagement of People with Neurodiversity in Behavioral Research
   Susana R. Patton, PhD, ABPP, CDCES
11:55 a.m.-12:05 p.m. Recruitment, Retention, and Engagement of LGBTQIA+ People in Behavioral Research
   Lauren B. Beach, Esq., JD, PhD
12:05 p.m.-12:30 p.m. Question and Discussion Period

Professional Interest Group
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-IG03-1
Discussion on Diabetes Self-Management Education and Support (DSMES)—It's Time to Change the Way We Talk about DSMES!
Room: W308
Chair: Joyce Y. Lee, PharmD, APPh, FCCP, BCPS, BCACP, CDCES

11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-11:50 a.m. Prioritizing Health Equity in Diabetes Overview—Centers for Disease Control and Prevention DP23-0020
   Leslie Harrison, MPH
11:50 a.m.-12:05 p.m. Centers for Disease Control and Prevention DSMES Toolkit
   Melissa Bing, MPH
12:05 p.m.-12:20 p.m. Centers for Disease Control and Prevention DSMES Playbook—Let’s Get to It!
   Betsy Rodriguez, BSN, MSN, CDCES, FADCES
12:20 p.m.-12:30 p.m. Question and Discussion Period
Professional Interest Group
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-IG02-1
Discussion on Diabetes in Primary Care—Tackling Diabetes in Primary Care—Training and Workforce Development
Room: W304 A-D
Chair: Rozalina G. McCoy, MD MS
11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-12:00 p.m. Training Primary Care Providers to Be Diabetes Specialists
Jay H. Shubrook, DO
12:00 p.m.-12:25 p.m. Leveraging Specialty Diabetology within Primary Care
Sarah Cote, NP, CDCES, BC-ADM
12:25 p.m.-12:30 p.m. Question and Discussion Period

Professional Interest Group
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-IG06-1
Discussion on Clinical Centers and Programs—Challenges in Management of Diabetes in Older Adults and in Primary Care
Room: W304 E-H
Chair: Ali A. Rizvi, MD
11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-12:00 p.m. Success in Suboptimally Controlled Type 2 Diabetes—The Magic of CGM and Collaboration
Andrew Behnke, MD
12:00 p.m.-12:25 p.m. Challenges in the Management of Diabetes in Older Adults
Tali Cukierman-Yaffee, MD, MSC
12:25 p.m.-12:30 p.m. Question and Discussion Period

Workshop
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-WS37-1
Improving Care for Deaf People with Diabetes Who Use ASL Interpreters—A Hands-On Workshop
Room: W311
Chair: Michelle L. Litchman, PhD, FNP-BC
11:30 a.m.-11:50 a.m. Language Access Disparity—The Link between Being Deaf and Having Diabetes
Karissa Mirus, MHSA
11:50 a.m.-12:10 p.m. Best Practices for Working with Deaf Populations and ASL Interpreters
Susan Layton, CI, CT, NAD IV
12:10 p.m.-12:30 p.m. Hands-on Simulation of Working with Deaf Populations and ASL Interpreters
Michelle L. Litchman, PhD, FNP-BC
Jeremy Quiroga
SUNDAY, JUNE 23, 2024

11:30 a.m.-12:30 p.m. (continued)

Professional Development
Theme Area: Professional Development
Session Number: PD-02-1
Art of Writing a Winning Grant (Includes Livestream)
Room: W307
Chair: William T. Cefalu, MD

11:30 a.m.-11:50 a.m. Basic Science Perspective
    Philipp E. Scherer, PhD
11:50 a.m.-12:10 p.m. Clinical/Translational Science Perspective
    Dana Dabelea, MD, PhD
12:10 p.m.-12:30 p.m. Question and Discussion Period
11:30 a.m.-12:30 p.m.
(continued)

**ePoster Theater**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: ePoster07*
(*Improving Efficacy and Safety of Incretin-Based Therapies*
*Room: Exhibit Hall (West A1-A3) ePoster Theater A*
*Moderator: Stewart B. Harris, CM, MD, MPH, FCFP, FACPM*

(*Continuing Education Credit Is Not Awarded for this Session.*

11:30 a.m.-11:40 a.m.
736-P **Comparison of Semaglutide vs. Tirzepatide Therapy in Adults with Type 1 Diabetes (T1D)**
Presenting Author: Henon Gebre, MPH

11:40 a.m.-11:50 a.m.
737-P **Acute Healthcare Utilization, Mortality, and Cardiovascular Events following GLP-1RA Initiation by Patients with Advanced Chronic Kidney Disease—A Real-World Comparative Study**
Presenting Author: Shuyao Zhang, MD

11:50 a.m.-12:00 p.m.
738-P **Real-World Effectiveness among Patients with Type 2 Diabetes (T2D) Initiating Tirzepatide (TZP)**
Presenting Author: Reema Mody, MBA, PhD

12:00 p.m.-12:10 p.m.
739-P **Efficacy and Safety of Tirzepatide in Overweight (OW) and Obese (OB) Patients with Type 1 Diabetes (T1D)**
Presenting Author: Janet K. Snell-Bergeon, PhD, MPH

12:10 p.m.-12:20 p.m.
740-P **Persistence and Adherence of Once-Weekly GLP-1 Receptor Agonists in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in a Real-World Setting**
Presenting Author: Tyler Dunn, PhD
11:30 a.m.-12:30 p.m.  
(continued)

**ePoster Theater**

*Theme Area: Islet Biology/Insulin Secretion*

Session Number: ePoster08

(*) Islet Biology
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Joana Almaca, PhD

(*) Continuing Education Credit Is Not Awarded for this Session.

11:30 a.m.-11:40 a.m.
**1728-P** The Nkx6.1 Binding Partner Mef2D Modulates Beta-Cell Insulin Secretion and Cell Survival  
Presenting Author: Jeffery S. Tessem, PhD

11:40 a.m.-11:50 a.m.
**1729-P** Hypertonicity Mediates Glucose-Induced First-Phase Insulin Secretion  
Presenting Author: Ian Sweet, PhD

11:50 a.m.-12:00 p.m.
**1730-P** In Vitro and In Vivo Effects of Increased IAPP Expression on Human Islet Function  
Presenting Author: Jordan J. Wright, MD, PhD

12:00 p.m.-12:10 p.m.
**1731-P** Screening Human Islets to Identify Small Molecules Enhancing Glucagon Secretion under Hypoglycemia  
Presenting Author: Thomas Bate, PhD

**1761-P** WITHDRAWN
12:30 p.m.-1:30 p.m.

**ePoster Theater**
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

Session Number: ePoster09

(*) Exploring Eating Behaviors and Weight Loss in Youth and Adults with Type 1 and Type 2 Diabetes  
Room: Exhibit Hall (West A1-A3) ePoster Theater A  
Moderator: Lindsay S. Mayberry, PhD

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.  
**640-P**  
Disordered Eating Screening within a Pediatric Diabetes Clinic  
Presenting Author: Nicole Andorko, PhD

12:40 p.m.-12:50 p.m.  
**641-P**  
Body Image and Insulin Restriction among Adolescents with Type 1 Diabetes  
Presenting Author: Rachna Sannegowda, BS

12:50 p.m.-1:00 p.m.  
**642-P**  
Reasons behind Fasting Ramadan against Medical Advice for Individuals under 18 Years with Uncontrolled Type 1 Diabetes—A Tertiary Center Experience  
Presenting Author: Zahra Rahme, MSc

1:00 p.m.-1:10 p.m.  
**643-P**  
Exploring Eating Styles of Older Adults with Type 1 Diabetes (T1D)  
Presenting Author: Angelica Cristello Sarteau, MSPH

1:10 p.m.-1:20 p.m.  
**644-P**  
Racial Ethnic Disparities in Prescription of GLP-1 Receptor Agonists for People at High Risk for Diabetes on Atypical Antipsychotics  
Presenting Author: Jithin Sam Varghese, PhD, MTech
12:30 p.m.-1:30 p.m.
(continued)

**ePoster Theater**
Theme Area: *Acute and Chronic Complications*
Session Number: ePoster10

(*) **New Progress in Clinical Screening and Interventions for ASCVD Risk Mitigation in Metabolic Disease**
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Jonathan Q. Purnell, MD

(*) **Continuing Education Credit Is Not Awarded for this Session.**

12:30 p.m.-12:40 p.m.

**433-P** Status of Type 2 Diabetes among Young Adults in Community Health Centers
Presenting Author: Sean E. DeLacey, MD

12:40 p.m.-12:50 p.m.

**434-P** Type 2 Diabetes Rather than the Presence of Significant Coronary Stenoses Is Associated with Quality of Life in Angiographied Coronary Patients
Presenting Author: Magdalena Ratz, Mag.

12:50 p.m.-1:00 p.m.

**435-P** UNABLE TO ATTEND

1:00 p.m.-1:10 p.m.

**436-P** Stringent Glycemic Control and Long-Term Macrovascular Outcomes in People with Type 2 Diabetes in China—A Retrospective Study
Presenting Author: Qi Pan, Professor

1:00 p.m.-1:10 p.m.

**437-P** Three Decades of Lipid-Lowering Therapy in Type 2 Diabetic Patients with Angiographically Proven Stable Coronary Artery Disease
Presenting Author: Johannes Vogel, Mag.
12:30 p.m.-1:30 p.m.

**Session Break**
(Take this opportunity to visit the Exhibit and Poster Halls)

1:30 p.m.-3:00 p.m.

**Debate**
*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*
*Session Number: BM-DB07-1.5*

**The Role of Artificial Intelligence in Transforming Nutrition and Diabetes Care—Ready for Prime Time or Not Quite?**
*Room: W311*
*Chair: Janice MacLeod, MD*

1:30 p.m.-1:50 p.m. **Yes, the Future Is Now—Harness the Benefits Artificial Intelligence Has to Offer**
Samatha Kleinberg, PhD

1:50 p.m.-2:10 p.m. **Not Quite, but We Are on Our Way to Building the Evidence**
Holly Nicastro, PhD, MPH

2:10 p.m.-2:20 p.m. **Rebuttal**
Samatha Kleinberg, PhD

2:20 p.m.-2:30 p.m. **Rebuttal**
Holly Nicastro, PhD, MPH

2:30 p.m.-3:00 p.m. **Question and Discussion Period**

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY32-1.5*

**Global Burden of Cardiovascular Disease in People with Diabetes (Includes Livestream)**
*Room: W320 (Chapin Theater)*
*Co-Chairs: Nuha El Sayed, MD, MMSc and Raveendhara Bannuru, MD, PhD, FAGE*

1:30 p.m.-1:45 p.m. **Cardiometabolic Disease Introduction and United Kingdom Region**
Kamlesh Khunti, PhD, MD, FRCGP, FRCP, FMedSci

1:45 p.m.-2:00 p.m. **Cardiovascular Disease in China**
Linong Ji, MD

2:00 p.m.-2:15 p.m. **Cardiovascular Disease in India**
Rakesh Kumar Sahay, MD, DNB, DM

2:15 p.m.-2:30 p.m. **Cardiometabolic Disease in Arabian Gulf Region**
Mohammed Hassanein, FRCP, CCST, MPHIL

2:30 p.m.-3:00 p.m. **Question and Discussion Period**
Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR04-1.5
Continuous Glucose Monitoring—Can it Reduce Hypoglycemia Burden?
Room: W307
Chair: Ilias (Elias) Spanakis, MD

1:30 p.m.-1:45 p.m.
239-OR CGM Has a Specific Effect on the Reduction of Nocturnal Hypoglycemia in People with Type 1 Diabetes on an MDI Treatment Regimen
Presenting Author: Norbert Hermanns, PhD

1:45 p.m.-2:00 p.m.
240-OR Longitudinal Assessment of Glycemia and Severe Hypoglycemia among Adults with Type 1 Diabetes—An Online Survey
Presenting Author: Jennifer L. Sherr, MD, PhD

2:00 p.m.-2:15 p.m.
241-OR Health-Related Quality of Life and Burden of Type 1 Diabetes and Severe Hypoglycemia in Adult Continuous Glucose Monitor Users
Presenting Author: Adriana Boateng-Kuffour, MS, MPH

2:15 p.m.-2:30 p.m.
242-OR The Impact of Glucose Threshold on the Number and Duration of Glucose Episodes
Presenting Author: Vaios Koutroukas, MBBS, MA

2:30 p.m.-2:45 p.m.
243-OR Characterization of Behavioral Patterns Involving Hypoglycemic Episodes in Type 1 Diabetes—Results from the T1DEXI Study Cohort
Presenting Author: Jose F. Garcia-Tirado, PhD

2:45 p.m.-3:00 p.m.
244-OR Association of Type 1 Diabetes Duration or Duration of Advanced Technology Utilization with Severe Hypoglycemic Event Frequency
Presenting Author: Patrick Callahan, PharmD, MS
Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR09-1.5
Emerging Small Molecule Biomarkers of ASCVD Risk in Metabolic Disease
Room: W208
Chair: Zsu-Zsu Chen, MD

1:30 p.m.-1:45 p.m.
245-OR Proteomic Analysis of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA)—Results and Integrated Predictors of Response
Presenting Author: Armando Vergara-Martel, MS

1:45 p.m.-2:00 p.m.
246-OR Association of Erythritol and Erythronate with Cardiovascular Outcomes and Death
Presenting Author: Layla A. Abushamat, MD, MPH

2:00 p.m.-2:15 p.m.
247-OR Blood Monocyte Phenotype Predicts Cardiovascular Risk in Type 2 Diabetes
Presenting Author: Nicolas Venteclef, PhD

2:15 p.m.-2:30 p.m.
248-OR Pro-B-Type Natriuretic Peptide Strongly Predicts Major Cardiovascular Events and Cardiovascular Mortality in Cardiovascular Disease Patients with NAFLD as Well as in Those without NAFLD
Presenting Author: Christoph H. Saely, Prof

2:30 p.m.-2:45 p.m.
249-OR Cystatin C Predicts Cardiovascular Events in Patients with Coronary Artery Disease Both among Patients with and among Those without Type 2 Diabetes
Presenting Author: Christoph H. Saely, Professor

2:45 p.m.-3:00 p.m.
250-OR Ceramides Surpass LDL-Cholesterol in Predicting Cardiovascular Mortality in Diabetic and Nondiabetic Patients
Presenting Author: Andreas Leiherer, Doz. Dr.
1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-OR02-1.5
Multifaceted Insights into Behavioral and Psychosocial Care for Youth and Families
Room: W314
Chair: Lori M. Laffel, MD, MPH

1:30 p.m.-1:45 p.m.
251-OR COIN2DOSE—Proof of Concept That a Behavioral Economics Intervention Can Increase Mealtime Insulin Use in Adolescents with Type 1 Diabetes
Presenting Author: Susana R. Patton, PhD, ABPP, CDCES

1:45 p.m.-2:00 p.m.
252-OR Psychosocial Predictors of Diabetes Self-Efficacy in Young Adults with Youth-Onset Type 2 Diabetes
Presenting Author: Paula M. Trief, PhD

2:00 p.m.-2:15 p.m.
253-OR Exploring Incorporation of Type 1 Diabetes into Identity and Perceptions of Diabetes Technologies in Adolescents and Young Adults (AYAs)
Presenting Author: Persis V. Commissariat, PhD, CDCES

2:15 p.m.-2:30 p.m.
254-OR Sleep Disturbance and Diabetes Symptom Burden in Young Adults with Type 1 Diabetes
Presenting Author: Stephanie Griggs, PhD, RN

2:30 p.m.-2:45 p.m.
255-OR The Relationship between Daytime Child Glycemic Levels and Parent Fear of Hypoglycemia
Presenting Author: Alexandra Monzon, PhD

2:45 p.m.-3:00 p.m.
256-OR Understanding Parent and Youth Diabetes Device Satisfaction
Presenting Author: Jessie J. Wong, PhD
SCIENTIFIC SESSIONS PROGRAM

SUNDAY, JUNE 23, 2024

1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR06-1.5
Novel Approaches to Treatment and Characterization of Diabetes in Pregnancy (With Norbert Freinkel Award Lecture) (With ADA Presidents' Select Abstract Presentation) (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: William L. Lowe, Jr., MD

1:30 p.m.-2:00 p.m.
Norbert Freinkel Award Lecture

Atlantic DIP—Changing the Landscape for Better Maternal and Infant Health
Fidelma P. Dunne, MD, PhD, FRCP, FRCPI

2:00 p.m.-2:15 p.m.
257-OR ADA Presidents' Select Abstract: The Effect of a Reduced-Energy Diet upon Maternal Weight and Pregnancy Outcomes in Women with Gestational Diabetes—The DiGest Trial
Presenting Author: Claire L. Meek, MB, ChB, MRCP, FRCPath, PhD

2:15 p.m.-2:30 p.m.
258-OR The Effect of Early Initiation of Treatment on Glycemia and Pregnancy Outcomes in Women with Early Gestational Diabetes Mellitus
Presenting Author: Jincy Immanuel, PhD

2:30 p.m.-2:45 p.m.
259-OR Real-Time CGM Achieves Higher TIR among Pregnant Persons with GDM
Presenting Author: Amy M. Valent, DO, MCR

2:45 p.m.-3:00 p.m.
260-OR Differences in Adipocyte Expandability and Function between Healthy Pregnancies and Pregnancies Complicated by Gestational Diabetes Mellitus and Preeclampsia
Presenting Author: Zoe Lees, MSc
SUNDAY, JUNE 23, 2024

1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR08-1.5
Weighing Opportunities of Incretin-Based Therapy in Obesity (With ADA Presidents' Select Abstract Presentation)
Room: W415C (Valencia Ballroom)
Chair: Ildiko Lingvay, MD, MPH, MSCS

1:30 p.m.-1:45 p.m.
261-OR ADA Presidents' Select Abstract: Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia after Semaglutide Withdrawal in a Murine Model of Obesity
Presenting Author: Harith Rajagopalan, MD, PhD

1:45 p.m.-2:00 p.m.
262-OR Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial
Presenting Author: Louis Aronne, MD

2:00 p.m.-2:15 p.m.
263-OR Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain
Presenting Author: Owen Carmichael, PhD

2:15 p.m.-2:30 p.m.
264-OR Effect of Tirzepatide on Kidney Function in People with Excess Body Weight and Type 2 Diabetes—A Post-Hoc Analysis of the SURMOUNT-2 Trial
Presenting Author: Hiddo L. Heerspink, PhD

2:30 p.m.-2:45 p.m.
265-OR Understanding Patterns of GLP-1/GLP-1 RA Use among Individuals with Type 1 Diabetes—A T1D Exchange (T1DX) Online Registry Analysis
Presenting Author: Yogish C. Kudva, MD

2:45 p.m.-3:00 p.m.
266-OR Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity
Presenting Author: Melissa K. Thomas, MD, PhD
1:30 p.m.-3:00 p.m. (continued)

Oral Presentations
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-OR14-1.5
New Technology—AID Focus
Room: W315
Chair: Elena Toschi, MD

267-OR WITHDRAWN

1:30 p.m.-1:45 p.m.

268-OR Perioperative Fully Closed-Loop vs. Standard Insulin Delivery in Adults Undergoing Major Abdominal Surgery—A Two-Center Randomized Controlled Trial
Presenting Author: Gabija Krutkyte, MD

1:45 p.m.-2:00 p.m.

269-OR Glucose Control in Free-Life under Hybrid Closed-Loop 6 and 12 Months after Initiation from a Nationwide Survey
Presenting Author: Jean-Pierre Riveline, MD, PhD

2:00 p.m.-2:15 p.m.

270-OR Real-World Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System for >7,500 Users with High HbA1c (>9%) at Baseline
Presenting Author: Gregory P. Forlenza, MD, MS

2:15 p.m.-2:30 p.m.

271-OR Automated Hybrid Closed-Loop (AHCL) Systems for the Treatment of Cystic Fibrosis Related Diabetes (CFRD)
Presenting Author: Valeria Grancini, MD, PhD

2:30 p.m.-2:45 p.m.

272-OR Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth with Type 1 Diabetes
Presenting Author: Julia Ware, MBChB
1:30 p.m.–3:00 p.m.  
(continued)

Oral Presentations
Theme Area: Epidemiology/Genetics
Session Number: EG-OR05-1.5

Common and Rare Genetic Variant Associations and MolecularQTL Scans in Type 2 Diabetes Tissues
Room: W207
Chair: Marijana Vujkovic, PhD

1:30 p.m.–1:45 p.m.
273-OR Initial eQTL Discovery in Individual Pancreatic Cell Types from the Human Pancreas Analysis Program  
Presenting Author: Mary A. Weidekamp, BS

1:45 p.m.–2:00 p.m.
274-OR Population-Scale Single-Nucleus Skeletal Muscle Chromatin Dynamics and Nucleosome Positioning in the Context of Type 2 Diabetes  
Presenting Author: Xiaoou Wang, MS

2:00 p.m.–2:15 p.m.
275-OR Associations of Combined Genetic and Lifestyle Risks with Incident Type 2 Diabetes in the UK Biobank  
Presenting Author: Cassandra N. Spracklen, PhD

2:15 p.m.–2:30 p.m.
276-OR Common Variant Polygenic Risk Score Influences Penetrance of Rare Variants in Monogenic Diabetes Genes  
Presenting Author: Alicia Huerta, PhD

2:30 p.m.–2:45 p.m.
277-OR Whole-Genome Sequencing Identifies a Rare Noncoding Variant Proximal to METRN Associated with HbA1c Levels  
Presenting Author: Gareth Hawkes, PhD

2:45 p.m.–3:00 p.m.
278-OR Single-Nucleus Multiomics Profiling across 49 Individuals of Hispanic Ancestry Reveals Cell-Specific Skeletal Muscle Insulin-Responsive Gene Regulatory Signatures  
Presenting Author: Benjamin Li, BS
1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-OR03-1.5
Metabolic Control of Insulin Action and Secretion (Includes Livestream)
Room: W414
Chair: Young-Bum Kim, PhD

1:30 p.m.-1:45 p.m.
279-OR FBLN7 in Pre-adipocytes Promotes Adipose Tissue Fibrosis and Disrupts
Metabolic Homeostasis in Obesity
Presenting Author: Hairong Yu, PhD

1:45 p.m.-2:00 p.m.
280-OR Manganese Regulates Hepatic Insulin Sensitivity and Glucose Tolerance
Presenting Author: Jennifer Gamarra, MA

2:00 p.m.-2:15 p.m.
281-OR Pyruvate Carboxylase Flux Is Increased in the Type 1 Diabetic Exocrine
Pancreas
Presenting Author: Anna Rushin, BS

2:15 p.m.-2:30 p.m.
282-OR Nod1 Plays a Causal Role in Western-Diet-Induced Insulin Resistance and
Glucose Intolerance in Microbiota-Deficient Conditions
Presenting Author: S. M. Niazur Rahman, MD, MSc

2:30 p.m.-2:45 p.m.
283-OR Adipose Stromal Cells Increase Insulin Sensitivity and Decrease Liver
Gluconeogenesis in a Type 1 DM Mouse Model
Presenting Author: Lee-Wei Chen, MD

2:45 p.m.-3:00 p.m.
284-OR Androgen-Dependent Tissue Factor Pathway Inhibitor-Regulating Protein
(ADTRP) Regulates Macrophage Polarization and Migration to Adipocytes
Presenting Author: Sze Min Ong, Bachelor’s Degree
1:30 p.m.–3:00 p.m.  
(continued)

Oral Presentations  
Theme Area: Islet Biology/Insulin Secretion  
Session Number: IB-OR02-1.5  
Islet Signal Transduction  
Room: W206  
Chair: Jeffrey S. Tessem, PhD

1:30 p.m.–1:45 p.m.  
285-OR m6A carRNA Methylation Regulates Chromatin State and Transcription in Islets from Humans with Type 2 Diabetes  
Presenting Author: Namrata Shukla, MSc, PhD

1:45 p.m.–2:00 p.m.  
286-OR JNK3—A Key Downstream Target of Incretin Responses in β-Cells  
Presenting Author: Ruy Andrade Louzada Neto, PhD

2:00 p.m.–2:15 p.m.  
287-OR Traf6 Directs a Noncanonical Role for Innate Immune Signaling in Pancreatic β-Cells  
Presenting Author: Elena Levi D. Ancona, BS

2:15 p.m.–2:30 p.m.  
288-OR Inflammation-Induced Repression of Insulin Production by Targeting Its mRNA to Stress Granules via ADP-Ribosylation Machinery  
Presenting Author: Soumyadeep Sarkar, MS, PhD

2:30 p.m.–2:45 p.m.  
289-OR Autophagy Promotes Islet α-Cell Function by Maintaining ER Proteostasis and Glucagon Production  
Presenting Author: Wenzhen Zhu, PhD

2:45 p.m.–3:00 p.m.  
290-OR Acetylation Induces a SUMOylation–Phosphorylation Switch to Enhance MafA Transactivation  
Presenting Author: Margot Chirikjian, BS
SUNDAY, JUNE 23, 2024

1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR02-1.5
Research Advances in Metabolic Liver Disease
Room: W308
Chair: Michael R. Rickels, MD, MS

1:30 p.m.-1:45 p.m.
291-OR A Noninvasive Index for Significant Liver Fibrosis and Stratifying Risk of Cirrhosis in Patients with Type 2 Diabetes Mellitus in Primary Care
Presenting Author: Xiaolong Qi, MD

1:45 p.m.-2:00 p.m.
292-OR Coenzyme A Synthase Knockdown Alleviates Metabolic Dysfunction–Associated Steatohepatitis via Decreasing Cholesterol in Liver Lipid Droplets
Presenting Author: Ikki Sakuma, MD, PhD

2:00 p.m.-2:15 p.m.
293-OR Improvement of Tissue-Specific Insulin Sensitivity after Bariatric Surgery Does Not Restore Hepatic OXPHOS Capacity
Presenting Author: Sabine Kahl, MD

2:15 p.m.-2:30 p.m.
294-OR The Role of Inositol Polyphosphate Multikinase in Progression of Nonalcoholic Steatohepatitis
Presenting Author: Ikrak Jung, PhD

2:30 p.m.-2:45 p.m.
295-OR The PNPLA3 G-allele Reduces the Beneficial Effects of a Healthy Diet on Hepatic Lipid Content in Type 2 Diabetes
Presenting Author: Kalliopi Pafili, Doctor

2:45 p.m.-3:00 p.m.
296-OR Glucagon and Insulin Cross Talk Regulates Hepatic Glycogen Metabolism
Presenting Author: Megan Capozzi, PhD
Oral Presentations

Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR04-1.5
New Insights into Therapeutic Strategies for Obesity and Diabetes
Room: W304 E-H
Chair: Julio E. Ayala, PhD

1:30 p.m.-1:45 p.m.
297-OR A Novel GLP-1/FGF21 Dual Agonist ZT003 Has Therapeutic Potential for Obesity, Diabetes, and Nonalcoholic Steatohepatitis
Presenting Author: Yuanyuan Zhang, PhD

1:45 p.m.-2:00 p.m.
298-OR Precision-Engineered Activin and GDF Ligand Trap HS235—A Novel Lean Mass-Preserving Treatment for Obesity
Presenting Author: Gauthier Schang, PhD

2:00 p.m.-2:15 p.m.
299-OR Discovery of Long-Acting Unimolecular Peptide Tetra-agonists Targeting GLP-1, GIP, Amylin, and Calcitonin Receptors for Enhanced Metabolic Benefits in Animal Models of Obesity
Presenting Author: Cristina M. Rondinone, PhD

2:15 p.m.-2:30 p.m.
300-OR Beneficial Effect of the Combination Therapy of Cagrilintide, a Dual Amylin/Calcitonin Agonist, and Tirzepatide, a Dual GLP-1/GIP Agonist, on Body Weight Loss in Obese Rats
Presenting Author: Pilar Valdecantos, PhD

2:30 p.m.-2:45 p.m.
301-OR Synergistic Effects of Dapagliflozin and Tirzepatide Combination Treatment on Weight Loss and Glucose Regulation in Diet-Induced Obese Animals
Presenting Author: Mohamed Abu-Farha, PhD

2:45 p.m.-3:00 p.m.
302-OR The Anti-myostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity
Presenting Author: Melissa A. Fulham, PhD
SUNDAY, JUNE 23, 2024

1:30 p.m.-3:00 p.m.
(continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology
Session Number: IP-OR07-1.5
Novel Modulators of Adipose Tissue Function and Adiposity
Room: W304 A-D
Chair: Kevin Y. Lee, PhD

1:30 p.m.-1:45 p.m.
303-OR Notch Signaling Inhibitor ADPO-002 Promotes Browning in Human Adipose Tissue Explants
Presenting Author: Muhammad Raisul Abedin, PhD

1:45 p.m.-2:00 p.m.
304-OR The Obesity-Related Natriuretic Handicap Involves the Coordinated Regulation of Multiple Genes in Adipose Tissue to Blunt Natriuretic Peptide Signaling
Presenting Author: Ryan P. Ceddia, PhD

2:00 p.m.-2:15 p.m.
305-OR Adipose Tissue Perilipin 1 Insulin Responsiveness in Obesity
Presenting Author: Kelli Lytle, PhD

2:15 p.m.-2:30 p.m.
306-OR Diet-Induced Hyperlipidation of Adiponectin Contributes to Adiponectin Dysfunction
Presenting Author: Maia Smith, BS

2:30 p.m.-2:45 p.m.
307-OR Defective G-CSF in the Secretome of Epicardial Adipose Cells Favors Apoptosis and Cellular Stress of Cardiac Progenitor Cells in Human Obesity
Presenting Author: Giuseppe Palma, PhD

308-OR WITHDRAWN
1:30 p.m.-3:00 p.m.  
(continued)

**ePoster Theater**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: ePoster11*  
(*) Type 2 Diabetes—Prevention, Treatment, and Technology  
*Room: Exhibit Hall (West A1-A3) ePoster Theater A*  
*Moderator: Sara Stafford, BSc, MDCM*

(*) Continuing Education Credit Is Not Awarded for this Session.

1:30 p.m.-1:40 p.m.  
1856-LB Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1)  
*Presenting Author: Linong Ji, MD*

1:40 p.m.-1:50 p.m.  
1862-LB Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Suicide and Self-Harm among Patients with Type 2 Diabetes  
*Presenting Author: Samantha B. Shapiro, MSc*

1:50 p.m.-2:00 p.m.  
1904-LB Glycemic Improvement with Use of the Omnipod 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes—Results of the SECURE-T2D Pivotal Trial  
*Presenting Author: Francisco J. Pasquel, MD, MPH*

2:00 p.m.-2:10 p.m.  
1907-LB Estimating Optimal CGM Wear Time for Individuals with Type 2 Diabetes Not on Insulin  
*Presenting Author: Souptik Barua, PhD*

2:10 p.m.-2:20 p.m.  
1927-LB Impact of Continuous Glucose Monitoring Use on Hospitalizations in People with Type 2 Diabetes—Real-World Analysis  
*Presenting Author: Satish K. Garg, MD*

2:20 p.m.-2:30 p.m.  
1930-LB A Randomized Trial of Real-Time Continuous Glucose Monitoring (RT-CGM) with Culturally Tailored Education for Latino Patients with Type 2 Diabetes (DM)  
*Presenting Author: Nicole Marie Ehrhardt, MD*

(continued on next page)
2:30 p.m.-2:40 p.m.

1932-LB Cost-Effectiveness of the National Diabetes Prevention Program—A Real-World, Two-Year Prospective Study
Presenting Author: Shihchen Kuo, RPh, PhD

2:40 p.m.-2:50 p.m.

2071-LB Reduced Risk of Obesity-Related Cancers with Real-World Weight Loss
Presenting Author: Kenda Alkwatli, MD
1:30 p.m.-3:00 p.m.  
(continued)

**ePoster Theater**
*Theme Area: Epidemiology/Genetics*
*Session Number: ePoster12*

(*) **Growing Older with Diabetes**
*Room: Exhibit Hall (West A1-A3) ePoster Theater B*
*Moderator: Naveed Sattar, MD, PhD*

(*) *Continuing Education Credit Is Not Awarded for this Session.*

1:30 p.m.-1:40 p.m.
**1252-P** Markers of Alzheimer's Disease (AD) in Young Adults with Type 1 Diabetes, With and Without Diabetic Retinopathy (DR)  
*Presenting Author: Meghan E. Pauley, DO*

1:40 p.m.-1:50 p.m.
**1253-P** Differential Risk of Dementia in Older Adults with Diabetes by Race/Ethnicity, Gender, and Age—Health and Retirement Study 1992–2020  
*Presenting Author: Aprill Z. Dawson, PhD*

1:50 p.m.-2:00 p.m.
**1254-P** Association between Hemoglobin A1c, Time in Range, and Dementia in Veterans with Diabetes Mellitus  
*Presenting Author: Patricia C. Underwood, PhD, NP*

2:00 p.m.-2:10 p.m.
**1255-P** Sulfonylurea Prescription in Elderly Patients with Diabetes Survey Using Real World Data in Japan  
*Presenting Author: Masaya Sakamoto, MD, PhD*

2:10 p.m.-2:20 p.m.
**1256-P** Studying Mortality in Patients with Diabetes over 75 Years  
*Presenting Author: Sakiho Koide*

2:20 p.m.-2:30 p.m.
**1367-P** Cognitive Assessment in Type 2 Diabetes—A Pilot Study in an Outpatient Clinic  
*Presenting Author: Roger Chen, MB BS, FRACP, PhD*

2:30 p.m.-2:40 p.m.
**1368-P** Early-Life Adversity, Indicated by Difference between Observed and Genetically Predicted Height, and Risks of Diabetes and 48 Related Diseases  
*Presenting Author: Yanbo Zhang, PhD*

2:40 p.m.-2:50 p.m.
**1378-P** The Association between Baseline Hemoglobin A1c (A1C) and Risk of Progression from Prediabetes to Diabetes across Adult Age Groups  
*Presenting Author: Ghazal S. Fazli, MPH, PhD*
3:15 p.m.–4:00 p.m.

Kelly West Award for Outstanding Achievement in Epidemiology Lecture *Includes Livestream*

*Lessons Learnt from Epidemiology of Diabetes in South Asians—The Kelly West Lecture 2024*

Viswanathan Mohan, MD, PhD, DSc, FRCP, FNA, FACE, MACP, FRSE

Room: W320 (Chapin Theater)

3:15 p.m.–4:15 p.m.

Symposium

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

Session Number: BM-SY16-1

**The Future of Diabetes Nutrition Interventions—Innovation in Practice *Includes Livestream***

Room: W415B (Valencia Ballroom)

Chair: Barbara Eichorst, MS, RD, CDCES

3:15 p.m.–3:35 p.m. *Nutrition Education and Food Security Resource for American Indians and Alaska Natives—A Multilevel Intervention to Improve Type 2 Diabetes Outcomes*

Sarah A. Stotz, PhD, MS, RDN, CDCES

3:35 p.m.–3:55 p.m. *Produce Prescription as Intervention Method for Achieving Sustainable Impact on Individual and Community*

Elise Mitchell, MS, MPH

3:55 p.m.–4:15 p.m. *Gamification of Nutrition Interventions throughout the Lifespan*

Grace E. Shearrer, PhD

3:15 p.m.–3:35 p.m. *The United Kingdom Perspective*

Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD

3:35 p.m.–3:55 p.m. *The United States Perspective*

Rodolfo J. Galindo, MD

3:55 p.m.–4:15 p.m. *Question and Discussion Period*
3:15 p.m.–4:00 p.m.
(continued)

**Oral Presentations**

*Theme Area: Acute and Chronic Complications*

**Session Number: AC-OR01-1**

**Lower Extremity Complications with Systemic Effects**

Room: W206
Chair: Ryan T. Crews, PhD, CCRP

**309-OR WITHDRAWN**

3:15 p.m.–3:30 p.m.

**310-OR** Bacteremia and Endocarditis Complicating Moderate and Severe Diabetic Foot Infections
Presenting Author: Mario C. Reyes, DPM

3:30 p.m.–3:45 p.m.

**311-OR** High Transepidermal Water Loss (TEWL) Associates with Failure to Maintain Wound Closure in Diabetic Foot Ulcers
Presenting Author: Brian M. Schmidt, DPM

3:45 p.m.–4:00 p.m.

**312-OR** OPAT Is Protective of Major Amputation following Hospitalization for Diabetic Foot Infection
Presenting Author: Arthur Tarricone, DPM, MPH
SUNDAY, JUNE 23, 2024

3:15 p.m.-4:15 p.m.
(continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR05-1
Physiologic Responses to Hypoglycemia—New Insights
Room: W207
Chair: David A. Baidal, MD

3:15 p.m.-3:30 p.m.
313-OR Metoclopramide Improves Hypoglycemic Counterregulation in Diabetic Rats
Presenting Author: Micah H. Devore, BSc

3:30 p.m.-3:45 p.m.
314-OR A Randomized Study of a GPR119 Agonist on Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes Mellitus (T1DM)
Presenting Author: Richard E. Pratley, MD

3:45 p.m.-4:00 p.m.
315-OR Task-Induced Alterations in the Salience Network amongst Patients with Type 1 Diabetes
Presenting Author: Elizabeth Sanchez Rangel, MD

4:00 p.m.-4:15 p.m.
316-OR Interoception Predicts Impaired Awareness of Hypoglycemia (IAH) in Adults with Type 1 Diabetes (T1D)
Presenting Author: Austin M. Matus, PhD
3:15 p.m.-4:15 p.m. (continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR12-1
Diabetic Kidney Disease (Includes Livestream)
Room: W307
Chair: Jennifer A. Schaub, MD

3:15 p.m.-3:30 p.m.
317-OR Identification of Genetic Regulators of Circulating Biomarkers of Kidney Decline in Diabetes
Presenting Author: Marcus G. Pezzolesi, PhD, MPH

3:30 p.m.-3:45 p.m.
318-OR Podocyte-Specific Expression of REDD1 Promotes Altered Glomerular Pathology and Renal Function Deficits in a Rodent Model of Diabetic Nephropathy
Presenting Author: Siddarth Sunilkumar, PhD

3:45 p.m.-4:00 p.m.
319-OR Renoprotective Effects of Glucagon and Incretin Agonist Combinations Mediated by Macula Densa Cells
Presenting Author: Georgina Gyarmati, MD, PhD, MPH

4:00 p.m.-4:15 p.m.
320-OR Pyruvate Kinase M2 (PKM2) Activation in the Podocyte Prevented Subset Differentiation of Glomerular Cells Induced by Diabetes
Presenting Author: Jialin Fu, MD, PhD
3:15 p.m.-4:15 p.m.  (continued)

Oral Presentations
Theme Area: Acute and Chronic Complications
Session Number: AC-OR16-1
Insights into Diabetic Retinopathy—From Molecular Characterization to Therapeutic Considerations
Room: W208
Chair: Mohamed Elmasry, MD, PhD

3:15 p.m.-3:30 p.m.
321-OR  Haptoglobin (Hp) Levels and Phenotype Are Unrelated to Severe Retinopathy in Type 2 Diabetes, but Lower Hp Reductions by Fenofibrate Are Associated with Greater Retinopathy Benefit—A FIELD Trial Study
Presenting Author: Kwok Leung Ong, PhD

3:30 p.m.-3:45 p.m.
322-OR  Delaying Progression of Diabetic Retinopathy Worsens the Risk for Age-Related Macular Degeneration
Presenting Author: Ward Fickweiler, MD, PhD

3:45 p.m.-4:00 p.m.
323-OR  Genetic Basis of Diabetic Macular Edema and Proliferative Diabetic Retinopathy—Insights from Next Generation Sequencing in the DRGen Study
Presenting Author: Sampath Rangasamy, PhD

4:00 p.m.-4:15 p.m.
324-OR  Characterization of Aqueous Retinol Binding Protein 3 Concentrations and Diabetic Retinopathy Progression in Type 1 and Type 2 Diabetes
Presenting Author: Tanvi Choksi, BS
3:15 p.m.-4:15 p.m.  
(continued)

Oral Presentations  
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
Session Number: BM-OR09-1  
Clinical Contributions in Type 1 Diabetes and Exercise  
Room: W314  
Chair: Jane E. Yardley, PhD

3:15 p.m.-3:30 p.m.  
325-OR  Enhancing Physical Activity Engagement among Individuals with Type 1 Diabetes—Exploring Perceived Barriers in the Era of New Technologies  
Presenting Author: Capucine Guédet, MSc

3:30 p.m.-3:45 p.m.  
326-OR  Activity Feature Attenuates Drop in Glucose for Individuals with Type 1 Diabetes Using Omnipod 5 Automated Insulin Delivery System  
Presenting Author: Lauren V. Turner, MSc

3:45 p.m.-4:00 p.m.  
327-OR  Does Exercise in Cool Water Result in a Greater Decrease in Blood Glucose Concentration than Exercise in Thermoneutral Water or on Land in People with Type 1 Diabetes?  
Presenting Author: Kristina Abramoff, BS (Hons), PhD Candidate

4:00 p.m.-4:15 p.m.  
328-OR  Hypoglycemia Associated with Physical Activity in Automated Insulin Delivery Users—Frequency and Prevention Strategies  
Presenting Author: Valerie Boudreau, RD, PhD
SUNDAY, JUNE 23, 2024

3:15 p.m.–4:15 p.m.
(continued)

**Oral Presentations**

*Theme Area: Clinical Diabetes/Therapeutics*

Session Number: CT-OR19-1

**New Insights and Treatments in Management of Youth with Type 1 Diabetes Mellitus**

Room: W315

Chair: Laura M. Nally, MD

3:15 p.m.–3:30 p.m.

**329-OR** Dynamics of Treatment Regimens and Glycemic Outcomes in >100,000 Children from International Pediatric Diabetes Registries

Presenting Author: Anthony Zimmermann, MBBS, FRACP

3:30 p.m.–3:45 p.m.

**330-OR** Narrow Variation of Glucose Inflection Points (IPs) during Progression to Type 1 Diabetes (T1D) Stratified by Demographic and Genetic Differences in Autoantibody-Positive (Ab+) Individuals

Presenting Author: Heba M. Ismail, MB, BCh, PhD

3:45 p.m.–4:00 p.m.

**331-OR** Clinical and Immunologic Features Differ in Children at Type 1 Diabetes Onset by Ethnicity

Presenting Author: Kagan E. Karakus, MD

4:00 p.m.–4:15 p.m.

**332-OR** Multiomic Profiling of Extended Honeymoon Unveils New Therapeutic Targets

Presenting Author: Cristian Loretelli, PhD
3:15 p.m. - 4:15 p.m.
(continued)

Oral Presentations
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-OR06-1
Preclinical/Clinical Efforts for Beta-Cell Replacement Therapy
Room: W304 A-D
Chair: David M. Harlan, MD

3:15 p.m.-3:30 p.m.
333-OR  Hypoimmune Islet Cells Mediate Insulin Independence after Allogeneic
         Transplantation in a Fully Immunocompetent Nonhuman Primate without
         Immunosuppression
         Presenting Author: Xiaomeng Hu, PhD

3:30 p.m.-3:45 p.m.
334-OR  Allogeneic Neo-Islets Reduce Insulin Need by up to 1.2 U/kg bw in Autoimmune
         Type 1 Diabetes Dogs over Three Years without Requiring Antirejection Drugs,
         Enough to Meet Human Type 1 Diabetes Mellitus Needs
         Presenting Author: Anna Gooch, PhD

3:45 p.m.-4:00 p.m.
335-OR  Preliminary Results of Islet Survival in a Novel Biovascular Pancreas Implanted
         in Primates
         Presenting Author: Mehmet H. Kural, PhD

4:00 p.m.-4:15 p.m.
336-OR  Females Undergoing Islet Transplantation with CNI-Based Immunosuppression
         May Be at Higher Risk of Renal Function Decline
         Presenting Author: Alice L.J. Carr, PhD, MSci
3:15 p.m.–4:15 p.m. (continued)

Oral Presentations
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-OR04-1
Endgame—Oral Abstracts on Beta-Cell Apoptosis (With ADA Presidents’ Select Abstract Presentation) *Includes Livestream*
Room: W414
Chair: Danielle Dean, PhD

3:15 p.m.–3:30 p.m.
337-OR ADA Presidents’ Select Abstract: The LonP1 Protease Maintains Pancreatic β-Cell Survival by Governing Mitochondrial Protein Folding
Presenting Author: Jin Li, PhD

3:30 p.m.–3:45 p.m.
338-OR Regulation of Pancreatic Beta-Cell Survival and Function during Aging
Presenting Author: Jimin Park, PhD

3:45 p.m.–4:00 p.m.
339-OR Enhanced Expression of Zinc Finger Protein 385D Leads to Type 2 Diabetes Phenotype in Human Beta Cells
Presenting Author: Geming Lu, MD

4:00 p.m.–4:15 p.m.
340-OR Transcriptional Activation in Beta Cells during ER Stress Linking iPLA2β with NFκB
Presenting Author: Sasanka Ramanadham, PhD
3:15 p.m.-4:15 p.m.  
(continued)

Oral Presentations
Theme Area: Obesity/Integrated Physiology  
Session Number: IP-OR03-1

Novel Pathways in Metabolic Regulation  
Room: W304 E-H  
Chair: Mark A. Herman, MD

341-OR WITHDRAWN

3:15 p.m.-3:30 p.m.

342-OR Systemic Identification of Functionally Conserved IncRNA Metabolic Regulators between Humans and Mice  
Presenting Author: Chengfei Jiang, PhD

3:30 p.m.-3:45 p.m.

343-OR Identifying Nogo-B Receptor as a Resilience Factor in Preventing Obesity Associated Type 2 Diabetes  
Presenting Author: Qing Miao, PhD

3:45 p.m.-4:00 p.m.

344-OR The MOTS-c/CK2 Pathway Is a Novel Molecular Target for Type 2 Diabetes in East Asians  
Presenting Author: Hiroshi Kumagai, PhD
3:15 p.m.–4:15 p.m.
(continued)

**Oral Presentations**
*Theme Area: Obesity/Integrated Physiology*
*Session Number: IP-OR09-1*

**Risk Factors Reimagined—Beyond Obesity in Metabolic Risk**
Room: W308
Chair: Mary-Elizabeth Patti, MD

3:15 p.m.–3:30 p.m.

**345-OR** Beyond Size Matters—The Impact of Pancreatic Volume and Pancreatic Fat on Type 2 Diabetes
Presenting Author: Hajime Yamazaki, MD, PhD

3:30 p.m.–3:45 p.m.

**346-OR** Hypothalamic Gliosis Is Associated with CVD Risk Factors in the Framingham Heart Study (FHS)
Presenting Author: Justin Lo, MS

3:45 p.m.–4:00 p.m.

**347-OR** Plasma Lipidome in People with Insulin-Sensitive and Insulin-Resistant Obesity
Presenting Author: Max C. Petersen, MD, PhD

4:00 p.m.–4:15 p.m.

**348-OR** Multiancestry Whole Genome Sequencing (WGS) Meta-analysis to Identify Loci Associated with Imaging-Measured Hepatic Steatosis
Presenting Author: Nicholette Allred, PhD
SUNDAY, JUNE 23, 2024

4:30 p.m.-6:00 p.m.

Panel
Theme Area: Acute and Chronic Complications
Session Number: AC-PN04-1.5
Diabetic Foot Disparities—Treatment With and Without a Multidisciplinary Team
Room: W208
Chair: Amanda L. Killeen, DPM, FACPM, CWSP, FFPM RCPS (Glasg)
4:30 p.m.-4:50 p.m. How It Looks When It Works—Multidisciplinary Team Approach to Diabetic Foot Infection
   Peter A. Crisologo, DPM, FFPM, RCPS (Glasg)
4:50 p.m.-5:10 p.m. Practicing as an Island—When a Multidisciplinary Team Isn’t Available
   Vilayvanh Saysoukha, DPM
5:10 p.m.-5:30 p.m. From Home to Hospital—A Paramedic’s Perspective on the Diabetic Foot
   Andrew J. Torres, NRP, CP
5:30 p.m.-6:00 p.m. Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY03-1.5
Survey Says—Psychosocial Screening Tools and Their Psychometric Properties for Youth and Adults with Diabetes
Room: W314
Chair: Marisa E. Hilliard, PhD
4:30 p.m.-5:00 p.m. Screening Tools for Executive Function
   Jessie J. Wong, PhD
5:00 p.m.-5:30 p.m. Screening Tools for Depression
   Jeffrey S. Gonzalez, PhD
5:30 p.m.-6:00 p.m. Screening Tools for Anxiety Disorders
   Holly K. O’Donnell, PhD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY12-1.5
Mind the Gap—Health Benefits of Exercise in Women With or at Risk for Diabetes (Includes Livestream)
Room: W307
Chair: Lia Bally, MD, PhD
4:30 p.m.-4:55 p.m. Exercise and Health in Women with Diabetes through the Lifespan
   Cuilin Zhang, MD, PhD
4:55 p.m.-5:20 p.m. Exercise for the Prevention/Management of Type 2 Diabetes in Breast Cancer Survivors
   Sam Orange, PhD
5:20 p.m.-5:45 p.m. Mechanism Underlying the Benefits of Maternal Exercise on Offspring Health
   Laurie Goodyear, PhD
5:45 p.m.-6:00 p.m. Question and Discussion Period
Debate
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-DB05-1.5*
**Keeping Up with Hollywood—Who Should Be Prioritized for New Antiobesity Medications?***
*Room: W308*
*Co-Chairs: Caroline K. Kramer, MD, PhD and W. Timothy Garvey, MD, MACE*

4:30 p.m.-4:40 p.m. *The Person Who Has Already Benefited from the Medication*
   Deborah Horn, DO, MPH, MFOMA

4:40 p.m.-4:50 p.m. *The Person with Overweight and Cardiovascular Disease*
   Pam R. Taub, MD, FACC, FASPC

4:50 p.m.-5:00 p.m. *The Person with Class 3 Obesity and No Comorbidities*
   Neda Rasouli, MD

5:00 p.m.-5:05 p.m. *Rebuttal*
   Deborah Horn, DO, MPH, MFOMA

5:05 p.m.-5:10 p.m. *Rebuttal*
   Pam R. Taub, MD, FACC, FASPC

5:10 p.m.-5:15 p.m. *Rebuttal*
   Neda Rasouli, MD

5:15 p.m.-5:30 p.m. *The Health Economics Perspective*
   William H. Herman, MD, MPH

5:30 p.m.-6:00 p.m. *Question and Discussion Period*

Panel
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-PN17-1.5*
**Prioritizing Diversity in Clinical Trials***
*Room: W315*
*Chair: Viral N. Shah, MD*

4:30 p.m.-4:50 p.m. *Lack of Equitable Representation in Clinical Trials Compounds Disparities*
   Nana-Hawa Yayah Jones, MD

4:50 p.m.-5:10 p.m. *The Importance of Diversity from the Regulatory Perspective*
   Dolly Misra, MD

5:10 p.m.-5:30 p.m. *Equitable Science Is Good Science—The Importance of Diversity from the PI's Perspective*
   Ananta Addala, DO, MPH

5:30 p.m.-5:50 p.m. *The Importance of Diversity from the Advocacy Perspective*
   Kyle Banks

5:50 p.m.-6:00 p.m. *Question and Discussion Period*
SUNDAY, JUNE 23, 2024

4:30 p.m.–6:00 p.m.
(continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY02-1.5
Controversies in Continuous Glucose Monitoring (CGM) Use during Pregnancy—Time in Range and Beyond Time in Range
Room: W415C (Valencia Ballroom)
Chair: Emily D. Szmulowicz, MD, MS
4:30 p.m.–4:50 p.m.  Time in Range vs. Conventional Fasting/Postprandial Targets—Which Should Take Precedence?
                       Sarit Polsky, MD, MPH
4:50 p.m.–5:10 p.m.  Confronting A1C in the Era of Continuous Glucose Monitoring (CGM)
                       Claire L. Meek, MB, ChB, MRCP, FRCPath, PhD
5:10 p.m.–5:30 p.m.  Time in Range and Beyond Time in Range—Which Continuous Glucose Monitoring Metrics to Follow during Pregnancy, and What Should the Targets Be?
                       Ashley Battarbee, MD, MSCR
5:30 p.m.–5:50 p.m.  Glycemic Targets in Early vs. Late Gestation as a Predictor of Fetal Overgrowth
                       Eleanor M. Scott, BM, BS, MD, FRCP
5:50 p.m.–6:00 p.m.  Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY31-1.5
Multiple Faces of Therapeutic Inertia in Diabetes
Room: W311
Chair: Alexander Turchin, MD, MS
4:30 p.m.–4:50 p.m.  Therapeutic Inertia in Treatment of Diabetes—Are We Making Progress?
                       Steven Edelman, MD
4:50 p.m.–5:10 p.m.  The Other End of the Spectrum—Therapeutic Inertia in Treatment of Hypoglycemia
                       Stewart B. Harris, CM, MD, MPH, FCFP, FACPM
5:10 p.m.–5:30 p.m.  Therapeutic Inertia Is Not Just About Medications—Lifestyle Counseling in Diabetes
                       Huabing Zhang, MD
5:30 p.m.–5:50 p.m.  When Patients Decline Diabetes Treatment Recommendations
                       William H. Polonsky, PhD, CDCES
5:50 p.m.–6:00 p.m.  Question and Discussion Period
Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY38-1.5
Joint ADA/PAHO Symposium—Latin America and the Caribbean Regional Approach to Prevent and Control Diabetes
Room: W304 E-H
Chair: Anselm Hennis, MD, PhD, FRCP, FACP
4:30 p.m.-4:50 p.m. The Growing Burden of Diabetes in Latin America and the Caribbean
Anselm Hennis, MD, PhD, FRCP, FACP
4:50 p.m.-5:10 p.m. Mexico’s Experience to Address Obesity and Improve Diabetes Control
Ruy López Ridaura, MD, PhD
5:10 p.m.-5:30 p.m. Improving Diabetes Care in Jamaica
Tamu Davidson, MD, MPH
5:30 p.m.-6:00 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY42-1.5
THE STEP-HFpEF and STEP-HFpEF-DM Trials—Targeting Obesity to Treat Heart Failure (Includes Livestream)
Room: W320 (Chapin Theater)
Chair: Naveed Sattar, MD, PhD
4:30 p.m.-4:45 p.m. STEP-HFpEF and STEP-HFpEF-DM Trials—Why and What?
Mikhail N. Kosiborod, MD
4:45 p.m.-5:00 p.m. STEP-HFpEF-DM—A Deep Dive into the Metabolic Outcomes
Melanie J. Davies, CBE, MB, ChB, MD, FRCP, FRCGP, FMedSci
5:00 p.m.-5:15 p.m. Does Weight Reduction Modulate Heart Failure Benefit? Insights from STEP-HFpEF
Javed Butler, MD
5:15 p.m.-5:30 p.m. Clinical Implications of the STEP-HFpEF Program and Defining the Next Steps Forward
Subodh Verma, MD, PhD, FRCSC
5:30 p.m.-5:45 p.m. Discussant
Vanita R. Aroda, MD
5:45 p.m.-6:00 p.m. Question and Discussion Period
4:30 p.m.–6:00 p.m.
(continued)

**Symposium**
*Theme Area: Epidemiology/Genetics*
*Session Number: EG-SY03-1.5*
**Big P, Little P—Diabetes Policies for Public Health**
*Room: W207*
*Chair: Gabriel Q. Shaibi, PhD*

4:30 p.m.–4:50 p.m. *Global Policies for Diabetes Prevention—Successful Policies and Proposed Action Plans*
Jennifer Manne-Goehler, MD, ScD

4:50 p.m.–5:10 p.m. *Medicaid Expansion (or Lack Thereof) and Diabetes Health Outcomes*
Meng-Yun Lin, PhD, MPH

5:10 p.m.–5:30 p.m. *State-Level Policies That Promote Diabetes Prevention and Successful Disease Management*
Matthew J. O'Brien, MD, MSc

5:30 p.m.–5:50 p.m. *Working to Prevent Diabetes—Workplace Policies in Canada That Promote Health*
Diana Sherifali, PhD, RN, CDE

5:50 p.m.–6:00 p.m. *Question and Discussion Period*

---

**Symposium**
*Theme Area: Immunology/Beta-Cell Replacement*
*Session Number: IBC-SY07-1.5*
**Long-Term Goals and Challenges for Beta-Cell Replacement Therapy (Includes Livestream)**
*Room: W414*
*Chair: Edward Phelps, PhD*

4:30 p.m.–4:50 p.m. *Sites for Delivery*
Melanie L. Graham, PhD, MPH

4:50 p.m.–5:10 p.m. *Porcine/Xeno Approaches*
David K.C. Cooper, MB, MD, PhD

5:10 p.m.–5:30 p.m. *Induction of Long-Term Tolerance*
Norma Sue Kenyon, PhD

5:30 p.m.–5:50 p.m. *Role for Basic Science/Animal Models*
Eckhard Wolf, PhD

5:50 p.m.–6:00 p.m. *Question and Discussion Period*
Symposium
Theme Area: Insulin Action/Molecular Metabolism
Session Number: IA-SY05-1.5
Lipid Regulation of Mitochondrial Metabolism
Room: W304 A-D
Chair: Meilian Liu, PhD
4:30 p.m.-4:45 p.m. Mitochondrial Phospholipid Metabolism
   Katsu Funai, PhD
4:45 p.m.-5:00 p.m. Structure/Function of Regulators of Lipid Droplet Formation
   Michael Airola, PhD
5:00 p.m.-5:15 p.m. Mitochondrial Dynamics and Function
   Erin Seifert, PhD
5:15 p.m.-5:30 p.m. Mitochondria Association with Lipid Droplets—Regulation and Function
   Orian Shirihai, MD, PhD
5:30 p.m.-6:00 p.m. Question and Discussion Period

Symposium
Theme Area: Obesity/Integrated Physiology
Session Number: IP-SY02-1.5
Weight-Reducing Mechanisms of GLP-1-Based Therapies—New Insights from Animal Studies
(Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Zhiping Pang, PhD
4:30 p.m.-4:50 p.m. Novel Insights into Regulation of Energy Metabolism by GIPR Agonism
   and GIPR—GLP-1R Coagonism
   Timo D. Müller, PhD
4:50 p.m.-5:10 p.m. Systemically-Administered GLP-1 Receptor Agonists vs. Brain-Derived
   GLP-1—Does It Matter for Weight-Reducing Therapy?
   Stefan Trapp, PhD
5:10 p.m.-5:30 p.m. Unraveling the Distributed Neural Circuits Underlying Food Intake and
   Body Weight Effects of GLP-1 and Its Analogues
   Karolina P. Skibicka, PhD
5:30 p.m.-5:50 p.m. Strategies for Mitigating Nausea and Emesis Side Effects of GLP-1R
   Agonism
   Tito Borner, PhD
5:50 p.m.-6:00 p.m. Question and Discussion Period
4:30 p.m.–6:00 p.m.
(continued)

Oral Presentations
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-OR03-1.5
Beta-Cell Blueprints—Oral Abstracts on Islet Development and Postnatal Growth
Room: W206
Chair: Ronadip R. Banerjee, MD, PhD

4:30 p.m.–4:45 p.m.
349-OR Reduction of RNA-Editing Enzyme ADAR1 in Human Islets Triggers an Interferon Response and Impairs Beta-Cell Function
Presenting Author: Chunhua Dai, MD

4:45 p.m.–5:00 p.m.
350-OR Parturition Event Regulates Endocrine Genesis during Pancreas Differentiation
Presenting Author: Agena Suzuki, Master's Degree

5:00 p.m.–5:15 p.m.
351-OR Role of Mef2a in Beta-Cell Differentiation and Function during ER Stress
Presenting Author: Rohit B. Sharma, PhD

5:15 p.m.–5:30 p.m.
352-OR Selective Loss of the Spliced Form of Xbp1 Causes Early-Onset Diabetes in Male but Not Female Mice
Presenting Author: Yingfeng Deng, PhD

5:30 p.m.–5:45 p.m.
353-OR Chd3 Helicase Modulates Pancreatic β-Cell Function in Absence of Chd4
Presenting Author: Sukrati Kanojia, MS

5:45 p.m.–6:00 p.m.
354-OR The Role of Clic-Like Chloride Channel 1 in the Pancreatic Beta Cell
Presenting Author: Yaohuan Zhang, Bachelor's Degree
Scientific Sessions
8:00 a.m.–9:30 a.m.

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY15-1.5
A Means to an Endpoint—Establishing Meaningful Outcomes in Clinical Neuropathy Trials
Room: W206
Chair: Lynn Ang, MD
8:00 a.m.-8:20 a.m. Epidemiology Overview of Diabetic Neuropathy
Barbara H. Braffett, PhD, MS
8:20 a.m.-8:40 a.m. Meaningful Endpoints in Clinical Trials—Lessons Learned
Rodica Busui, MD, PhD
8:40 a.m.-9:00 a.m. Perspectives on Small-Fiber Endpoints
Bruce A. Perkins, MD, MPH, FRCP(C)
9:00 a.m.-9:30 a.m. Question and Discussion Period

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY08-1.5
Innovative Programs That Take on the Challenge of Hard-to-Reach Populations (Includes Livestream)
Room: W415B (Valencia Ballroom)
Chair: Veronica J. Brady, PhD, MSN, BSN
8:00 a.m.-8:30 a.m. Delivering Diabetes Self-Management Education in the Wild West
Deb Bjorsness, MPH, BC-ADM, RD, CDCES
8:30 a.m.-9:00 a.m. Delivering Diabetes Self-Management Support in the Diabetes Belt
Windsor W. Sherrill, PhD, MHA, MBA
9:00 a.m.-9:30 a.m. Delivering Diabetes Prevention and Self-Management Support in Latino Communities in the Rockies
Rocio I. Pereira, MD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY03-1.5
Myth Busters on “Category X” Drugs in Pregnancy—Evidence for Stopping Commonly Used Medications during Pregnancy, Preconception, and Lactation (Includes Livestream)
Room: W414
Chair: Carol J. Levy, MD, CDCES
8:00 a.m.-8:20 a.m. Pharmacology Overview—Which Types of Medications Are Most Likely to Cause Problems in Pregnancy?
Jason G. Umans, MD, PhD
8:20 a.m.-8:40 a.m. Lipid-Lowering Drugs—The Good, The Bad, and The Not That Ugly
Ira J. Goldberg, MD
8:40 a.m.-9:00 a.m. GLP-1 Receptor Agonists—How Should We Counsel Our Patients?
Maisa N. Feghali, MD, MSCR
9:00 a.m.-9:20 a.m. ACE Inhibitors and ARBs—Timing Is Everything
Jessica S. Tangren, MD
9:20 a.m.-9:30 a.m. Question and Discussion Period
MONDAY, JUNE 24, 2024

8:00 a.m.-9:30 a.m.
(continued)

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY21-1.5*
**Cost and Quality—Improving Diabetes Care and the Cost of Ongoing Inequities**
*Room: W311*
*Chair: Celeste Thomas, MD*

8:00 a.m.-8:20 a.m.  *Virtual Peer Groups in Adolescents and Young Adults with Type 1 Diabetes*
Jennifer Raymond, MD, MCR

8:20 a.m.-8:40 a.m.  *Improving Diabetes Outcomes and Reducing Inequities through Collaboration—Perspective from the T1D Exchange*
Osagie Ebekozien, MD, MPH, CPHQ

8:40 a.m.-9:00 a.m.  *Insurance Coverage, Medical Costs and Productivity Loss among Working Age Adults with Diabetes*
Primary Speaker: TBD

9:00 a.m.-9:20 a.m.  *Disparities in Diabetes Prevalence and Management*
Saria Hassan, MD, MPH

9:20 a.m.-9:30 a.m.  *Question and Discussion Period*

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY22-1.5*
**Towards Innovative and Equitable Care in Youth-Onset Type 2 Diabetes**
*Room: W315*
*Chair: Sheela N. Magge, MD, MSCE*

8:00 a.m.-8:20 a.m.  *Advances in Pathophysiology and Novel Treatments in Youth-Onset Type 2 Diabetes*
Stephanie T. Chung, MBBS

8:20 a.m.-8:40 a.m.  *Diabetes Care Technology Use and Barriers in Youth-Onset Type 2 Diabetes*
Laya Ekhlaspour, MD

8:40 a.m.-9:00 a.m.  *The Genetics of Youth-Onset Type 2 Diabetes—Where Are We and What Lies Ahead?*
Jennifer N. Todd, MD

9:00 a.m.-9:20 a.m.  *New Insights into Pathophysiology and Screening of Early Microvascular Complications in Youth-Onset Type 2 Diabetes*
Risa M. Wolf, MD

9:20 a.m.-9:30 a.m.  *Question and Discussion Period*
MONDAY, JUNE 24, 2024

8:00 a.m.-9:30 a.m.
(continued)

**Symposium**

*Theme Area: Clinical Diabetes/Therapeutics*

Session Number: CT-SY39-1.5

**ADA Symposium—Major Advances and Discoveries in Diabetes—The Year in Review**

Room: W415C (Valencia Ballroom)
Chair: Alice Y.Y. Cheng, MD, FRCPC

8:00 a.m.-8:20 a.m. **Clinical**
   - Vanita R. Aroda, MD

8:20 a.m.-8:40 a.m. **Translational**
   - Mary-Elizabeth Patti, MD

8:40 a.m.-9:00 a.m. **Basic**
   - Bruce Verchere, PhD

9:00 a.m.-9:30 a.m. **Question and Discussion Period**

**Symposium**

*Theme Area: Epidemiology/Genetics*

Session Number: EG-SY07-1.5

**Omics to Understand Genome-Wide Association Study—What’s the Mechanism?**

Room: W207
Chair: H. Efsun Arda, PhD

8:00 a.m.-8:30 a.m. **Genome-Wide Association Study—From Variant to Function**
   - Debora Sobreira, PhD

8:30 a.m.-9:00 a.m. **Genome-Wide Association Study Functional Follow-up at a Single Locus**
   - Nicole Krentz, PhD

9:00 a.m.-9:30 a.m. **Leveraging Omics in the Study of Type 2 Diabetes in Underrepresented Populations**
   - Ayo P. Doumatey, PhD

**Symposium**

*Theme Area: Immunology/Beta-Cell Replacement*

Session Number: IBC-SY01-1.5

**Cross Talk between Beta Cells and Immune Cells**

Room: W304 A-D
Chair: Laura M. Jacobsen, MD

8:00 a.m.-8:20 a.m. **Mining Spatial Transcriptomics for Beta-Cell—Immune-Cell Cross Talk**
   - Miguel Medina-Serpas, BS

8:20 a.m.-8:40 a.m. **Profiling Islet—Immune Cell Interactions in the Human Pancreas**
   - Klaus H. Kaestner, PhD, MS

8:40 a.m.-9:00 a.m. **Imaging Beta-Cell—Immune-Cell Interactions**
   - Dirk Homann, MD

9:00 a.m.-9:20 a.m. **What Do Immune Cells See in the Pancreas?**
   - Eddie A. James, PhD

9:20 a.m.-9:30 a.m. **Question and Discussion Period**
8:00 a.m.-9:30 a.m.  
(continued)

**Symposium**  
*Theme Area: Insulin Action/Molecular Metabolism*  
*Session Number: IA-SY06-1.5*

**Molecular Integration of Amino Acid and Fat Metabolism in Health and Metabolic Disease**  
*Room: W304 E-H*  
*Chair: Richard Kibbey, IV, MD, PhD*

8:00 a.m.-8:15 a.m.  
**Amino Acid Metabolism and Brown Fat Activation**  
Shingo Kajimura, PhD

8:15 a.m.-8:30 a.m.  
**Amino Acid Signaling and Glucose Regulation**  
Phillip J. White, PhD

8:30 a.m.-8:45 a.m.  
**Mitochondrial Branched-Chain Amino Acid Oxidation and Metabolism**  
Kelsey Fisher-Wellman, PhD

8:45 a.m.-9:00 a.m.  
**Pleotropic Effects of Exercise on Amino Acid and Fat Metabolism in Metabolic Disease**  
Kristin I. Stanford, PhD

9:00 a.m.-9:30 a.m.  
**Question and Discussion Period**

**Symposium**  
*Theme Area: Obesity/Integrated Physiology*  
*Session Number: IP-SY03-1.5*

**Metabolism and Aging-Related Diseases**  
*Room: W308*  
*Chair: Liangyou Rui, PhD*

8:00 a.m.-8:20 a.m.  
**LRP1 Is a Major Link between Obesity, Memory, and Neurodegenerative Disease**  
Young-Bum Kim, PhD

8:20 a.m.-8:40 a.m.  
**Caloric Restriction and Aging in Nonhuman Primates**  
Ricki Colman, PhD

8:40 a.m.-9:00 a.m.  
**Skeletal Aging, the Role of Cellular Senescence in Aging and Endocrine Disease**  
Joshua N. Farr, PhD

9:00 a.m.-9:20 a.m.  
**Aging-Dependent Regulatory Cells Emerge in Subcutaneous Fat to Inhibit Adipogenesis**  
Hei Sook Sul, PhD

9:20 a.m.-9:30 a.m.  
**Question and Discussion Period**
8:00 a.m.-9:30 a.m.
(continued)

**Symposium**
*Theme Area: Obesity/Integrated Physiology*
*Session Number: IP-SY04-1.5*
**Beyond the Scale—Exploring Causes and Consequences of Weight Fluctuation (Includes Livestream)**
*Room: W307*
*Chair: Siegfried Ussar, PhD*
8:00 a.m.-8:30 a.m. *Immune Cell Memory and Weight Cycling*  
Heather Caslin, PhD
8:30 a.m.-9:00 a.m. *Signs of Antiaging in Lifestyle Interventions*  
Iris Shai, PhD
9:00 a.m.-9:30 a.m. *Nutrient Uptake and Metabolism during Weight Loss*  
Marcus DaSilva Goncalves, MD, PhD

**Symposium**
*Theme Area: Clinical Diabetes/Therapeutics*
*Session Number: CT-SY50-1.5*
**Consensus Monitoring Guidance in Early-Stage Type 1 Diabetes (Includes Livestream)**
*Room: W320 (Chapin Theater)*
*Co-Chairs: Anastasia Albanese-O’Neill, PhD, APRN, CDCES and Chantal Mathieu, MD, PhD*
8:00 a.m.-8:10 a.m. *Why Do We Need Monitoring Guidance?*  
Moshe Phillip, MD
8:10 a.m.-8:20 a.m. *Coming to Consensus*  
Linda DiMeglio, MPH, MD
8:20 a.m.-8:35 a.m. *Overview of Pediatric Advice*  
Kurt J. Griffin, PhD, MD
8:35 a.m.-8:50 a.m. *Overview of Adult Advice*  
Rifka C. Schulman-Rosenbaum, MD, FACE, FACP
8:50 a.m.-9:10 a.m. *Psychosocial and Educational Considerations*  
Brigitte Frohnert, MD, PhD
9:10 a.m.-9:20 a.m. *Next Steps and Real World Applications*  
Sanjoy Dutta, PhD
9:20 a.m.-9:30 a.m. *Panel Discussion*
MONDAY, JUNE 24, 2024

8:00 a.m.-9:30 a.m.
(continued)

**Oral Presentations**

*Theme Area: Clinical Diabetes/Therapeutics*

*Session Number: CT-OR15-1.5*

**New Technology—Continuous Glucose Monitoring**

Room: W314

Chair: Ebne Rafi, PharmD

8:00 a.m.-8:15 a.m.

**355-OR** Glycemic Outcomes with CGM Use in Patients with Type 2 Diabetes—Real World Analysis  
Presenting Author: Satish K. Garg, MD

8:15 a.m.-8:30 a.m.

**356-OR** A Randomized Controlled Trial Using Continuous Glucose Monitoring (CGM) to Guide Food Choices and Diabetes Self-Care in People with Type 2 Diabetes Not Taking Insulin  
Presenting Author: Thomas W. Martens, MD

8:30 a.m.-8:45 a.m.

**357-OR** Association between Continuous Glucose Monitoring and Diabetes-Related Complications in Children with Type 1 Diabetes—Nationwide Cohort Study  
Presenting Author: Ji Yoon Kim, MD, MS

8:45 a.m.-9:00 a.m.

**358-OR** Remote CGM Monitoring in People with Type 2 Diabetes (T2D) in an Underresourced Setting  
Presenting Author: Valerie F. Ruelas, MSW

9:00 a.m.-9:15 a.m.

**359-OR** CGM in Primary Care—Practice Characteristics and Choice of CGM Implementation Strategy in PREPARE 4 CGM  
Presenting Author: Sean Oser, MD, MPH

9:15 a.m.-9:30 a.m.

**360-OR** Defining New Targets for Interventions to Increase Continuous Glucose Monitoring (CGM) Use in Primary Care  
Presenting Author: Jovan Milosavljevic, MD
9:45 a.m.-11:15 a.m.

**Special Lectures and Addresses**
Session Number: OSAA-01

**Outstanding Scientific Achievement Award Lecture and Banting Medal for Scientific Achievement Award Lecture (Includes Livestream)**
Room: West Hall B3-4 (General Session)
9:45 a.m.-9:50 a.m. **Introduction of Outstanding Scientific Achievement Awardee**
   Mandeep Bajaj, MD
9:50 a.m.-10:20 a.m. **Insulin and Instructions—How the Epigenome Directs Diabetes**
   Stephen C.J. Parker, PhD
10:20 a.m.-10:25 a.m. **Introduction of Banting Award Winner**
   Mandeep Bajaj, MD
10:25 a.m.-10:55 a.m. **The Science of Diabetes and A Life of Trials**
   Rury R. Holman MBChB, FRCP(Lond.), FMedSci
10:55 a.m.-11:15 a.m. **Conclude**

11:30 a.m.-12:30 p.m.

**Professional Interest Group**
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-IG01-1

**Discussion on Diabetes Technology—Enhancing Clinic Efficiency through the Integration of Diabetes Technologies**
Room: W304 A-D
Chair: Viral N. Shah, MD
11:30 a.m.-11:35 a.m. **Introduction**
11:35 a.m.-11:45 a.m. **Overview of Currently Available Technologies and Downloading Platforms**
   Laya Ekhlaspour, MD
11:45 a.m.-11:55 a.m. **Outpatient Clinic Flow for Efficient Work Order**
   Halis K. Akturk, MD
11:55 a.m.-12:05 p.m. **Efficient Workflow for Inpatient Technology Use**
   Estelle M. Everett, MD, MHS
12:05 p.m.-12:30 p.m. **Question and Discussion Period**

**Professional Interest Group**
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-IG04-1

**Discussion on Health Care Delivery and Quality Improvement**
Room: W304 E-H
Chair: Francisco J. Pasquel, MD, MPH
11:30 a.m.-11:35 a.m. **Introduction**
11:35 a.m.-11:55 a.m. **An Algorithm for Preoperative Management of Diabetes in Elective Surgery Patients**
   Ketan Dhatariya, MBBS, MSc, MD, MS, FRCP, PhD
11:55 a.m.-12:15 p.m. **Designing a Program for Preoperative Management of Diabetes**
   Rajesh K. Garg, MD
12:15 p.m.-12:30 p.m. **Question and Discussion**
11:30 a.m.-12:30 p.m. (continued)

Professional Interest Group
Theme Area: Epidemiology/Genetics
Session Number: EG-IG01-1
Discussion on Public Health and Epidemiology—Kids Are Not Little Adults—Challenges and Opportunities in the Use of Pharmacotherapy for Youth With and at Risk for Type 2 Diabetes
Room: W207
Chair: Noël C. Barengo, MD, PhD, MPH
11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-11:55 a.m. Role of Antiobesity Pharmacotherapy in Youth With and At Risk for Type 2 Diabetes
    Megan Oberle Bensignor, MD, MSHP
11:55 a.m.-12:15 p.m. Moving Beyond Insulin and Metformin—Learning from Adult Experience to Improve Care for Youth with Type 2 Diabetes
    Mary Ellen Vajravelu, MD, MSHP
12:15 p.m.-12:30 p.m. Question and Discussion Period

Professional Interest Group
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-IG01-1
Discussion on Immunology/Beta-Cell Replacement—Beta-Cell Stressors, Autoantigen Targets, and How This Provokes Immune Attack
Room: W206
Chair: Meaghan Stumpf, MD
11:30 a.m.-11:35 a.m. Introduction
11:35 a.m.-11:50 a.m. Dissecting the Autoimmune T-Cell Repertoires in Type 1 Diabetes
    Alok Joglekar, PhD
11:50 a.m.-12:05 p.m. Beta-Cell Adaptive Stress Response and Immune System Cross Talk in Diabetes
    Amelia K. Linnemann, PhD
12:05 p.m.-12:20 p.m. Stress-Induced Pathways in Beta Cells Increase Immune Perception of Pancreatic Islets—Implications for Type 1 Diabetes
    Aisha Callebut, PhD
12:20 p.m.-12:30 p.m. Question and Discussion Period

Professional Development
Theme Area: Professional Development
Session Number: PD-03-1
Getting The Career You Envision—How To Negotiate For What You Need (And Want) (Includes Livestream)
Room: W307
Chair: Jane E.B. Reusch, MD
11:30 a.m.-12:10 p.m. Getting The Career You Envision—How To Negotiate For What You Need (And Want)
    Judith G. Regensteiner, PhD
12:10 p.m.-12:30 p.m. Question and Discussion Period
MONDAY, JUNE 24, 2024

11:30 a.m.-12:30 p.m. (continued)

**ePoster Theater**
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: ePoster13

(*) Tailoring Diabetes Self-Management Education to Improve Success
Room: Exhibit Hall (West A1-A3) ePoster Theater A
Moderator: Helen A. Habib, PharmD, BCACP, CDCES

(*Continuing Education Credit Is Not Awarded for this Session.

11:30 a.m.-11:40 a.m.  
*533-P* Geospatial Analysis of a Diabetes Management Program—Program Participation and Social Determinants of Health  
Presenting Author: Samantha Kanny, MS

11:40 a.m.-11:50 a.m.  
*534-P* Structured CGM Education Delivered via Mobile Phone Is Associated with Increased Time in Range—Proof-of-Concept Study Results  
Presenting Author: Melissa P. Holloway, BA, MSt

11:50 a.m.-12:00 p.m.  
*535-P* Success of Interactive, Online, Case-Based Education Related to Use of CGM for Type 2 Diabetes  
Presenting Author: Amy Larkin, PharmD

12:00 p.m.-12:10 p.m.  
*536-P* Characteristics of People with Type 2 Diabetes Based on the Extended Parallel Processing Model (EPPM)  
Presenting Author: Daniel J. Rubin, MD, MSc, FACE

12:10 p.m.-12:20 p.m.  
*537-P* Community-Based Diabetes Management—Evaluating the Efficacy of Do Right! Diabetes Challenge  
Presenting Author: Nithya S. Trichy, BS
11:30 a.m.-12:30 p.m.
(continued)

ePoster Theater
Theme Area: Obesity/Integrated Physiology
Session Number: ePoster14
(*) Research Advances in Metabolic Regulation
Room: Exhibit Hall (West A1-A3) ePoster Theater B
Moderator: Daisy Duan, MD

(*) Continuing Education Credit Is Not Awarded for this Session.

11:30 a.m.-11:40 a.m.
1523-P Anorexia Induced by the Central Action of Fibroblast Growth Factor 1 (FGF1) Is Dependent on Activation of Parabrachial CGRP Neurons
Presenting Author: Jarrad M. Scarlett, MD, PhD

11:40 a.m.-11:50 a.m.
1524-P UNABLE TO ATTEND

11:50 a.m.-12:00 p.m.
1601-P Regulation of Circadian Rhythmicity of Human Adipose Tissue in Obesity
Presenting Author: Kelli Lytle, PhD

12:00 p.m.-12:10 p.m.
1602-P Exercise Training Reverses Skeletal Muscle DRP1 Hyperactivation and Improves Respiratory Capacity in Patients with Type 2 Diabetes
Presenting Author: Elizabeth C. Heintz, MS, BS

12:10 a.m.-12:20 p.m.
1603-P The Cardiovascular Impact of Appropriately-Timed Prandial Insulin in Type 1 Diabetes—A Randomized Crossover Study
Presenting Author: William B. Horton, MD, MSc, FACP
MONDAY, JUNE 24, 2024

12:30 p.m.-1:30 p.m.

ePoster Theater
Theme Area: Clinical Diabetes/Therapeutics
Session Number: ePoster15
(*) Creative Strategies for Care Improvement
Room: Exhibit Hall (West A1-A3) ePoster Theater A
Moderator: Jessica L. Harding, PhD

(*) Continuing Education Credit Is Not Awarded for this Session.

12:30 p.m.-12:40 p.m.
1060–P MOMs—Improved Glycemic Control and Diabetes Self-Management for Underserved Pregnant Patients
Presenting Author: Courtney U. Cart, MSW, MPH

12:40 p.m.-12:50 p.m.
1061–P Interdisciplinary Approach to Outpatient Diabetes Management with Pharmacist-Led Interventions
Presenting Author: John Woodley, DO

12:50 p.m.-1:00 p.m.
1062–P Peer Coaching Reduces Medication Barriers in African American Patients with Comorbid Diabetes and Hypertension—Results from the SEC Study
Presenting Author: Doyle M. Cummings, PharmD

1:00 p.m.-1:10 p.m.
1063–P A Carbohydrate-Restricted Intervention and Continuous Remote Care Improves Health Outcomes across All Socioeconomic Groups at Two Years
Presenting Author: Brittanie M. Volk, PhD, RD

1:10 p.m.-1:20 p.m.
1064–P Order Set Design and "Nudges" to Change Care in Diabetes—Towards a Novel Pragmatic Clinical Trial Design
Presenting Author: James Flory, MD, MSCE
12:30 p.m.-1:30 p.m.

**ePoster Theater**

*Theme Area: Islet Biology/Insulin Secretion*

Session Number: ePoster16

(*) **Hepatocytes, Adipocytes, Beta cells, Oh My!**

Room: Exhibit Hall (West A1-A3) ePoster Theater B

Moderator: Erin E. Mulvihill, PhD

(*) *Continuing Education Credit Is Not Awarded for this Session.*

12:30 p.m.-12:40 p.m.

**1796-LB Adipocyte-Derived Extracellular Vesicles (AdEVs) Contribute to Insulin Resistance and Atherosclerosis in Obesity**

Presenting Author: Xilal Y. Rima, PhD

12:40 p.m.-12:50 p.m.

**1960-LB A 3D Analysis of CD8+ Leukocytic Infiltration in Human Endocrine and Exocrine Pancreas at Type 1 Diabetes Onset**

Presenting Author: Alexandra Rippa, PhD

12:50 p.m.-1:00 p.m.

**2036-LB Identification of a Hepatocyte Subpopulation That Simultaneously Expresses Gluconeogenic and Lipogenic Genes in the Fed State**

Presenting Author: Junichi Okada, MD, PhD

1:00 p.m.-1:10 p.m.

**2087-LB Novel Human Islet Spheroid Models of Type 1 Diabetes**

Presenting Author: Burcak Yesildag, PhD

1:10 a.m.-1:20 p.m.

**2089-LB An Adult Clock Component Links Circadian Rhythms to Pancreatic β-Cell Maturation**

Presenting Author: Juan R. Alvarez, PhD
MONDAY, JUNE 24, 2024

12:30 p.m.-1:30 p.m.

Session Break
(Take this opportunity to visit the Exhibit and Poster Halls)

1:30 p.m.-3:00 p.m.

Symposium
Theme Area: Acute and Chronic Complications
Session Number: AC-SY06-1.5
Demystifying Impaired Awareness of Hypoglycemia—Diagnosis, Experience, and Treatment in the Real World
Room: W207
Chair: Alexandria Ratzki-Leewing, PhD
1:30 p.m.-2:00 p.m. Impaired Awareness of Hypoglycemia—Screening and Diagnosis in Clinical Practice
    Scott J. Pilla, MD, MHS
2:00 p.m.-2:30 p.m. Evidence-Based Interventions to Restore Awareness of Hypoglycemia
    Jeremy Pettus, MD
2:30 p.m.-3:00 p.m. Living with Impaired Awareness of Hypoglycemia—What People Living with Diabetes Wish You Knew
    Eva Kathmann, PhD

Symposium
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise
Session Number: BM-SY09-1.5
How Diabetes Technology Is Changing Diabetes Care in the Real World
Room: W311
Chair: Michelle D. Stancil, MS, BSN, RN, CDCES
1:30 p.m.-2:00 p.m. Don’t Say No to Continuous Glucose Monitors in Primary Care
    Caitlin Nass, MSN, CRNP
2:00 p.m.-2:30 p.m. Implementation of Remote Patient Monitoring in Rural Settings—Barriers and Facilitators
    Emily E. Johnson, PhD
2:30 p.m.-3:00 p.m. How Connected Insulin Pens and Caps Are Facilitating Precision Insulin Management
    Janice MacLeod, MA, RD, CDCES, FADCES
1:30 p.m.–3:00 p.m.  
(continued)

Symposium  
Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise  
Session Number: BM-SY17-1.5  
Nutrition and Diabetes Self-Management Education and Support (DSMES)  
Room: W415C (Valencia Ballroom)  
Chair: Barbara Eichorst, MS, RD, CDCES

1:30 p.m.–2:00 p.m.  Collaborations between Providers and DCES's—Bringing Standards of Care Alive  
Louis H. Philipson, MD, PhD, FACP  
Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES

2:00 p.m.–2:15 p.m.  Integrating Therapeutic Education into Obesity Interventions  
Zoltan Pataky, MD

2:15 p.m.–2:30 p.m.  Culturally Sensitive Conversations When Approaching Nutrition Changes  
Victoria Bouhairie, MD, DipACLM

2:30 p.m.–2:45 p.m.  Integrating Multidisciplinary Team in Diabetes Management—Germany Perspective  
Peter E.H. Schwarz, PhD

2:45 p.m.–3:00 p.m.  Question and Discussion Period

Symposium  
Theme Area: Clinical Diabetes/Therapeutics  
Session Number: CT-SY07-1.5  
Impact of Precision Medicine on Diabetes  
Room: W314  
Chair: Anna L. Gloyn, DPhil

1:30 p.m.–2:00 p.m.  How Is Precision Medicine Changing the Paradigm in Type 1 Diabetes?  
Chantal Mathieu, MD, PhD

2:00 p.m.–2:30 p.m.  How Is Precision Medicine Changing the Paradigm in Type 2 Diabetes?  
Jose C. Florez, MD, PhD

2:30 p.m.–3:00 p.m.  How Is Precision Medicine Changing the Paradigm in Monogenic Diabetes?  
Rochelle N. Naylor, MD
**Symposium**

*Theme Area: Clinical Diabetes/Therapeutics*

**Session Number: CT-SY20-1.5**

**Just Do It—Incorporating What We Know into What We Do**

Room: W315  
Chair: Amisha Wallia, MD, MS

1:30 p.m.-1:50 p.m.  
**EHR-Based Tools to Overcome Therapeutic Inertia and Improve Health Equity in Diabetes Technology Prescriptions**  
Brittany S. Bruggeman, MD

1:50 p.m.-2:10 p.m.  
**REALITY Check—Preventing Diabetes in the “Real World”—Early Findings of the Real-World Effectiveness of Interventions of the Type 2 Diabetes Mellitus Prevention Network**  
Tannaz Moin, MD, MBA, MSHS

2:10 p.m.-2:30 p.m.  
**The Michigan Collaborative for Type 2 Diabetes**  
Lauren Oshman, MD, MPH

2:30 p.m.-2:50 p.m.  
**Screening for Type 1 Diabetes—From Evidence**  
Laura M. Jacobsen, MD

2:50 p.m.-3:00 p.m.  
**Question and Discussion Period**

---

**Symposium**

*Theme Area: Clinical Diabetes/Therapeutics*

**Session Number: CT-SY26-1.5**

**ADA Diabetes Care/Diabetes/Diabetologia Symposium—The Heterogeneity of Type 1 Diabetes—Pathogenesis, Treatment, and Prevention (Includes Livestream)**

Room: W320 (Chapin Theater)  
Co-Chairs: Hindrik Mulder, MD, PhD and David A. D’Alessio, MD

1:30 p.m.-1:45 p.m.  
**Beta-Cell Pathology in Type 1 Diabetes—Immune, Inflammatory, Functional**  
Primary Speaker: TBD

1:45 p.m.-2:00 p.m.  
**Insulin Replacement in Type 1 Diabetes—Needles, Pumps, and Islets**  
Primary Speaker: TBD

2:00 p.m.-2:15 p.m.  
**The Emerging Spectrum of Strategies to Prevent Type 1 Diabetes**  
Primary Speaker: TBD

2:15 p.m.-3:00 p.m.  
**Question and Discussion Period**
1:30 p.m.-3:00 p.m.  
(continued)

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY28-1.5*

**Lancet Journal Symposium—Time for a Paradigm Shift? Should We Treat Early Gestational Diabetes Mellitus?**  
*Room: W304 E-H*  
Co-Chairs: Jessamy Bagenal, MBBS and David Simmons, MA, MBBS, FRACP, FRCP, MD (Cantab)

1:30 p.m.-1:50 p.m.  
**Epidemiology of Early Gestational Diabetes Mellitus**  
Hannah Wesley, BDS, MPH, PhD

1:50 p.m.-2:10 p.m.  
**Pathophysiology of Early Gestational Diabetes Mellitus**  
Marie-France Hivert, MD, MMSc

2:10 p.m.-2:30 p.m.  
**How Should We Diagnose Early Gestational Diabetes Mellitus?**  
Arianne Sweeting, MBBS, PhD

2:30 p.m.-2:50 p.m.  
**Further Considerations for the Early Diagnosis of Gestational Diabetes Mellitus**  
Patrick Catalano, MD

2:50 p.m.-3:00 p.m.  
**Question and Discussion Period**

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY41-1.5*

**The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist—Once-Weekly Semaglutide and the FLOW Trial Results (Includes Livestream)**  
*Room: W415B (Valencia Ballroom)*  
Co-Chairs: Richard E. Pratley, MD and Vlado Perkovic, MBBS, PhD, FRACP, FASN, FAHMS

1:30 p.m.-1:40 p.m.  
**Current Treatment Strategies, Unmet Medical Need, FLOW Rationale**  
Peter Rossing, MD, DMSc

1:40 p.m.-2:00 p.m.  
**FLOW Trial Design and Baseline Characteristics, Glycemic Control, and Body Weight**  
Richard E. Pratley, MD

2:00 p.m.-2:10 p.m.  
**FLOW Kidney Outcomes**  
Vlado Perkovic, MBBS, PhD, FRACP, FASN, FAHMS

2:10 p.m.-2:20 p.m.  
**FLOW CV Outcomes**  
Kenneth W. Mahaffey, MD, PhD

2:20 p.m.-2:30 p.m.  
**FLOW Results by Baseline Use of SGLT2i**  
Johannes F.E. Mann, MD

2:30 p.m.-2:40 p.m.  
**FLOW Results—Summary and Clinical Implication**  
Katherine R. Tuttle, MD, FACP, FASN, FNKF

2:40 p.m.-3:00 p.m.  
**FLOW Results—Independent Commentary**  
Sylvia Rosas, MD, MSCE
MONDAY, JUNE 24, 2024

1:30 p.m.-3:00 p.m.
(continued)

Panel
Theme Area: Immunology/Beta-Cell Replacement
Session Number: IBC-PN03-1.5
Modulating Cytokines—Mechanisms Underlying Type 1 Diabetes Treatment *(Includes Livestream)*
Room: W414
Chair: Cate Speake, PhD
1:30 p.m.-1:55 p.m. How Does Baricitinib Block Type 1 Diabetes Progression?
   Michaela Waibel, PhD
1:55 p.m.-2:20 p.m. How Does IL-2 Treatment Prevent Type 1 Diabetes Progression?
   Ricardo Ferreira, PhD
2:20 p.m.-2:45 p.m. How Does Ustekinumab Prevent Type 1 Diabetes Progression?
   Stephanie Hanna, PhD
2:45 p.m.-3:00 p.m. Question and Discussion Period

Symposium
Theme Area: Obesity/Integrated Physiology
Session Number: IP-SY05-1.5
Mitochondria as a Therapeutic Target for Diabetes
Room: W308
Chair: Irena A. Rebalka, PhD
1:30 p.m.-2:00 p.m. Harnessing Amino Acid Metabolism for Diabetic Therapy
   Esther Phielix, PhD
2:00 p.m.-2:30 p.m. Targeting Mitochondria via Probiotics to Restore Microbiota Health in Type 2 Diabetes
   Natalia Shulzenko, MD, PhD
2:30 p.m.-3:00 p.m. Exercise and Skeletal Muscle Mitochondrial Adaptations in Type 1 Diabetes
   Dean Minnock, PhD

Symposium
Theme Area: Obesity/Integrated Physiology
Session Number: IP-SY10-1.5
Food Noise Explained—Satiety Responsiveness and Motivation Processing in the Brain *(Includes Livestream)*
Room: W307
Chair: Alyssa Huang, MD
1:30 p.m.-2:00 p.m. Genetic and Environmental Influences on Satiety and Food Motivation in Obesity
   Susan Carnell, PhD
2:00 p.m.-2:30 p.m. Gut–Brain Signaling Underlying Motivational Behavior
   Ivan de Araujo, DPhil
2:30 p.m.-3:00 p.m. Effect of Behavioral Weight Loss on Satiety and Food Motivation
   Ellen Schur, MD, MS
Panel
Theme Area: Islet Biology/Insulin Secretion
Session Number: IB-PN04-1.5
Are We Using the Right Tools to Establish Causality in Islet Function and Dysfunction?
Room: W206
Chair: Alejandro Caicedo, PhD
1:30 p.m.-1:45 p.m. Transgenic Mouse Models Can Be Used to Study In Vivo Beta-Cell Biology
Jennifer L. Estall, PhD
1:45 p.m.-2:00 p.m. Of Mice and Mankind—Why Human Samples are Necessary to Advance Understanding of Pancreatic Islet (Patho)Physiology
Katie C. Coate, PhD
2:00 p.m.-2:15 p.m. Large Omics Data Sets Allow for Key Insights into Beta-Cell Biology
Kyle J. Gaulton, PhD
2:15 p.m.-2:30 p.m. A New Open Resource for the Islet Community—Towards Causality by Connecting -Omics and Function
Patrick MacDonald, PhD
2:30 p.m.-2:45 p.m. New Models Are Needed for Optimal Testing of Beta-Cell Biology
Rayner Rodriguez Diaz, PhD
2:45 p.m.-3:00 p.m. Question and Discussion Period
MONDAY, JUNE 24, 2024

1:30 p.m.-3:00 p.m.
(continued)

**Oral Presentations**
*Theme Area: Insulin Action/Molecular Metabolism*
*Session Number: IA-OR04-1.5*

**Revving Up the Adipose to Impact Insulin Sensitivity and Glucose Homeostasis**
Room: W304 A-D
Chair: Mary Teruel, PhD

1:30 p.m.-1:45 p.m.
**361-OR**  A Multiomics Approach to Identify Genes Important for the Regulation of Antidiabetic and Anti-inflammatory Lipids
Presenting Author: Anna Santoro, PharmD, PhD

1:45 p.m.-2:00 p.m.
**362-OR**  Divergent Roles of METTL14-Mediated m6A in Regulating Brown and White Adipose Tissue Transcriptomes and Systemic Metabolism
Presenting Author: Ling Xiao, PhD

2:00 p.m.-2:15 p.m.
**363-OR**  Matrix Metalloprotease-2 as a Novel Regulator of Glucose Utilization by Adipocytes and High-Fat Diet-Induced Glucose Intolerance
Presenting Author: Melissa D. Lempicki, BS

2:15 p.m.-2:30 p.m.
**364-OR**  Beta-Cell SF1 as a Thermogenic Regulator against Diet-Induced Obesity in Mice—Elucidating Its Role in Islet–Adipose Cross Talk
Presenting Author: Yan Guo, Doctor

2:30 p.m.-2:45 p.m.
**365-OR**  Maladaptive Sensory Plasticity via α2δ1-subunit Promotes Adipose Tissue Lipolysis after Spinal Cord Injury
Presenting Author: Debasish Roy, PhD
3:15 p.m.-4:15 p.m.

**Symposium**

*Theme Area: Acute and Chronic Complications*

Session Number: AC-SY11-1

**Cardiovascular Disease Risk Prediction in Obesity and Type 2 Diabetes—Emerging Tools for the Clinician**

Room: W206

Chair: Darren K. McGuire, MD, MHSc, FAHA, FACC, FESC

3:15 p.m.-3:35 p.m. *High-Risk Cardiovascular Disease Phenotypes in Obesity—Beyond Body Mass Index*

Marie-Eve Piché, MD, PhD, FRCPC, FAHA

3:35 p.m.-3:55 p.m. *Predicting Risk for Heart Failure in Type 2 Diabetes—Insights from the TRS-HFDM and WATCH-DM Risk Scores*

Ambarish Pandey, MD, MSCS

3:55 p.m.-4:15 p.m. *Predicting Risk for Atherosclerotic Cardiovascular Disease in Type 2 Diabetes—Insights from SCORE2-Diabetes Risk Score*

Caroline J. Magri, MD, MRCP(UK), FEFIM, MPhil, MSc(Brighton), PhD

**Ask the Expert**

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

Session Number: BM-AE04-1

**The Highs and Lows of Cannabis Use in Diabetes—Behavioral and Psychosocial Considerations**

Room: W314

Chair: Elizabeth A. Beverly, PhD

3:15 p.m.-3:35 p.m. *The Highs and Lows of Cannabis Use in Diabetes—Overview and Landscape of Use*

Jay H. Shubbrook, DO

3:35 p.m.-3:55 p.m. *The Highs and Lows of Cannabis Use in Diabetes—Associations between CBD, THC, or CBD+THC Use vs. Nonuse on Insulin Sensitivity, Inflammation, and Behavior*

Angela Bryan, PhD

3:55 p.m.-4:15 p.m. *The Highs and Lows of Cannabis Use in Diabetes—Behavioral and Psychosocial Considerations*

Halis K. Akturk, MD

**Panel**

*Theme Area: Behavioral Medicine, Clinical Nutrition, Education, and Exercise*

Session Number: BM-PN11-1

**Are We Close to Closing the Loop? Automated Insulin Delivery during Exercise**

Room: W415C (Valencia Ballroom)

Chair: Michael C. Riddell, PhD

3:15 p.m.-4:15 p.m. *Are We Close to Closing the Loop? Automated Insulin Delivery during Exercise*

Rêmi Rabasa-Lhoret, MD, PhD

Aude Bandini, PhD

Chiara Dalla Man, PhD

Dale Morrison, PhD
3:15 p.m.-4:15 p.m.  
(continued)

**Debate**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-DB04-1*  
*Early Abnormal Glucose Metabolism in Pregnancy—To Treat or Not to Treat*  
*Room: W311*  
*Chair: Erin S. LeBlanc, MD, MPH*

3:15 p.m.-3:35 p.m. **PRO—Early Abnormal Glucose Metabolism in Pregnancy SHOULD Be Treated**  
David Simmons, MA, MBBS, FRACP, FRCP, MD (Cantab)

3:35 p.m.-3:55 p.m. **CON—Early Abnormal Glucose Metabolism in Pregnancy SHOULD NOT Be Treated**  
Lorie M. Harper, MD, MSCI

3:55 p.m.-4:00 p.m. **Rebuttal**  
David Simmons, MA, MBBS, FRACP, FRCP, MD (Cantab)

4:00 p.m.-4:05 p.m. **Rebuttal**  
Lorie M. Harper, MD, MSCI

4:05 p.m.-4:15 p.m. **Question and Discussion Period**

**Symposium**  
*Theme Area: Clinical Diabetes/Therapeutics*  
*Session Number: CT-SY25-1*  
*Improving Culture of Quality in Pediatric Centers—Lessons from the Type 1 Diabetes Exchange Quality Improvement Collaborative*  
*Room: W315*  
*Chair: Eda Cengiz, MD, MHS*

3:15 p.m.-3:35 p.m. **Increasing Insulin Pump Utilization in Public-Insured Patients**  
Anna Cymbaluk, MD

3:35 p.m.-3:55 p.m. **Current Approaches to Addressing Racial Equity—Insights from the T1D Exchange Q1 Collaborative**  
Trevon Wright, MHA

3:55 p.m.-4:15 p.m. **Data-Driven Predictions to Determine High-Risk Patients with Type 1 Diabetes**  
Mark A. Clements, MD, PhD
3:15 p.m.-4:15 p.m.
(continued)

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY47-1
Use of SGLT2i in Youth with Type 1 Diabetes—Results from ATTEMPT (The Adolescent Type 1 Diabetes Treatment with SGLT2i for hyperglycEMia & hyPerfilTration Trial)
Room: W414
Chair: Peter A. Senior, MBBS, PhD
3:15 p.m.-3:30 p.m. Rationale for SGLT2i Adjunctive Therapy in Youth with Type 1 Diabetes
   Petter Bjornstad, MD
3:30 p.m.-3:50 p.m. ATTEMPT Study—Renal and Glycemic Outcomes
   Farid H. Mahmud, MD
3:50 p.m.-4:00 p.m. ATTEMPT Study—Patient Perspectives of SGLT2i For Diabetes Management
   Samantha Anthony, PhD, MSW, RSW
4:00 p.m.-4:10 p.m. ATTEMPT Study Commentary—SGLT2i in Youth with Type 1 Diabetes
   Jennifer L. Sherr, MD, PhD
4:10 p.m.-4:15 p.m. Question and Discussion Period

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY48-1
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Room: W415B (Valencia Ballroom)
Chair: Rodica Busui, MD, PhD
3:15 p.m.-3:25 p.m. The Spectrum of Hypercortisolism—An Evolution of Understanding
   Richard Auchus, MD, PhD
3:25 p.m.-3:35 p.m. Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes
   Ralph A. DeFronzo, MD
3:35 p.m.-3:45 p.m. Rationale for and Design of the CATALYST Trial
   Athena Philis-Tsimikas, MD
3:45 p.m.-3:55 p.m. Results of the CATALYST Trial Part 1
   Vivian Fonseca, MD
3:55 p.m.-4:05 p.m. Clinical Implications of the CATALYST Trial Part 1
   John B. Buse, MD, PhD
4:05 p.m.-4:15 p.m. Question and Discussion Period
3:15 p.m. - 4:15 p.m.  
(continued)

**Symposium**

*Theme Area: Epidemiology/Genetics*
*Session Number: EG-SY06-1*

**Diabetes Genetic Convergence—Shared Networks of Rare and Common Variants**

*Room: W207*  
*Chair: Melina Claussnitzer, PhD*

- **3:15 p.m.-3:35 p.m.**  
  *Diabetes Genetic Convergence—Rare to Common Variants in Networks*  
  Kashyap A. Patel, MRCP, PhD

- **3:35 p.m.-3:55 p.m.**  
  *Single Cell Transcriptomics, Networks, Genetic Convergence, HNF1A*  
  Yan Li, PhD

- **3:55 p.m.-4:15 p.m.**  
  *Genetic Convergence in Rare and Common Diabetes (HNF1A and RFX6), MPRA*  
  Adelaide Tovar, PhD

**Debate**

*Theme Area: Immunology/Beta-Cell Replacement*
*Session Number: IBC-DB02-1*

**Do Immune or Beta Cells Drive Transition from Stage 1 to Stage 3 Type 1 Diabetes?**

*Room: W304 A-D*  
*Chair: Alberto Pugliese, MD*

- **3:15 p.m.-3:30 p.m.**  
  *Type 1 Diabetes Progression Is Precipitated by Immune Cells*  
  Jamie L. Felton, MD

- **3:30 p.m.-3:45 p.m.**  
  *Type 1 Diabetes Progression Is Precipitated by Beta Cells*  
  Edward Phelps, PhD

- **3:45 p.m.-3:50 p.m.**  
  *Rebuttal*  
  Jamie L. Felton, MD

- **3:50 p.m.-3:55 p.m.**  
  *Rebuttal*  
  Edward Phelps, PhD

- **3:55 p.m.-4:15 p.m.**  
  *Question and Discussion Period*

**Symposium**

*Theme Area: Immunology/Beta-Cell Replacement*
*Session Number: IBC-SY08-1*

**The Future of Diabetes Care as Cell Replacement or Regeneration Therapies (Includes Livestream)**

*Room: W307*  
*Chair: Mark A. Atkinson, PhD*

- **3:15 p.m.-3:40 p.m.**  
  *Designing the Next Generation of Beta Cells for Stem Cell Rx*  
  Matthias Hebrok, PhD

- **3:40 p.m.-4:05 p.m.**  
  *Beta-Cell Regeneration Strategies*  
  Andrew F. Stewart, MD

- **4:05 p.m.-4:15 p.m.**  
  *Question and Discussion Period*
3:15 p.m.–4:15 p.m.  (continued)

Panel
Theme Area: Obesity/Integrated Physiology
Session Number: IP-PN01-1
Leptin, 30 Years Later
Room: W304 E-H
Chair: Jeffrey S. Flier, MD
3:15 p.m.–4:15 p.m.  Leptin, 30 Years Later
Martin G. Myers, Jr., MD, PhD
Stephanie Fulton, PhD
Philipp E. Scherer, PhD
Rudolph L. Leibel, MD

Panel
Theme Area: Obesity/Integrated Physiology
Session Number: IP-PN09-1
Ripple Effects after the Advent of Highly Effective Antiobesity Pharmacotherapy—Pharmacoequity in the United States
Room: W308
Chair: Jessica Schwartz, MD, MHS
3:15 p.m.–3:35 p.m.  Principles of Pharmacoequity
Utibe Essien, MD, MPH
3:35 p.m.–3:55 p.m.  Antiobesity Medication Access on the Clinical Frontlines
Kristina H. Lewis, MD, MPH, SM
3:55 p.m.–4:15 p.m.  Economic and Public Policy Considerations in the United States
Alison Ward, PhD

Symposium
Theme Area: Clinical Diabetes/Therapeutics
Session Number: CT-SY46-1
Results from a Randomized Trial of Intensive Glucose Management Using Continuous Glucose Monitoring (CGM) Versus Usual Care in Hospitalized Adults with Type 2 Diabetes—The TIGHT Study (Includes Livestream)
Room: W320 (Chapin Theater)
Chair: Celia C. Low Wang, MD
3:15 p.m.–3:26 p.m.  Study Background and Rationale
Boris Draznin, MD, PhD
3:26 p.m.–3:37 p.m.  Study Methods
Jagdeesh Ullal, MD, MS, FACE, FACP, ECNU
3:37 p.m.–3:48 p.m.  Study Results
Guillermo Umpierrez, MD, CDCES, MACP, FACE
3:48 p.m.–3:59 p.m.  Discussion of Results and Conclusions
Irl B. Hirsch, MD
3:59 p.m.–4:15 p.m.  Question and Discussion Period
Product Theaters

Product Theaters are informative sessions focusing on products or a single facet of diabetes. These sessions will not provide any continuing education credit. They are for health care professionals only with practices relevant to the presented information.

SATURDAY, JUNE 22, 2024
10:15 a.m.-11:00 a.m.

Meet Tandem Mobi: Tiny Pump, Big Control. The Future of AID.
Presented by Tandem Diabetes Care

In this product theater, Jordan Pinsker, Chief Medical Officer for Tandem Diabetes Care, will discuss the latest automated insulin delivery innovation, the Tandem Mobi system. Tandem Mobi, the world’s smallest, durable automated insulin delivery system,1 became commercially available in the United States in February of 2024. This product theater will feature Dr. Halis Khan Akturk, Associate Professor of Medicine and Pediatrics at the Barbara Davis Center for Diabetes, University of Colorado, who will offer valuable insights about the early, real-world experience with Tandem Mobi. Additionally, Cari Berget, MPH, RN, CDE, Director of the PANTHER Program and Research Instructor in, Pediatrics at the Barbara Davis Center, will discuss how the unique wearability features of Tandem Mobi, combined with the Control-IQ technology algorithm, ushers in a new generation for AID systems. The speakers will also discuss the benefits of a small-sized insulin system that can be disconnected for sports, swimming, and real-life scenarios, and how optimizing algorithm settings can help improve patient outcomes. Tandem will also share details about the future of its AID and the pursuit of fully closed-loop systems. Reference: 1. As of June, 2024. Data on file, Tandem Diabetes Care.

Presenters:
- Jordan Pinsker, MD
  Tandem Diabetes Care, Inc.
  Santa Barbara, CA
- Halis Khan Akturk, MD
  Associate Professor of Pediatrics and Medicine
  Barbara Davis Center for Diabetes, University of Colorado
  Aurora, CO
- Cari Berget, RN, MPH, CDCES
  Instructor
  Barbara Davis Center for Diabetes, University of Colorado
  Aurora, CO

Location: Product Theater 1
10:15 a.m.-11:00 a.m.

**Revolutionizing CGM Technology: A Journey Through Mindful Innovation**  
*Presented by Abbott*

Join us for an enlightening session that will explore the latest advancements in FreeStyle Libre systems and their transformative impact on diabetes management. Our expert presenters will discuss how real-time CGM data personalizes care, enhances patient engagement, and improves clinical outcomes. We will unveil FreeStyle Libre partnerships and innovative developments in sensor technology that will empower both patients and healthcare providers. Don't miss this opportunity to gain valuable insights into the future of diabetes management and how our pioneering approaches can make a difference in patient care.

**Moderator:** Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP  
Endocrinology & Metabolism Institute  
Cleveland Clinic Diabetes Center  
Cleveland, OH

**Presenters:**  
David T. Ahn, MD  
Mary & Dick Allen Diabetes Center  
Newport Beach, CA

Scott Harper  
Division Vice President R&D  
Abbott  
Alameda, CA

**Location:** Product Theater 2

10:15 a.m.-11:00 a.m.

**Championing LDL-C Management in Diabetes Care**  
*Presented by Amgen*

This is a comprehensive presentation dedicated to prioritizing LDL-C lowering for diabetic patients with hyperlipidemia and ASCVD. We will also discuss a treatment option during this presentation.

**Presenter:** Jennifer D. Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP  
Professor of Pharmacy Practice  
Massachusetts College of Pharmacy and Health Sciences (MCPHS)  
Clinical Instructor  
Tufts University  
Clinical Pharmacist, Clinical Director, Cardiometabolic Program  
Well Life  
Boston, MA

**Location:** Product Theater 3
Empowering People with Type 2 Diabetes: Early Utilization of Dexcom CGM to Support Behavior Change and Improve Health Outcomes

*Presented by Dexcom*

Dexcom leads the development of evidence to support the use of real-time CGM (RT-CGM) in people living with type 2 diabetes (T2D), emphasizing the opportunity for early glycemic goal achievement for effective T2D management. Join this session and share in a dynamic conversation, moderated by Dr. Thomas Grace, MD, CDCES, as experts dive into the transformative impact of Dexcom CGM in T2D. Discover a dual perspective, examining both the attainment of clinical goals as well as improvement in patient-reported outcomes. We'll highlight how individuals leverage Dexcom CGM to successfully understand the impact of lifestyle choices on diabetes management goals. You'll realize the multifaceted role Dexcom CGM has in early intervention in T2D. Dexcom personalizes diabetes management and empowers people to take control of their health.

**Moderator:** Thomas Grace, MD, CDCES, ABOM  
Director, Blanchard Valley Diabetes Center  
Head, Clinical Advocacy and Outcomes  
Dexcom  
Findlay, OH

**Presenters:**  
Rachel Sood, RN, MSN, NP-C  
Diabetes Nurse Practitioner, Primary Care & Population Health  
Owner  
The Diabetes Collective & Faculty LSU School of Nursing  
Metairie, LA

Daniel Katselnik, MD  
Adult Endocrinologist  
Diabetes and Metabolism Specialists  
San Antonio, TX

**Location:** Product Theater 1
How Soon Should AID Be Offered? Success in Typically Hard-to-Manage Populations with the MiniMed™ 780G System

Presented by Medtronic

Despite the increase in CGM utilization in the U.S., people with T1D are not reaching goals. The latest data and trends support the use of AID in achieving outcomes and decreasing burden. Hear from leading experts as they share case studies and publications showing how the MiniMed™ 780G system is closing the gap between youth and adults when it comes to glycemic management.

**Moderator:** Jennifer McVean, MD
Sr. Medical Affairs Director
Medtronic
Northridge, CA

**Presenters:**
Richard Bergenstal, MD
Executive Director
International Diabetes Center, University of Minnesota
Minneapolis, MN

Laya Ekhlaspour, MD
Assistant Professor
University of California, San Francisco
San Francisco, CA

Gregory Forlenza, MD, MS
Associate Professor of Medicine
Barbara Davis Center, University of Colorado Anschutz Medical Campus
Aurora, CO

Benjamin Wheeler, MD, PhD
Professor
University of Otago
Dunedin, New Zealand

**Location:** Product Theater 2
12:30 p.m.-1:30 p.m.

Jardiance® (empagliflozin) Tablets: A Review of Multiple Clinical Trials and Approved Indications
*Presented by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA LLC*

This program will review multiple clinical trials and approved indications for JARDIANE. The presentation will cover efficacy and safety data. As well as the dosing information for JARDIANE. Attendees will also have the opportunity to ask the presenter questions about the data presented.

**Moderator:**  
Kari Haynie  
Associate Director, Brand Marketing  
Eli Lilly and Company

**Presenters:**  
Christian W. Mende, MD, FACP, FACN, FASN, FAHA  
Clinical Professor  
Department of Medicine  
University of California at San Diego  
San Diego, CA

Rosemarie Lajara, MD, FACE  
Staff Endocrinologist  
Southern Endocrinology Associates  
Clinical Associate Professor of Medicine  
UT Southwestern Medical Center  
Dallas, TX

**Location:**  
Product Theater 3
3:00 p.m.-3:45 p.m.

Creating the Next Chapter in Diabetes Management by Leveraging Interoperability and Dynamic Collaboration - Introducing the twiist™ AID System for Personalized, Flexible Control.

Presented by Sequel

The next chapter in diabetes management is here - introducing the twiist™ Automated Insulin Delivery (AID) System powered by Tidepool. During this panel session moderated by Jenn LeBlanc, you will hear from Sequel colleagues Alan Lotvin and Kate Farnsworth, alongside esteemed endocrinology experts Rayhan Lal and David Ahn. The session starts with a quick trip back to the 1970s when the first wearable insulin pump therapy from Dean Kamen (Sequel Med Tech Co-Founder and President of DEKA Research & Development Corp.) was introduced to the world, paving the way for DEKA's development of a new insulin delivery technology that fundamentally changes the way we think about AID systems. Learn how the twiist AID system takes advantage of the FDA's medical device interoperability standards which will help patients personalize their diabetes management to their individual preferences - a result of dynamic collaboration between Sequel and Tidepool driven by a common mission to make life easier for people with diabetes. You'll hear from this panel of experts on how the twisst AID system is the first to integrate the Tidepool Loop algorithm, while expanding patient access to consumer-friendly technology and powerful data. The twiist AID system is brought to you by Sequel(tm).

Presenters:  Jenn LeBlanc, MBA, BSN, RN, CDCES  
Vice President, Clinical Strategy  
Sequel

Alan Lotvin, MD  
CEO/Co-Founder & Director  
Sequel

Kate Farnsworth  
Associate Director of Marketing  
Sequel

Rayhan Lal, MD  
Adult and Pediatric Endocrinologist  
Standard

Chief Medical Advisor  
Tidepool

David Ahn, MD  
Chief of Diabetes Services  
Mary & Dick Allen Diabetes Center at Hoag

Location:  Product Theater 1
3:00 p.m.-3:45 p.m.

**Product Theater for ZepboundTM (tirzepatide) Injection**  
*Presented by Lilly USA LLC*

Join a presentation from one of your peers on the efficacy and safety of once-weekly Zepbound, and learn about how to get appropriate patients started on this treatment. Attendees will have the opportunity to pose questions to the speaker at the end of the session. Refreshments will be provided. Please see the Important Safety Information for Zepbound, including Boxed Warning about possible thyroid tumors, including thyroid cancer, the full Prescribing Information, and Medication Guide provided at the Product Theater. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

**Presenter:** Jesse Richards, DO  
Department of Internal Medicine, School of Community Medicine  
University of Oklahoma  
Tulsa, OK

**Location:** Product Theater 2
SUNDAY, JUNE 23, 2024
10:15 a.m.-11:00 a.m.

Omnipod® 5: Advancing Automated Insulin Delivery for All
*Presented by Insulet*

Learn how Omnipod 5, the #1 prescribed and patient-preferred AID system, delivers strong glycemic results across various patient populations. Hear from Omnipod clinical trial investigators Dr. Greg Forlenza and Dr. Francisco Pasquel (Chair of SECURE-T2D), who will unveil clinical outcomes and share how Omnipod is a proven therapy for many patients beyond traditional pump candidates. Get a sneak peek at what’s to come for Insulet from Dr. Trang Ly, Insulet’s Senior Vice President and Medical Director, who will provide an update on Omnipod’s exciting clinical and innovation pipeline. USA 2023, Data on file.2. The Omnipod 5 System was named 2023 Patient Choice Award Winner for preferred pump in the United States; Seagrove Patient Perspectives Survey Report (413 Total Responses, 260 T1D, 153 T2D - 245 pumpers, 98 MDI, 70 non-MDI). Seagrove Partners, LLC Patient Perspectives Report, December 2023. Insulet data on file.3. Forlenza G, et al. Diabetes Technol Ther (2024). Real-world evidence of Omnipod 5 Automated Insulin Delivery System use in 69,902 people with type 1 diabetes.

**Presenters:**
- Trang Ly, MBBS, FRACP, PhD
  Senior Vice President & Medical Director
  Insulet
  Acton, MA

- Gregory Forlenza, MD
  Associate Professor of Pediatrics & Director of Pediatric Diabetes Technology Research
  Barbara Davis Center at the University of Colorado Anschutz Medical Campus
  Aurora, CO

- Francisco Pasquel, MD, MPH
  Associate Professor of Medicine
  Emory School of Medicine
  Medical Director of Endocrinology
  Grady Health System
  Atlanta, GA

**Location:** Product Theater 1

10:15 a.m.-11:00 a.m.

From Awareness to Action: The Importance of Screening for Type 1 Diabetes
*Presented by Sanofi*

Type 1 diabetes (T1D) is a life-altering condition. Learn more about the epidemiology, burden of disease, and unmet need for patients with T1D. Join us for a discussion on the progressive nature of T1D and review best practices for identifying who to screen, when to screen, and how to screen, including managing the patient and/or caregiver after screening.

**Presenters:**
- Kimber Summons, MD, MPH/MSPH
  Barbara Davis Center for Diabetes
  Aurora, CO

- Holly O’Donnell, PhD
  Barbara Davis Center for Diabetes
  Aurora, CO

**Location:** Product Theater 2
10:15 a.m.-11:00 a.m.

Discover a New Treatment Option that is Available for Patients with NASH with Liver Fibrosis

*Presented by Madrigal Pharmaceuticals, Inc.*

Please join us for an engaging and highly anticipated educational presentation focusing on this new option for patients with NASH, including the clinical data.

**Presenter:** Mazen Noureddin, MD, MHSc
- Professor of Medicine
- Houston Methodist Hospital
- Director
- Houston Research Institute
- Houston, TX

**Location:** Product Theater 3

12:30 p.m.-1:30 p.m.

Explore Advancements in Type 1 Diabetes Management

*Presented by Sanofi*

Type 1 diabetes (T1D) can have a devastating impact on both patients and their loved ones. Explore advancements in T1D management and the importance of proactive screening, particularly among individuals at increased risk for T1D. Join us to learn more about the paradigm shift in caring for patients with T1D.

**Moderator:** Steven Edelman, MD
- University of California San Diego
- San Diego, CA

**Presenters:**
- Anita Swamy, MD
  - Chicago Children's Diabetes Center
  - Chicago, IL
- Jason Baker, MD
  - Weill Cornell Medicine
  - New York, NY

**Location:** Product Theater 1
12:30 p.m.-1:30 p.m.

**Perspectives in Hyperglycemia Secondary to Hypercortisolism – A Path to Diagnosis**

*Presented by Corcept Therapeutics*

Case-based panel discussion on evolving perspectives in endogenous Cushing Syndrome.

**Presenters:**
- John Anderson, MD
  Internal Medicine and Diabetes
  The First Clinic
  Nashville, TN
- Ralph DeFronzo, MD
  Professor of Medicine
  Chief, Diabetes Division
  University of Texas Health
  San Antonio, TX
- James Suliburk, MD, FACS
  Associate Professor and Chief, Endocrine Surgery
  Division of Surgical Oncology
  Baylor College of Medicine
  Houston, TX

**Location:** Product Theater 2

12:30 p.m.-1:30 p.m.

**Hepatitis B: You Hold the Key to Prevention. The Importance of Hepatitis B Vaccination Among Adults with Diabetes**

*Presented by GSK*

Do you vaccinate your patients against hepatitis B? Do you know the CDC and ADA guidelines for hepatitis B vaccination? Why is it important for adults with diabetes to be vaccinated against hepatitis B? Learn the answers to these questions and more by joining our symposium highlighting the critical importance of hepatitis B prevention among adults with diabetes. Our experts will review the recent hepatitis B vaccination recommendations, examine current disease incidence and vaccination coverage, and discuss barriers to vaccination and consider how these could be overcome – all with a focus on the specific implications for adults with diabetes. Attendees will leave with an enhanced understanding of why this population needs to be vaccinated against hepatitis B, and will bring hepatitis B vaccine knowledge and know-how back to the clinic for implementation.

**Moderators:**
- Dorothy Brown, PharmD, MBA
  Medical Science Liaison, US
  Vaccines Clinical and Medical Affairs, GSK
  Philadelphia, PA
- Anna M. Acosta, MD
  Medical Director, Hepatitis Vaccines US
  Vaccines Clinical and Medical Affairs, GSK
  Philadelphia, PA

**Presenter:**
- Michael Valitutto, DO
  Medical Director, Ascension Borgess Diabetes & Endocrine Center
  Kalamazoo, MI

**Location:** Product Theater 3
3:00 p.m.–3:45 p.m.

Attention on MASH: The Hepatic Manifestation of the Metabolic Syndrome
*Presented by Novo Nordisk*

Join us as we discuss MASH (metabolic dysfunction-associated steatohepatitis) and the impact of the underlying metabolic dysfunction on disease progression. We will also discuss the importance of early identification and screening for at-risk patients and review current management considerations.

**Presenter:** Nadege Gunn, MD, CPI  
Gastroenterology, Hepatology, and Obesity Medicine  
Medical Director and Senior Scientific Advisor  
Velocity Clinical Research  
Hepatology Clinical Director, Coryell Health  
Adjunct Faculty, Baylor University and Texas A&M College of Medicine  
Waco, TX

**Location:** Product Theater 1

3:00 p.m.–3:45 p.m.

Discover the Tempo™ Personalized Diabetes Management Platform
*Presented by Lilly USA LLC*

Join our product theater to learn about Tempo, a personalized diabetes management platform that combines the Tempo prefilled insulin pen, diabetes management devices, and app-driven support to deliver individualized guidance for adults with diabetes. This presentation will review the challenges to effective diabetes self management, how Tempo may support healthcare professionals and people with diabetes, and how to start patients with diabetes on Tempo. Please see the Important Safety Information and Intended Uses for the Tempo Personalized Diabetes Management Platform provided at the product theater. This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with U.S. Food and Drug Administration guidelines and is not approved for continuing education credit.

**Presenter:** Nitrin Trivedi, MD, DM, FACE, FACP  
Division Director, Endocrine and Metabolic Medicine  
Saint Vincent Hospital  
Worcester, MA

**Location:** Product Theater 2
3:00 p.m.-3:45 p.m.

Eversense Long-Term CGM: Addressing Traditional CGM Usage Barriers
Presented by Ascensia Diabetes Care

CGM continues to revolutionize diabetes care, but some patients experience barriers to the usage of traditional short-term CGMs. Our multidisciplinary panel of experts and a person living with diabetes will discuss the common issues patients face with traditional CGMs, including disruptions leading to adverse glycemic events, alarm fatigue, compression lows, and many more. They will show how Eversense E3, the only long-term CGM available, helps overcome these challenges and offers patients a truly differentiated CGM experience. You will also learn about the Eversense Roadmap — including the iCGM designation and pending FDA clearance of a CGM system lasting as long as 365 days.

**Moderator:** Francine R. Kaufman, MD  
Chief Medical Officer of Senseonics, Inc.  
Distinguished Professor Emerita of Pediatrics and Communications  
Keck School of Medicine  
Annenberg School of Communications, University of Southern California  
Beverly Hills, CA

**Presenters:**  
David T. Ahn, MD  
Chief of Diabetes Services  
Mary & Dick Allen Diabetes Center  
Hoag Memorial Hospital Presbyterian  
Newport Beach, CA

William H. Polonsky, PhD, CDCES  
President and Co-Founder of the Behavioral Diabetes Institute  
Associate Clinical Professor in Medicine  
University of California  
San Diego, CA

Chris Ruden  
Fort Lauderdale, FL

**Location:** Product Theater 3
Diabetes Learning Bytes

Diabetes Learning Bytes are an opportunity for companies to highlight their newest innovations in an informal setting with a 20-minute presentation window.

SATURDAY, JUNE 22, 2024
11:00 a.m.-11:20 a.m.

Omnipod 5: Unusual Suspects for AID
Presented by Insulet

Join Dr. DeSalvo for a bite-sized case review on challenging traditional norms of AID candidacy and practical tips on:

- How Omnipod 5 can facilitate AID use for diverse patient populations
- How to incorporate technology to improve clinical results while simplifying diabetes management for you and simplifying life for your patients

Presenter: Daniel DeSalvo, MD
Assistant Professor Pediatric Endocrinology
Baylor College of Medicine
Houston, TX

Location: Diabetes Learning Bytes (Booth 430)

2:20 p.m.-2:40 p.m.

Early Incorporation of a Noninvasive, In-Office Treatment for Painful Diabetic Peripheral Neuropathy of the Feet
Presented by Averitas

Averitas Pharma, Inc. invites you to join our session to learn more about the mechanism of action, efficacy and safety data, and a demonstration of a 30-minute in-office procedure for painful diabetic peripheral neuropathy of the feet.

Presenter: Gary Graf, APRN
Sr. Distinguished Engineer
Medtronic
Northridge, CA

Location: Diabetes Learning Bytes (Booth 430)
SUNDAY, JUNE 23, 2024
11:00 a.m.-11:20 a.m.

The MiniMed™ 780G System Algorithm Explained
Presented by Medtronic

Learn about the MiniMed™ 780G algorithm and answers to the most frequently asked questions so you can better speak to your patients about the system.

Presenter: Louis Lintereur, MS
Medtronic
Northridge, CA

Location: Diabetes Learning Bytes (Booth 430)
1:30 p.m.-1:50 p.m.

Revolutionizing Diabetic Eye Screening: Introducing the Optomed Aurora AEYE. Empowering Early Detection with AI.

*Presented by Optomed USA*

The Optomed Aurora AEYE is a groundbreaking handheld fundus camera combined with advanced artificial intelligence (AI) designed to revolutionize diabetic retinopathy (DR) screening. As the first FDA-approved handheld fundus camera with integrated AI, it offers primary care physicians (PCPs) an effective tool for early detection and management of DR, significantly enhancing patient care.

The device’s portability and ease of use make it a versatile addition to any primary care setting. Its handheld design allows for convenient retinal imaging without the need for extensive equipment or specialized training. This seamless integration into existing workflows ensures minimal disruption to routine patient visits while expanding the scope of services offered by PCPs.

The AI-powered AEYE-DS system within the Optomed Aurora analyzes retinal images with remarkable accuracy, boasting a sensitivity of 92-93% and specificity of 89-94%. These metrics indicate the device’s ability to correctly identify both positive and negative cases of DR, ensuring reliable screening results. This high level of performance matches or exceeds many tabletop models, positioning the Optomed Aurora AEYE as a preferred choice due to its affordability and portability.

Beyond its technical capabilities, the Optomed Aurora AEYE addresses significant barriers in DR screening—affordability and accessibility. Traditional screening methods often require expensive equipment and specialized personnel, limiting their availability in many primary care settings. In contrast, the Optomed Aurora AEYE offers a cost-effective solution that can be easily deployed, making routine DR screening more accessible to a broader patient population.

The device supports comprehensive patient management by providing detailed reports that can be sent to eye care providers for referrals, stored in electronic medical records (EMR), or shared with patients for educational purposes. This promotes a collaborative approach to patient care, ensuring timely follow-ups and interventions.

The Optomed Aurora AEYE is a transformative tool for primary care practices, combining cutting-edge AI technology with practical design to enhance DR screening, improve patient outcomes, and make high-quality eye care more accessible.

**Presenter:** Blake Cooper, MD, MPH  
Managing Partner  
Retina Associates  
Kansas City, MO

**Location:** Diabetes Learning Bytes (Booth 430)
American Diabetes Association

84th Scientific Sessions

ada2024.org

#ADASciSessions